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Macular pigment (MP) is the collective name for three carotenoids, lutein, zeaxanthin and 
meso-zeaxanthin, which are found at high concentrations in the central macula. The 
macular carotenoids, like all carotenoids, are entirely of dietary origin. The term ‘macular 
pigment optical density’ (MPOD) refers to the peak concentration of MP in the retina, 
which varies from one individual to the next and is measurable in vivo. On account of its 
blue-light-filtering and antioxidant properties, MP has become a subject of interest with 
respect to age-related macular degeneration (AMD), the hypothesis being that MP helps 
to protect against AMD; the higher the MPOD, the lower the risk for AMD. 
 
Recently, a new MPOD-measuring device, the MPS 9000 (MPS), entered the ophthalmic 
market. Using this device, the research described here aimed to contribute new 
information to the MP literature. A second MPOD instrument, the Macular Pigment 
Reflectometer, was also used at times, but a reliability study (included in the thesis) 
demonstrated that it was unsuitable for use on its own.  
 
First, a series of exploratory investigations were undertaken to maximize the accuracy 
and consistency of MPOD measurements taken with the MPS; a protocol was 
established that substantially improved repeatability. Subsequently, a series of MPOD-
based studies were conducted on anisometropia, South Asian race, blue-light-filtering 
contact lenses, and dietary modification with kale. The principle findings were as follows: 
interocular MPOD differences were not attributable to interocular refractive error 
differences; young adults of South Asian origin had significant gender-related MPOD 
differences (males>females, p<0.01), and they also had significantly higher MPOD than 
Caucasians (p<0.0005); wearing blue-light-filtering contact lenses for eight months did 
not affect MPOD; and dietary modification with kale for 16 weeks did not increase MPOD. 
 
This body of research adds new insights to MP knowledge, which in turn may contribute 
to MP knowledge in the context of AMD. 
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CHAPTER 1: INTRODUCTION 
 
Macular pigment (MP) is the collective name for three carotenoids, lutein (L), zeaxanthin 
(Z) and meso-zeaxanthin (MZ), which are found at high concentrations in the central 
macula, to the exclusion of all other carotenoids (Bone et al. 1993). They are only 
available to the body by dietary intake of foodstuffs or supplements containing them 
(Malinow et al. 1980; Neuringer et al. 2004). In this opening chapter, the dietary origins of 
the macular carotenoids and their pathway to the eye are briefly described, followed by 
an account of the history of MP discovery, its functions, the methods by which it can be 
quantified, its associations, and finally the evidence for its main proposed purpose. 
 
1.1 Lutein and zeaxanthin 
Lutein and Z are part of the carotenoid family of pigments, or more specifically they are 
xanthophyll hydroxycarotenoids (Snodderly et al. 1984b; Khachik et al. 1992). 
Xanthophylls (Greek for ‘yellow leaf’), and in indeed all carotenoids, are entirely of dietary 
origin, confirmed in the case of L and Z by Malinow et al. (1980) and later by Neuringer et 
al. (2004) with their studies on monkeys. Compared with monkeys raised on a diet 
containing xanthophylls, Malinow et al. found that monkeys raised on xanthophyll-free 
diets had no detectable xanthophylls in their blood serum (or retina). Neuringer et al. 
reported the same, but armed with a greater level of knowledge at that point in time, they 
were able to report more precisely that no L or Z was detectable in the monkeys’ serum 
(or retina). Furthermore, following supplementation with L and Z, these carotenoids did 
become evident in the serum (and retina), thus proving that while the primate body 
cannot synthesize L and Z, it can still absorb L and Z even after years of xanthophyll 
deprivation (the monkeys were 8 to 16 years old before the supplementation began).  
 
Good sources of L and/or Z include green vegetables, particularly spinach, kale and 
courgettes; brightly-coloured vegetables, particularly corn and orange peppers; egg yolks 
(the result of a high carotenoid intake by hens); certain spices, namely, paprika (made 
from peppers); and perhaps less intuitively, pistachio nuts (Sommerburg et al. 1998; 
Perry et al. 2009; Kay et al. 2010; USDA 2010). Although many fruits do contain L/Z, the 
levels are not especially high, with the exception of the goji berry, which contains a 
considerable amount of Z (Zhou et al. 1999; Leung et al. 2001). 
 
Following ingestion and digestion of appropriate food, L and Z are believed to be 
absorbed from the small intestine via a mainly protein-mediated mechanism (Reboul et 
al. 2005), after which they are transported to the liver on chylomicrons (Erdman et al. 
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1993; Gärtner et al. 1996), a type of lipoprotein, before being released into the plasma on 
other forms of lipoprotein. Although it is widely acknowledged that L and Z are 
transported on lipoproteins, it is not entirely clear which ones are involved. For example, 
Erdman et al. (1993), and Goulinet and Chapman (1997), reported that L and Z were 
distributed fairly evenly between low-density lipoproteins and high-density lipoproteins, 
whereas Cardinault et al. (2005), Wang et al. (2007) and Loane et al. (2010b) found that 
there was a preference for high-density lipoproteins. Either way, lipoproteins are the 
carrier method by which L and Z are delivered to bodily tissues, including the retina.  
 
The delivery of L and Z to the retina is not well understood, but in recent years the idea of 
retinal uptake via xanthophyll-binding proteins has grown in momentum (Bernstein et al. 
1997; Yemelyanov et al. 2001; Bhosale et al. 2004; Bhosale et al. 2009a), and Z-specific 
and L-specific binding proteins have now been identified in the human retina (Bhosale et 
al. 2004; Bhosale et al. 2009a). 
 
1.2 Macular pigment  
Macular pigment is the name used to describe the combined presence of L and Z in the 
retina, and in particular the fovea, where their concentration is greatest (Bone et al. 1985; 
Bone et al. 1988; Handelman et al. 1988). Although a conspicuous yellow pigmentation at 
the macula (or more specifically, the fovea) had been noted for well over 150 years 
(Nussbaum et al. 1981), it was George Wald in the 1940s who first suggested that MP 
was composed of a xanthophyll such as L (Wald 1945, 1949). Forty years later, his 
suggestion was proven to be correct, with official identification made by Bone and 
colleagues in 1985 (Bone et al. 1985). Using high-performance liquid chromatography 
(HPLC) on human donor retinas, these researchers also noted the presence of Z, and in 
1993 they identified the third carotenoid, MZ, which is a stereoisomer of Z (Bone et al. 
1993). Unlike L and Z, MZ is not found in foods typical of a human diet (Maoka et al. 
1986). As a result, it is undetectable in serum, and was thought by Bone et al. to be the 
result of L transformation within the retina (Bone et al. 1993). This was confirmed by 
Johnson et al. (2005) as part of their series of studies concerning the nutritional 
manipulation of monkeys raised on diets absent of L and Z. To the present day, L, Z and 
MZ remain the only carotenoids to be located in the retina, despite there being at least 14 
major carotenoids (e.g., lycopene, beta-carotene) circulating in the human body (Khachik 
et al. 1997a; Khachik et al. 1997b), and although many ocular structures do contain L and 
Z (e.g., the lens and uvea) (Yeum et al. 1995; Bernstein et al. 2001), it is the retina that 
holds the majority (Bernstein et al. 2001). 
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Anatomically, the macula covers a circular area of approximately 5.5 mm (19) diameter 
in the central retina (Remington 1998), with the fovea accounting for the middle 1.5 mm 
(5.2) diameter, followed by the parafovea with a width of 0.5 mm (i.e., 2.6-4.3 
eccentricity from the centre of the fovea), and then the perifovea with a width of 1.5 mm 
(i.e., 4.3-9.5 eccentricity from the centre of the fovea). The spatial distribution of MP 
peaks in the central 0.5 mm (1.7) of the fovea, with a rapid decline in concentration from 
0.25 mm eccentricity onwards (Bone et al. 1988). It reaches near zero levels by 2 mm 
(7) eccentricity, but it never disappears completely, even in the far peripheral retina 
(Bone et al. 1988). In the central fovea, up to 2.3 mm eccentricity, Z (and to a lesser 
degree, MZ) is the dominant carotenoid over L (Bone et al. 1988; Handelman et al. 1988; 
Bone et al. 1997), with a L:Z ratio of 1:2.4 at 0.25 mm eccentricity. Beyond 2.3 mm, L 
becomes dominant, and the L:Z ratio swaps over by 5.8 mm eccentricity onwards, such 
that the amount of L is more than double that of Z (Bone et al. 1988). 
 
Within the retinal layers, MP is primarily located in the cone photoreceptor axons of the 
rod-free central fovea, also known as Henle’s fibres (Snodderly et al. 1984a; Snodderly et 
al. 1984b). Beyond this point, MP continues to be located in photoreceptor axons (here 
part of the outer plexiform layer), but it is also present in high concentrations in the 
interneurons of the inner plexiform layer (Snodderly et al. 1984a; Snodderly et al. 1984b; 
Trieschmann et al. 2008). Somewhat surprisingly, until very recently the retinal layer 
localization of MP had only been established in monkey retinas, but in 2008 the same 
arrangement was confirmed in humans (Trieschmann et al. 2008). In addition to the 
plexiform layers, between 10 and 25 percent of MP has been located in rod 
photoreceptor outer segments in the perifoveal and peripheral retina (Sommerburg et al. 
1999; Rapp et al. 2000). As per MP distribution in general, the concentration is higher in 
the perifovea than the periphery, and the ratio of L:Z rises with increasing eccentricity 
(Rapp et al. 2000). Of note, there do not appear to be any published studies that have 
looked for MP in cone photoreceptor outer segments. 
 
The selective accumulation of L and Z in the retina and their high concentration in the 
fovea suggests that their presence may not be a mere coincidence, and that MP might be 
there to serve a bigger purpose. A good place to start in attempting to elucidate any such 
purpose is to consider the proposed functions of MP, of which there are two. 
 
First and foremost, it has been conclusively established that MP is a blue light filter. Its 
absorption spectrum peaks around 460 nm, and it reaches a minimum in the 
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ultraviolet/violet (around 380 nm) and green (around 540 nm) regions of the 
electromagnetic spectrum (Wyszecki and Stiles 1982; Snodderly et al. 1984b; 
Handelman et al. 1991; Bone et al. 1992). Research demonstrates that short-wavelength 
(blue) visible light is more damaging to the retina than longer-wavelength visible light 
(Ham et al. 1976; Ham et al. 1978), so with its pre-receptoral location, MP is well placed 
to attenuate the amount of blue light reaching the photoreceptors and beyond, thus 
limiting the subsequent damage that could ensue (Junghans et al. 2001). In fact, L and Z 
have been proven as more efficient blue light filters than some other carotenoids (beta-
carotene and lycopene) (Junghans et al. 2001), making their sole carotenoid presence in 
the macula all the more evocative. In particular, L appears to be better than Z in terms of 
blue light absorption efficiency, which is believed to be the result of its two orthogonal 
orientations (compared with Z’s one orientation) in lipid membranes making it more suited 
to absorbing blue light from all directions (Sujak et al. 1999; Junghans et al. 2001). 
 
For three main reasons, the retina is subjected to oxidative stress, i.e., cell damage or 
death that is caused by reactive oxygen species such as free radicals, singlet oxygen and 
hydrogen peroxide (Beatty et al. 1999; Beatty et al. 2000b). Firstly, it is exposed to a lot of 
visible light, secondly, it uses large amounts of oxygen, and thirdly, it contains a high 
number of polyunsaturated fatty acids (Beatty et al. 1999; Beatty et al. 2000b). Light and 
oxygen consumption, in isolation or in combination, result in the generation of reactive 
oxygen species, while membrane-bound polyunsaturated fatty acids are highly 
susceptible to cell damage by free radical-induced lipid peroxidation (Beatty et al. 1999; 
Beatty et al. 2000b). As discussed above, short-wavelength visible light has been shown 
to be more damaging to the retina than longer-wavelength visible light, so it could well be 
that MP helps to protect against oxidative stress passively in its capacity as a blue light 
filter. However, there is also the second proposed function of MP to consider, which is its 
role as an antioxidant. 
 
Antioxidants are substances that can mount a defence against oxidative stress, and 
carotenoids, including xanthophylls like L and Z, are known antioxidants (Sies and Stahl 
1995), which is why MP is thought to exercise this property in the retina. Numerous in 
vitro retinal studies have demonstrated the antioxidant abilities of L and Z (e.g., Sundelin 
and Nilsson 2001; Wrona et al. 2004; Kim et al. 2006; Chucair et al. 2007; Bhosale et al. 
2009b; Li et al. 2009; Nakajima et al. 2009; Li et al. 2010; Sasaki et al. 2010), but the 
most persuasive evidence for a MP antioxidant function comes from Khachik et al. 
(1997a), who identified the direct oxidation products of L and Z in human donor retinas 
(and monkey retinas); of note, the oxidation products were not attributable to postmortem 
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events. Whereas L has been reported to be a better blue light filter than Z (Sujak et al. 
1999; Junghans et al. 2001), it seems that Z may take the lead in terms of antioxidant 
ability, with some studies demonstrating that Z may be a more effective antioxidant than L 
(Kim et al. 2006; Trevithick-Sutton et al. 2006). 
 
The outer and inner plexiform layer location of MP is not especially conducive to an 
antioxidant role, so it may be that the blue-light-filtering characteristics of MP are more 
important than the antioxidant characteristics. However, it is not to be forgotten that MP is 
also present in the outer segments of perifoveal rods (Sommerburg et al. 1999; Rapp et 
al. 2000), an area with considerable oxidative stress due to a very high polyunsaturated 
fatty acid count (Beatty et al. 2000b). Consequently, a valuable antioxidant function for 
MP does seem likely (Rapp et al. 2000; Subczynski et al. 2010). 
 
Although MP invariably reaches its greatest concentration in the central fovea, the actual 
amount of MP here is not fixed; it varies widely between individuals, and as with the 
earlier-mentioned nutritional manipulation investigations on monkeys (Neuringer et al. 
2004; Johnson et al. 2005), it can be increased in many humans by regular consumption 
of foods or supplements rich in L and/or Z (e.g., Hammond et al. 1997a; Wenzel et al. 
2006b; Connolly et al. 2010). The measured level of MP in its peak area of concentration 
at the fovea has long been known as macular pigment optical density (MPOD) (Bone and 
Sparrock 1971), and logically, thinking of the two proposed functions of MP, it would be 
anticipated that the higher the MPOD, the greater the capacity for blue light absorption 
and combating of oxidative stress. Indeed, it has been estimated that an ‘average’ MPOD 
results in 20 to 40 percent absorption of 460 nm light, whereas a very high MPOD results 
in 90 to 98 percent absorption of 460 nm light (Hammond and Caruso-Avery 2000; 
Landrum and Bone 2001). 
 
1.3 Measuring macular pigment optical density in vivo 
The ex vivo techniques, such as HPLC, that have been used to measure MPOD in donor 
and animal retinas have proved invaluable for establishing the components of MP and its 
spatial location within the retina. Nonetheless, they are clearly not suitable for use in 
living populations, and therein lies their limitation. Fortunately, the spectral and spatial 
aspects of MP have afforded the development of in vivo techniques that can measure 
MPOD in the vast majority of individuals. These in vivo techniques are noninvasive, and 
they are normally categorized under one of two headings: psychophysical (requiring a 
response from the subject) or objective (requiring minimal input from the subject). Each 
method has confirmed the large range of MPOD in human population samples, from 
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virtually no MP to greater than one log unit optical density, with average levels ranging 
from 0.16 (Wüstemeyer et al. 2003) to 0.69 (van de Kraats et al. 2008), depending on the 
method used and/or the study population. A detailed review of the in vivo MPOD 
measurement techniques has been published (Howells et al. 2011) and can be found in 
appendix 1, so here only the basic measurement principles of each approach are 
described. 
 
PSYCHOPHYSICAL TECHNIQUES 
The psychophysical methods of measuring MPOD include the following: 
 
Threshold spectral sensitivity (e.g., Brown and Wald 1963; Bone and Sparrock 1971; 
Stabell and Stabell 1980; Pease and Adams 1983; Pease et al. 1987). 
Colour matching (e.g., Ruddock 1963; Moreland and Bhatt 1984; Moreland and 
Alexander 1997; Davies and Morland 2002). 
Dichroism-based measurements (e.g., Bone 1980; Bone et al. 1992). 
Minimum motion photometry and apparent motion photometry (see below). 
Heterochromatic flicker photometry (see below). 
 
The first three of the psychophysical methods have now been largely superseded by 
heterochromatic flicker photometry (HFP) and, to some extent, minimum motion 
photometry. This is in part due to their increased level of difficulty and/or the longer time 
needed to perform them (Hammond et al. 2005). 
 
HETEROCHROMATIC FLICKER PHOTOMETRY 
Developed by Ives in the early 1900s (cited by Viner 2003), HFP has so far been the 
most commonly used of all the techniques for measuring MPOD. As such, it is often used 
as a standard against which other techniques are validated (e.g., Delori et al. 2001; 
Neelam et al. 2005; van de Kraats et al. 2006; Bone et al. 2007a; Canovas et al. 2010), 
although at present there is no true ‘gold-standard’ in vivo measure of MPOD. 
 
The use of HFP to measure MP levels was first described over 30 years ago by Werner 
and Wooten (1979), but the technique wasn’t elaborated on until 1987, in a key paper by 
Werner and co-workers (Werner et al. 1987). Since then, HFP has been developed and 
used by numerous research groups investigating MP. Key papers incorporating detailed 
descriptions and variations of the technique include Hammond and Fuld (1992), 
Hammond et al. (1997c), Landrum et al. (1997), Wooten et al. (1999), Beatty et al. 
(2000a), Mellerio et al. (2002), Bone and Landrum (2004), Snodderly et al. (2004), Tang 
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et al. (2004), Iannaccone et al. (2007), Stringham et al. (2008), and van der Veen et al. 
(2009a). All other studies using HFP to measure MPOD tend to use the instruments 
originally designed or developed by these investigators. 
 
In conjunction with many of the MPOD techniques, HFP makes use of the spectral 
absorption properties and retinal location of MP. Essentially, HFP determines MPOD by 
presenting a light stimulus of two alternating wavelengths at the fovea and at an eccentric 
retinal area (technically the parafovea or perifovea but often referred to interchangeably 
as either the parafoveal or peripheral measure). The wavelengths are chosen such that 
one is a short-wavelength blue light that is maximally absorbed by MP, and the other is a 
longer-wavelength green to yellow light that is not absorbed by MP. If the lights are 
alternated at an appropriate frequency and their luminances are not perceived to be 
equal by the subject, the stimulus will appear to flicker; the perceived colour of the 
stimulus will be an amalgamation of the two source colours (Beatty et al. 2000a; Bone 
and Landrum 2004; Snodderly et al. 2004; Loane et al. 2007). Typically, the radiance 
(often also termed intensity) of the blue light is adjusted by the subject until the observed 
flicker is minimized (e.g., Hammond et al. 1997c; Landrum et al. 1997; Wooten et al. 
1999; Mellerio et al. 2002; Snodderly et al. 2004; Tang et al. 2004; Stringham et al. 
2008). This occurs when there is an equiluminance match between the blue and green 
lights (Loane et al. 2007; Kirby et al. 2009). The procedure is carried out with the subject 
looking directly at the stimulus (i.e., the foveal measure), and then it is repeated with the 
subject looking away from the stimulus so that the eccentric measure (where MP is 
assumed to be negligible) can be made (Snodderly and Hammond 1999). Since MP 
reaches its highest concentration in the fovea, it will absorb some of the blue light before 
it reaches the photoreceptors, whereas in the area of negligible MP, very little blue light 
will be absorbed. Consequently, a greater radiance of blue light is required at the fovea 
than at the parafovea to appreciate minimal flicker. The log ratio of the radiance of blue 
light needed at the fovea compared with that needed at the parafovea gives a measure of 
MPOD (see formula 1). It should be noted that the chief (but not only) purpose of the 
eccentric measure is to cancel out the effect of any blue light absorption by the crystalline 
lens (which happens as a consequence of age-related lens yellowing) so that the final 
density value is a representation of MP alone, and not MP plus lens yellowing (Makridaki 
et al. 2009) (see formula 2). 
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MPOD = log (Rfs / R
p
s) − log (R
f
γ / R
p
γ) 
 
Formula 1 Example calculation for macular pigment optical density (MPOD), from 
Stringham et al. (2008). Rfs = radiance of a peak MP absorption wavelength, e.g., 460 
nm, measured at a foveal location. Rps = radiance of a peak MP absorption wavelength, 
measured at an eccentric location, e.g., 7°. Rfγ = radiance of a negligible MP absorption 
wavelength, e.g., 570 nm, measured at a foveal location. Rpγ = radiance of a negligible 
MP absorption wavelength, measured at an eccentric location. 
 
B fov x Tlens x TMP = B ref x Tlens  (i) 
 
TMP = B ref / B fov    (ii) 
 
MPOD = log 1/TMP = log (B fov / B ref) (iii) 
 
Formula 2 Derivation of MPOD, from Snodderly and Hammond (1999). The transmission 
of blue light through the MP (TMP), and the transmission of blue light through the lens 
(Tlens) is taken into account. B fov and B ref are the radiances of blue light needed to 
minimize flicker at the fovea and parafovea (reference) respectively. Since Tlens is 
assumed to be the same at the fovea and parafovea, it is removed from equation (i). The 
final equation (iii) is a simplified version of formula 1. 
 
MOTION PHOTOMETRY 
The minimum motion paradigm was initially described 100 years ago by Stumpf (1911), 
although this went largely unnoticed until its translation into English by Todorović in 1996 
(Todorović 1996; Moreland 2004). With parallels to HFP, it refers to the perceived 
reduction in motion of a moving square or sine wave grating as equiluminance of the 
colours involved is reached. The concept was taken up for use in photometry by both 
Moreland (1980, 1982) and Anstis and Cavanagh (1983), but in subtly different ways. 
This then led to the use of minimum motion photometry for in vivo measurement of MP 
(e.g., Moreland and Bhatt 1984; Moreland et al. 1998). 
 
Many of the principles described for HFP also apply for motion photometry, i.e., a 
wavelength of light at the peak of MP absorption is compared with a wavelength of light 
not absorbed by MP, at central and eccentric locations. Moving square wave gratings are 
used, with the bars being alternately illuminated by the two light wavelengths. The 
radiance of the longer-wavelength stimulus is adjusted until the motion appears to either 
slow down or change direction (Moreland 1980, 1982; Anstis and Cavanagh 1983), 
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depending on the method being employed. The slowing down of the grating is minimum 
motion photometry, whereas the reversal of grating movement is known as apparent 
motion photometry (Moreland 2004). As with HFP, different radiances of the test 
wavelength are required for equiluminance at the foveal and parafoveal positions, on 
account of the higher levels of MP at the fovea. A log ratio of these radiances provides a 
measure of MPOD (Moreland et al. 1998; Moreland et al. 2001; Robson et al. 2003; 
Moreland 2004; Robson et al. 2005; Robson et al. 2006; Robson and Parry 2008). 
 
OBJECTIVE TECHNIQUES 
The objective methods for measuring MPOD are: 
 
Fundus reflectometry 
Fundus autofluorescence 
Resonance Raman spectroscopy 
Electrophysiology using visual evoked potentials 
 
FUNDUS REFLECTOMETRY 
Quantitative measurement of light reflected from the fundus is known as fundus 
reflectometry (FR), and the researchers Brindley and Willmer (1952) were the first to 
adopt this technique. Their aim was to estimate MPOD in vivo by comparing light 
reflected at the macula with light reflected from a peripheral area of retina. Since then, FR 
has gone on to become the most widely used of the objective methods for MPOD 
measurement, although many improvements and variations have happened along the 
way. 
 
When light enters the eye it passes through many structures, including the cornea, the 
lens, the retina and the choroid. Some of these structures (and their components) will 
reflect a small part of the light, whilst others will absorb part of it. Through measurement 
of reflected light from the retina and choroid, FR is able to assess several ocular features, 
including MP (Berendschot and van Norren 2004). 
 
Although there are several variations on the reflectometry procedure, there are two 
methods that predominate. The first is a comparison technique, similar to that used in 
HFP. Light reflected from the fovea is compared with light reflected from an eccentric 
retinal area, using two wavelengths (one absorbed by MP and one not) or using a 
spectrum of wavelengths. Since MP absorbs rather than reflects certain wavelengths, 
there will be a difference in the observed reflectance at the fovea and periphery, owing to 
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the assumed lack of MP at the eccentric site. Researchers who have used this method 
include Brindley and Willmer (1952), van Norren and Tiemeijer (1986), Delori and 
Pflibsen (1989), Elsner et al. (1998), Berendschot et al. (2000), Delori et al. (2001), Bour 
et al. (2002), Wüstemeyer et al. (2002), and Cardinault et al. (2003). 
 
The second core technique is known as a spectral analysis (Berendschot and van Norren 
2004). As the name suggests, this involves the analysis of a spectrum of reflected light 
from a spot of light on the retina. To achieve this, a detailed optical model of the 
pathways of light in the eye is required. A number of optical models of increasing 
complexity have been proposed over the years, from van Norren and Tiemeijer (1986) 
through to van de Kraats and van Norren (2008). Probably the most familiar optical model 
is that derived by van de Kraats et al. (1996), which has been used to work out MPOD in 
several studies (e.g., Berendschot et al. 2000; Berendschot et al. 2002b; Berendschot 
and van Norren 2005; van de Kraats et al. 2006; Kanis et al. 2007a, 2007b). In essence, 
the density of MP is determined using its known spectral characteristics, and by taking 
into account the amount of light reflected at the internal limiting membrane, the 
photoreceptor discs and the sclera (van de Kraats et al. 1996; Berendschot et al. 2000; 
Berendschot and van Norren 2005; van de Kraats et al. 2006; Kanis et al. 2007b). The 
densities of the lens, melanin and blood are likewise calculated. 
 
FUNDUS AUTOFLUORESCENCE 
One of the newer methods for MPOD measurement relies on the intrinsic fluorescence, 
or autofluorescence (AF), of lipofuscin in the retinal pigment epithelium (RPE). Lipofuscin 
in the RPE is a waste product of photoreceptor outer segment phagocytosis, and it 
accumulates with age (Delori 1994; Delori et al. 1995; von Rückmann et al. 1995). When 
excited with light wavelengths of 400 to 590 nm, lipofuscin fluoresces, emitting light in the 
wavelength range 520 to 800 nm (Delori 2004). Delori (1994) was the first to develop a 
technique for fundus AF, with the primary aim being to measure lipofuscin. Further 
studies by Delori et al. (1995) and von Rückmann et al. (1995) provided evidence for 
lipofuscin being the main fluorophore in AF. It was their observations of a decrease in AF 
at the macula that lead to the use of AF as a means for measuring MPOD. 
 
To recap, the absorption spectrum of MP is in the range of 380 to 540 nm, and the 
absorption spectrum of lipofuscin is in the range of 400 to 590 nm. Since MP is located 
anterior to lipofuscin, incoming light directed at the fovea will be absorbed by MP before it 
reaches the lipofuscin, provided the wavelength of the light is within the absorption range 
of MP. Accordingly, there will be an attenuation of lipofuscin fluorescence at the macula; 
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the more MP present, the higher the level of attenuation. By comparing the emitted AF at 
the fovea and parafovea of two excitation wavelengths, one that is well absorbed by MP 
and one that is not, MPOD can be calculated (Delori et al. 2001). 
 
Two AF procedures exist for measurement of MP. The first is a comparison method as 
used in HFP and some forms of FR; the emitted fluorescence is collected from a foveal 
and parafoveal sampling area, and then compared to give a measure of MPOD (e.g., 
Delori et al. 2001). The second and more common procedure is an imaging method 
whereby up to 32 images (Robson et al. 2003; Robson et al. 2005) are taken in 
succession with one or two wavelengths. The images are aligned (manually or using 
dedicated software) and averaged, then a greyscale index of intensity is used to generate 
density maps of MP, which includes a measure of peak MPOD. Key studies using the AF 
imaging technique include those of Wüstemeyer et al. (2003), Berendschot and van 
Norren (2005), Delori et al. (2006), Liew et al. (2006), Trieschmann et al. (2006), and 
Wolf-Schnurrbusch et al. (2007). 
 
RESONANCE RAMAN SPECTROSCOPY 
With the exception of electrophysiology methods, resonance Raman spectroscopy (RRS) 
is the most recent MPOD technique and, arguably, the most controversial. First described 
by Bernstein et al. (1998), RRS takes advantage of L and Z’s ability to exhibit a 
phenomenon called Raman scattering (Koyama et al. 1988). Over the last ten years, the 
use of RRS to measure MPOD has quickly gained momentum, with many papers 
published on its use (Ermakov et al. 2001; Bernstein 2002; Bernstein et al. 2002; 
Gellermann et al. 2002a; Gellermann et al. 2002b; Zhao et al. 2003; Bernstein et al. 
2004; Ermakov et al. 2004; Gellermann and Bernstein 2004; Ermakov et al. 2005; 
Neelam et al. 2005; Hogg et al. 2007; Obana et al. 2008; Sharifzadeh et al. 2008). 
 
When monochromatic light is directed at a molecule, some of the light is scattered. Most 
of the light is scattered elastically (Rayleigh scattering), but a small proportion is scattered 
inelastically (Raman scattering). When this inelastic scattering happens, there is a 
wavelength shift of the incident light, known as a Raman shift; the shift in wavelength is 
molecule-specific, and therefore the back-scattered light can be collected and analysed to 
identify the molecule in question (Bernstein et al. 2004). Usually the Raman signal is very 
weak, and as a result, is not easily identified. However, if the incident wavelength 
overlaps with the absorption spectrum of the molecule, a large resonance enhancement 
of the Raman-scattered light occurs, and the molecule can be recognized. Carotenoids, 
including L and Z, are an excellent example of this. When excited by 488 nm argon laser 
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light, they exhibit a resonance enhancement of up to five orders of magnitude (Bernstein 
2002), with three characteristic Raman spectral peaks (Koyama et al. 1988; Bernstein et 
al. 1998; Gellermann et al. 2002a). The Raman line with the strongest peak is 
subsequently quantified into Raman counts, an MPOD measurement unit that is unique 
to this technique. 
 
The Raman method is completely different from almost all other MPOD techniques, in 
that it measures absolute levels of MP in a one-mm (3.5°) area, with no peripheral 
consideration at all. The researchers in this field claim that this is acceptable because the 
signal is derived directly from the pigment itself, rather than relying on light that must 
travel to deeper layers of the retina (Gellermann et al. 2002a; Gellermann and Bernstein 
2004), and that furthermore, the signal is only strong enough to register at carotenoid 
concentrations found in the macula, rather than in any other ocular structures (Bernstein 
et al. 1998). 
 
ELECTROPHYSIOLOGY – VISUAL EVOKED POTENTIALS 
The first suggestion that visual evoked potentials (VEPs) could potentially be used to 
detect MP was made over ten years ago by Moreland et al. (1998). This was investigated 
further by Robson et al. (2006) some time later. However, it is only recently that this 
particular technique has looked like it could be a truly viable method for measuring 
MPOD. Using steady-state VEPs, Robson and Parry (2008) measured MPOD across a 
range of eccentricities in three subjects. Blue-green gratings on a colour monitor were 
employed, and these same gratings were also used to measure MPOD with HFP. The 
VEP and HFP results were compared with each other, as well as with the equivalent 
MPOD as measured by minimum motion photometry. This required a correction factor on 
the part of the VEP and HFP results, to allow for the overlapping phosphor emissions of 
the blue and green stimuli. The correlation between all three techniques was excellent 
(r≥0.94, p<0.0005, in all cases), suggesting that steady-state VEPs have potential as a 
valid, objective method for measuring MP and its distribution. 
 
1.4 Macular pigment and age-related macular degeneration 
Having such a diverse range of MPOD techniques is useful for MP research, but it does 
present difficulties for those wishing to compare MPOD values between techniques. Each 
method has its own benefits and limitations, and there is no clear ideal choice, as 
highlighted in a recent paper by Beatty et al. (2008). Nevertheless, the fact that the 
opportunity to measure MP in living subjects exists at all, despite any inherent limitations, 
must be a good thing, and owing to the availability of these techniques, a multitude of 
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studies have been able to investigate MPOD and its possible associations. Table 1.1 
(page 33) is a summary of all the main variables to date that have been reported to have 
a statistically significant association with MPOD in at least one study. What is clear from 
the list of variables is that many of them are things that have also been linked to some 
degree with age-related macular degeneration (AMD), and this is no coincidence, for the 
two properties of MP discussed earlier have led to a growing belief that MP may have a 
role in protecting against this visually debilitating eye disease (Snodderly 1995; Beatty et 
al. 1999; Loane et al. 2008; Carpentier et al. 2009). 
 
Time and again, AMD is reported to be the leading cause of irreversible visual impairment 
in Western societies (e.g., Leibowitz et al. 1980; Cooper 1990; Evans et al. 2004; Bunce 
and Wormald 2008). It is characterized in various stages by the development of 
degenerative age-related changes in the macula, such as soft drusen, hyperpigmentation 
and hypopigmentation of the RPE, geographic atrophy, RPE detachments, 
haemorrhages, and scarring (Bird et al. 1995). The exact aetiology of AMD is not yet fully 
understood, but it appears to be a highly multifactorial disease that is likely to have more 
than one underlying cause (AREDS 2000; Clemons et al. 2005). As a result, many factors 
(both modifiable and unmodifiable) could increase or decrease the risk of developing the 
disease, although to date, the only three undisputed risk factors are increasing age, 
family history and smoking (Smith et al. 2001; Connell et al. 2009).  
 
One of the major theories for the pathogenesis of AMD is that of oxidative stress (Beatty 
et al. 2000b), and linked to that there is the possibility of a secondary pathogenesis in the 
form of cumulative exposure to short-wavelength light (Algvere et al. 2006). These factors 
were mentioned earlier in the context of MP function, and this is why MP has become a 
subject of interest for AMD, the hypothesis being that MP helps protect against AMD; the 
higher the MPOD, the lower the risk is for AMD. The evidence to support this hypothesis 
is diverse and complex, but the following is a summary of the pertinent points.  
 
AMD AND MPOD PARALLELS 
Numerous studies have examined MPOD with respect to putative risk factors for AMD, in 
order to investigate whether there are any shared variables for the likelihood of AMD 
occurrence and the likelihood of low MPOD. Table 1.1 includes all the risk factors that 
have been examined. The evidence, like that for many of the proposed AMD risk factors, 
is inconsistent. However, it should perhaps be pointed out that the studies that dedicate 
their investigations to one specific variable (e.g., smoking, gender, iris colour), as with the 
series of experiments by Hammond and colleagues in the 1990s and 2000s, for example 
 28 
(Hammond et al. 1995; Hammond et al. 1996a; Hammond et al. 1996b; Hammond et al. 
1996c; Hammond et al. 1997b; Hammond et al. 1998; Hammond et al. 2002; Hammond 
and Wooten 2005), nearly always find a significant result, maybe because there are 
appropriate numbers of subjects in each group being examined, unlike the more all-
encompassing studies. The relationship between MPOD and smoking, for instance, is 
often hindered by a lack of current or ex-smokers in the sample population (see table 
1.1). 
 
Taking the three established risk factors for AMD – increasing age, family history and 
smoking – it is interesting that the largest MPOD study to date that sought to establish 
risk factors for low MPOD (828 healthy subjects aged 20-60 years) obtained a statistically 
significant lower MPOD for each of these variables, i.e., lower MPOD with increasing age, 
family history of AMD, and a history of cigarette smoking (Nolan et al. 2007b). 
 
OBSERVATIONAL STUDIES 
In a thorough review by Beatty et al. (2004), the inter-relationships between dietary L and 
Z, serum L and Z, and MPOD were discussed. Unsurprisingly, these three variables were 
found to be correlated more often than not; the relationship between dietary L/Z and 
serum L/Z appears to be the most consistent, while the relationship between dietary L/Z 
and MPOD seems to be the least consistent (Beatty et al. 2004, and see table 1.1). The 
latter is probably the result of variations between subjects in terms of how effectively the 
L/Z they ingest is absorbed, transported and eventually deposited in the retina or other 
bodily tissues and organs. Nevertheless, studies that examine dietary L/Z as well as 
serum L/Z and MPOD with respect to AMD are still important in the quest to determine 
whether MP can protect against or delay the progression of AMD, and for that reason 
those studies are included here. 
 
Of the cross-sectional or case-control observational studies that have compared healthy-
eyed subjects with AMD subjects, four have reported a statistically significant decreased 
risk for AMD in subjects with a high dietary intake of L and Z (Seddon et al. 1994; Snellen 
et al. 2002; SanGiovanni et al. 2007; Seddon et al. 2010), while one found no association 
(Morris et al. 2007). Another study only found an association for subjects in a younger 
age bracket rather than the whole study population (Mares-Perlman et al. 2001). For the 
equivalent result in terms of serum L and Z, three studies have reported a statistically 
significant decreased risk for AMD (Gale et al. 2003; Delcourt et al. 2006; Zhou et al. 
2011), and four found no association (Mares-Perlman et al. 1995; Mares-Perlman et al. 
2001; Cardinault et al. 2005; Dasch et al. 2005). Interestingly, all three of the significant 
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results were stronger for serum Z than for serum L, thus suggesting that Z may have a 
bigger influence on AMD than L. For MPOD (see below for details), eight studies have 
reported a statistically significant lower mean MPOD in AMD subjects (mostly early AMD) 
than healthy-eyed subjects (Beatty et al. 2001; Bone et al. 2001; Bernstein et al. 2002; 
Wüstemeyer et al. 2002; Trieschmann et al. 2003; Obana et al. 2008; Nolan et al. 2010; 
Schweitzer et al. 2010), and six found no significant difference (Berendschot et al. 2002b; 
Ciulla and Hammond 2004; Koh et al. 2004; Kanis et al. 2008; LaRowe et al. 2008; 
Moeller et al. 2009). However, one of the ‘insignificant’ studies only comprised a total of 
13 subjects (Koh et al. 2004), and another did report a statistically significant lower mean 
MPOD in late AMD subjects (as opposed to early) compared with healthy subjects (Kanis 
et al. 2008). 
 
Of the longitudinal observational studies that have examined the incidence of AMD over 
time in a cohort of healthy-eyed subjects, two have reported a statistically significant 
decreased risk for AMD in subjects with a high dietary intake of L and Z (Tan et al. 2008; 
Ho et al. 2011), while five found no association (VandenLangenberg et al. 1998; Flood et 
al. 2002; van Leeuwen et al. 2005; Moeller et al. 2006; Cho et al. 2008). There have been 
no equivalent studies for serum L and Z, but there has been one for MPOD, which did not 
find any significant link with AMD incidence, although out of 419 healthy subjects at the 
start, only 30 developed early AMD (and two late AMD) (Kanis et al. 2007a). Of interest, 
an MPOD research group based in Waterford, Ireland, has plans to take part in a 
collaborative ageing study that will assess, among other things, MPOD at regular 
intervals over many years in a ‘nationally representative sample’ of 8000 participants 
minimum (aged 50 years and over), in order to comprehensively examine whether MPOD 
is related to AMD (Nolan et al. 2010). 
 
In addition to the observational studies already discussed, very recently MPOD has been 
investigated in a group of 369 individuals with various stages of age-related maculopathy 
(ARM; in other words, early AMD). The researchers found no statistically significant 
differences in MPOD between the various stages (Dietzel et al. 2011). They also 
analysed MP levels in the ARM study eye while taking into account the disease status of 
the opposite eye. The results were not as perhaps anticipated, in that the mean MPOD of 
study eyes with ARM and opposite eyes with AMD (MPOD≈0.64, n=24) was significantly 
greater than the mean MPOD of study eyes with ARM and either no ARM (MPOD≈0.55, 
n=49, p=0.0207) or ARM (MPOD≈0.53, n=55, p=0.0070) in the opposite eye (Dietzel et 
al. 2011). The authors speculated that this difference might have been caused by 
previous L/Z supplement intake in those subjects diagnosed with AMD. 
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INTERVENTIONAL STUDIES 
Some studies have reported on the effects in AMD subjects of increased L and/or Z via 
dietary modification and supplementation. These have been focused on observing 
improvements in visual function, rather than the clinical appearance of AMD, although 
two large-scale studies are now in progress (Neelam et al. 2008; AREDS2 2011). 
 
Of the interventional studies that have examined the effect of L/Z supplementation on 
various aspects of visual function (e.g., visual acuity, glare response and contrast 
sensitivity), five have reported a statistically significant improvement (Olmedilla et al. 
2001; Falsini et al. 2003; Richer et al. 2004; Cangemi 2007; Parisi et al. 2008) and one 
no improvement (Bartlett and Eperjesi 2007). It may be that the L dosage in the 
supplement used by the latter study was not high enough to bring about an improvement 
(Bartlett and Eperjesi 2007), as its 6 mg of L was lower than the amount used in all the 
other studies – dosage ranged from 8 to 15 mg of L, and only two supplements included 
Z (Cangemi 2007; Parisi et al. 2008). Richer et al. (2004) reported a concurrent increase 
in MPOD with visual function improvements, but this was the only study that measured 
MPOD. That said, there have been a host of observational and interventional 
investigations into visual function and MPOD in healthy-eyed participants (see table 1.1), 
and these have recently been reviewed by Loughman et al. (2010b) and Stringham et al. 
(2010). One final intervention study used a dietary modification approach; eleven AMD 
patients were instructed to considerably increase their consumption of spinach. The 
results, again, were positive (Richer 1999).  
 
At the time of writing, there have not been any, nor do there appear to be any plans for, 
interventional studies on healthy subjects assessing whether L/Z supplementation is 
capable of reducing the incidence of AMD. 
 
Out of all the observational and interventional studies, whether the findings were 
significant or not, it is noteworthy that with the exception, perhaps, of the study by Dietzel 
et al. (2011), none have reported a relationship between high dietary L/Z, high serum L/Z 
or high MPOD, and an increased risk for AMD, nor a relationship between L/Z 
supplementation and reduced visual function. 
 
It is unfortunate that so few human studies have assessed MPOD in longitudinal and 
interventional AMD studies. In animal studies it has been shown that the retinas of quail 
and monkeys (which both selectively accumulate L and Z at the macula) fed a 
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xanthophyll-deficient diet are more susceptible to light-induced damage than animals fed 
a standard or xanthophyll-supplemented diet (Thomson et al. 2002; Barker et al. 2011), 
and interestingly, Thomson et al. reported that following Z supplementation, the amount 
of retinal damage was inversely related to the amount of MP but was unrelated to serum 
Z, which is perhaps suggestive of a more important role for MPOD in AMD than for 
dietary or serum L/Z (Thomson et al. 2002), although evidently there is some level of 
correlation between all three. 
 
MPOD IN SUBJECTS WITH AMD VERSUS HEALTHY-EYED SUBJECTS 
Convincing experimental evidence for an MPOD-AMD link comes from work by Bone et 
al. (2001) and Beatty et al. (2001). Bone and colleagues used HPLC to determine the 
amount of retinal L and Z in 56 donors with AMD and 56 donors without AMD (age, 
gender and race-matched controls). They found that the AMD eyes had significantly less 
L and Z across the whole retina (divided into inner, middle and outer regions, concentric 
with each other and centred on the fovea), therefore indicating that low MPOD is causally 
associated with AMD, rather than being the result of degenerative processes in the 
macula (Bone et al. 2001). Beatty and colleagues used living subjects and HFP to assess 
MPOD in nine individuals with and without AMD. The AMD subjects each had advanced 
AMD in one eye but no clinical signs of it in their other eye. The healthy eyes were 
designated ‘high-risk’ and their MPODs were compared in a case-control approach with 
nine healthy-eyed subjects, matched for age, gender, smoking status, iris colour and lens 
density. The mean MPOD of the high-risk eyes (0.147±0.144) was significantly lower than 
the mean of the control eyes (0.311±0.206, p=0.015). In fact, eight out of the nine high-
risk eyes had significantly lower MPOD than their matched control eye (Beatty et al. 
2001). Although not every in vivo study has found AMD subjects to have lower MPOD 
than healthy-eyed subjects (e.g., Berendschot et al. 2002b; LaRowe et al. 2008), a ‘high-
risk’ versus control study like this one has only been repeated once; the result was the 
same as that for Beatty et al., using a different in vivo measurement technique (Obana et 
al. 2008). 
 
CLINICAL OBSERVATIONS 
Clinical evidence for MP being protective against AMD comes from observations that the 
central fovea, i.e., where MP peaks, tends to be the last area affected by geographic 
atrophy (Maguire and Vine 1986; Sarks et al. 1988; Schatz and McDonald 1989). Weiter 
and co-workers localized the spared areas in 40 cases of annular maculopathy to the 
exact presence of MP (Weiter et al. 1988). Furthermore, monkeys reared on a long-term 
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L and Z-free diet (discussed earlier) went on to develop drusen-like pathology (Malinow et 
al. 1980; Feeney-Burns et al. 1989). 
 
Overall, the evidence regarding the role of MP in AMD is not conclusive, but given the 
multifactorial nature of AMD, this is not altogether unexpected. What’s more, it is highly 
likely that an individual’s MPOD is equally multifactorial, therefore adding to the 
inconsistency. Nevertheless, the evidence is highly suggestive of an association, and as 
one of the few modifiable potential factors in AMD, its continued investigation is extremely 
important.  
 
1.5 Summary 
Much progress has been made in our understanding of MP over the last 25 years, and 
with recent improvements in MPOD measurement technology, this is set to continue. 
Moreover, there are now three MPOD instruments available to optometrists and 
ophthalmologists for use in everyday clinical practice (the M|POD - Tinsley Ophthalmic, 
Redhill, Surrey, UK; the MacuScope - Macuvision Europe, Solihull, West Midlands, UK; 
and the Zeiss Visucam 200 - Carl Zeiss, Jena, Germany), which in time will hopefully 
allow MPOD testing to reach a wider populace. Using one of these devices, the body of 
research described in the upcoming chapters seeks to add to the growing conglomerate 
of MP knowledge. 
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Table 1.1 Summary findings of studies that have examined MPOD with respect to various dietary, lifestyle, ocular and physical factors. (For 
reference details, see appendix 2.) 
Variable 
Number of studies investigating the variable’s association 
with MPOD and finding: Comment 
Significant link (p < 0.05) Insignificant link (p > 0.05) 
Adipose tissue lutein Positive in 2 studies (M only)18,46 
Inverse in 1 study (F only)46 
1 study (F only)18 18 = FR 46 = HFP  
Age Positive in 7 
studies9,26,27,43,56,95,101 
Inverse in 19 studies4,6,10,11,12,32, 
38,39,43,54,66,67,68,71,73,75,85,105,107 
38 studies3,5,10,12,13,14,16,18,19,20,21, 
22,23,25,38,41,42,44,45,46,51,56,58,59,63,64, 
72,77,79,80,81,84,91,92,93,100,105,106 
 
Positive = HFPx3, AFx3, FRx2 
Inverse = HFPx11, RRS*x7, AFx1, FRx1 
Insignificant = HFPx20, FRx7, AFx6, HPLCx4, 
Colour matchingx1, Histologyx1 
51 = significant association found for older vs 
younger subjects in ‘central dip’ MPOD profile. 
81 = insignificant for both subject groups. 
AMD Inverse in 8 
studies6,11,16,73,75,84,90,104 
 
7 studies9,23,47,49,52,55,65 
 
Inverse = RRSx2, AFx1, FRx2, HFPx2, HPLCx1 
Insignificant = HFPx5, FRx3 
73 = only 12/64 subjects with early AMD. 
Lack of significance may have been due to lack of 
power and/or L supplement use in 23, 52 & 65. 
Body fat Inverse in 2 studies40,68 2 studies46,68 All HFP. 
40 = association driven by body fat ≥ 27%. 
68 = association in M only.  
Body mass index Inverse in 7 
studies18,19,40,51,63,68,72 
 
8 studies18,19,46,67,68,71,73,99 
 
All HFP except 18 (= FR).  
18 & 68 = association in M only. 
19 = insignificant when BMI analysed as a 
continuous variable but significant with BMI split 
into two groups. 
40 = association driven by BMIs ≥ 29. 
Diabetes (presence of) Inverse in 3 studies25,58,63 1 study65 25 = colour matching 58 = AF 63 = HFP 65 = HFP  
Dietary lutein and/or 
zeaxanthin 
 
NB This doesn’t include 
any supplementation 
studies. 
Positive in 10 
studies15,19,22,24,63,68,70,71,99,101 
 
7 studies1,6,29,33,34,51,65 All HFP. 
68 = significant for Z only. 
1 = insignificant for both subject groups. 
29 = insignificant for both subject groups. 
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Variable 
Number of studies investigating the variable’s association 
with MPOD and finding: Comment 
Significant link (p < 0.05) Insignificant link (p > 0.05) 
Family history AMD Inverse in 1 study71 4 studies51,61,63,102 All HFP except 102 (= AF).  
61 = significantly higher serum L in family history 
subjects; authors suggest impaired retinal uptake in 
these subjects. 
Fat intake Positive in 1 study (M only)34 
Inverse in 1 study (F only)34 
 
7 studies22,24,33,63,68,71,101 All HFP. 
Foveal architecture 10 studies1,2,29,30,50,57,72,80,81,96 
 
6 studies48,50,72,75,88,96 1 = HFP, positive for foveal thickness in both 
subject groups. 
2,29,80 = HFP, foveal thickness (2 = positive for 
both subject groups; 29 = measurements on CHM 
subjects only). 
30 = FR, foveal cone photopigment distribution 
corresponded with MP distribution. 
50 = HFP, positive for foveal width & FPPS, not 
foveal thickness.  
57 = AF & HFP, foveal thickness.  
72 = HFP, positive significance for foveal width, not 
foveal thickness (except in non-white subjects).  
81 = AF, positive for foveal thickness in both 
subject groups. 
96 = HFP, positive for foveal thickness, not foveal 
width. 
48 = FR, foveal thickness. 
75 & 88 = RRS, foveal thickness. 
Fruit and vegetable intake Positive in 2 studies19,64 4 studies18,22,63,65 All HFP except 2 (= FR). 
64 included eggs.  
65 may have been influenced by concurrent low fat 
intake in high fruit & vegetable group.  
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Variable 
Number of studies investigating the variable’s association 
with MPOD and finding: Comment 
Significant link (p < 0.05) Insignificant link (p > 0.05) 
Gender M>F in 9 
studies5,8,18,34,39,54,64,71,103 
F>M in 1 study73 
29 studies4,9,10,11,19,22,24,26,43,44,45, 
46,47,51,66,67,72,75,80,81,82,89,91,94,95,101, 
102,105,107 
 
Significant = HFPx8, FRx2 
Insignificant = HFPx16, FRx7, AFx7, RRSx5 
73 = HFP, not significant in final multiple linear 
regression model. 
No significance in 19 & 24 despite higher L/Z intake 
in F than M. 
81 = insignificant for both subject groups. 
94 = only 23 subjects (5M, 18F) – lack of power?  
Genetics 5 studies17,33,56,60,99 None 17 = FR, gene study. 
33 = AF & HFP, 76 MZ twin pairs & 74 DZ twin 
pairs; MPOD more highly correlated in MZ than DZ, 
with MZ heritability estimates of 0.85 (AF) & 0.67 
(HFP). 
56 = HFP, statistically similar MPOD in 5/10 
identical twin pairs. 
60 = HFP, gene study. 
99 = HFP, spousal study; results were suggestive 
of genetics playing a bigger role than other factors 
in MPOD. 
High cholesterol Inverse in 2 studies71,80 4 studies18,58,61,63 All HFP except 58 (= FR). 
Iris colour Dark>Light in 7 
studies22,35,39,51,64,80,103 
 
 
10 studies10,11,18,26,28,43,44,63,71,72 
 
 
Significant = all HFP. 
Insignificant = HFPx7, FRx3, AFx2, RRSx2. 
18 & 43 = few dark compared with light – lack of 
power? 
Lack of significance in 44 confounded by a sample 
of black subjects with low MPOD. 
Lens changes Inverse in 2 studies8,37 4 studies23,25,43,67 8 = FR, lens optical density. 
37 = HFP, lens density in subjects aged ≥48 years. 
23 = HFP, cataract mean MPOD not different from 
normals, but lack of significance may have been 
due to lack of power and/or L supplement use. 
25 = colour matching, lens density. 
43 = HFP & RRS, lens status, but very few subjects 
graded higher than zero – lack of power? 
67 = HFP, lens thickness, inverse trend with MPOD 
but not significant. 
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Variable 
Number of studies investigating the variable’s association 
with MPOD and finding: Comment 
Significant link (p < 0.05) Insignificant link (p > 0.05) 
Race Whites>Non-whites in 1 study44 
Non-whites>Whites in 2 
studies72,102 
2 studies11,35 44 & 72 = HFP 102=AF 11=RRS 35=HFP 
Very few non-white subjects in 11 & 35 – lack of 
power? 
Serum lutein and/or 
zeaxanthin 
 
NB This doesn’t include 
any supplementation 
studies. 
Positive in 20 studies1,2,7,15,19,22, 
24,29,34,51,61,63,67,68,70,71,80,83,91,99 
Inverse in 1 study75 
8 studies1,18,29,33,52,66,69,98 Positive = HFPx17, AFx1, FRx1, HPLCx1 
Inverse = RRS 
Insignificant = HFPx7, FRx1  
1 = positive in non-RP subjects, insignificant in RP 
subjects.  
2 = positive in both subject groups.  
29 = positive in non-CHM subjects, insignificant in 
CHM subjects. 
18 = almost positive significance in M (p<0.06). 
Compared with the majority of significant studies, 4 
of the 8 insignificant studies had few subjects (29: 
n=13 [CHM subjects], 33: n=20 [10 MZ twins], 52: 
n=13, 69: n=4) – lack of power? 
Smoking Inverse in 9 
studies26,36,39,47,64,70,71,73,103 
19 studies10,11,18,19,22,24,26,28,43,44, 
51,63,65,67,72,81,82,91,102 
Inverse = HFPx7, AFx1, FRx1  
Insignificant = HFPx11, AFx6, FRx3, RRSx2 
70 = a link between serum L/Z & MPOD became 
insignificant for heavy smokers (≥20/day). 
11,19,43,44,65,72,91 = no or very few current 
smokers in these studies – lack of power? 
51 = significant association found for smokers vs 
non-smokers in ‘central dip’ MPOD profile. 
81 = insignificant for both subject groups. 
Sunlight exposure Inverse in 1 study64 2 studies22,63 All HFP.  
64 = < 3 hours sun exposure per day compared 
with > 3 hours or regular sunbathing/sunbeds. 
Supplement use of lutein 
(self-reported) 
 
NB This doesn’t include 
any supplementation 
studies. 
Positive in 3 studies11,13,44 1 study75 11 = RRS 13 = HPLC 44 = HFP 75 = RRS 
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Variable 
Number of studies investigating the variable’s association 
with MPOD and finding: Comment 
Significant link (p < 0.05) Insignificant link (p > 0.05) 
Visual function 
 
NB Includes visual 
function changes as a 
result of L/Z 
supplementation studies. 
Positive in 11 
studies29,38,41,62,74,76,77,78,87,88,97  
5 studies31,53,62,74,101 All HFP. 
29 = central target absolute threshold 
(measurement on CHM subjects only). 
38 = age-related visual sensitivity. 
41 = critical flicker fusion threshold. 
62 = various visual performance measures; MPOD 
associations with contrast sensitivity & VA. 
74 = various visual performance measures; some 
level of improvement in glare disability & light/dark 
adaptation after supplementation. 
76 = contrast thresholds. 
77 = temporal visual function. 
78 = Amsler grid, contrast sensitivity & VA in a 
group of subjects with AMD. 
87 & 88 = glare disability & photostress recovery. 
97 = photophobia light thresholds. 
31 = gap acuity & hyperacuity. 
53 = mesopic contrast acuity thresholds, light 
scatter & wavefront aberrations. 
101 = age-related visual sensitivity. 
 
* The marked decline in MPOD with age demonstrated in studies using RRS is the subject of much debate (see appendix 1). 
AF = autofluorescence. BMI = body mass index. CHM = choroideraemia. CSR = central serous retinopathy. DZ = dizygotic. F = females. FPPS 
= foveal pit profile slope. FR = fundus reflectometry. HFP = heterochromatic flicker photometry. HPLC = high-performance liquid 
chromatography. L = lutein. M = males. MPOD = macular pigment optical density. MZ = monozygotic. n = number of subjects. RP = retinitis 
pigmentosa. RRS = resonance Raman spectroscopy. VA = visual acuity. Z = zeaxanthin. 
Reference 1 = RP and healthy-eyed subject group. Reference 2 = Stargardt disease/cone-rod dystrophy and healthy-eyed subject group. 
Reference 29 = CHM and healthy-eyed subject group. Reference 80 = RP subject group. Reference 81 = CSR and healthy-eyed subjects. 
Other variables that have been investigated with respect to MPOD include alcohol consumption, blood pressure, education, exercise, melanin 
optical density, and refractive error. No significant associations have been observed.
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CHAPTER 2: INVESTIGATING THE USE OF A NOVEL MACULAR PIGMENT 
MEASUREMENT DEVICE 
 
In 2007, a new instrument for measuring MPOD was released into the ophthalmic 
domain. Though known by several different names (M|POD, MPS 9000, QuantifEYE), 
here it will be referred to as the MPS. At the beginning of the research period there was 
no published data on its repeatability, so it was important to establish how to use the 
MPS to its full potential, in order that data could be interpreted appropriately and future 
studies could be suitably designed. It was also hoped that this information would aid eye 
care practitioners using the device in clinical practice. This chapter describes the 
exploratory studies undertaken. 
 
2.1 Background and rationale 
The MPS (Tinsley Ophthalmic, Redhill, Surrey, UK) uses the well-established technique 
of HFP, but it employs a novel approach to this. Instead of responding to minimal or no 
flicker (as per traditional HFP), subjects respond to the appearance of flicker as the blue-
green alternation rate is decreased at 6 Hz from a starting level of 60 Hz (van der Veen et 
al. 2009a). This is above the critical flicker fusion frequency for the test conditions and 
therefore subjects do not perceive any flicker initially. Rather than the radiance of one 
wavelength being adjusted by the subject, a sequence of blue-green ratios is used, and 
these are inverse-yoked to ensure that overall luminance remains constant. The 
instrument also offers the possibility of estimating MPOD from a central measure alone, 
the peripheral measure being estimated from the age of the subject and their expected 
level of lens yellowing (Pokorny et al. 1987; van de Kraats and van Norren 2007; 
Makridaki et al. 2009). 
 
As mentioned above, there were no published studies on the repeatability of the MPS at 
the time of data collection, nor was there any information regarding the validity of using 
the age-based peripheral estimate to derive MPOD. Therefore, the aims of the studies 
described here were to gather such data. Unsurprisingly, there have been several papers 
published in the meantime (Makridaki et al. 2009; van der Veen et al. 2009a; Bartlett et 
al. 2010c; de Kinkelder et al. 2011). 
 
2.2 Methods 
SUBJECTS 
The main repeatability study involved 25 subjects (4 males, 21 females) who were 
recruited by email and by word-of-mouth, and consisted of staff and students from Aston 
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University. They were all in good general health, with ages ranging from 20 to 50 years 
(mean±SD: 29.4±6.9 years). Refractive error (best vision sphere, BVS) was between 
+1.00 DS and -10.50 DS (mean±SD: -2.25±3.25 DS – all eyes averaged). Visual acuity 
(VA) was measured under standard testing conditions using a logMAR letter chart; all 
eyes had VAs of 0.06 logMAR (Snellen 6/7.5+2) or better. Exclusion criteria were: age 
younger than 18 years; VA worse than 0.2 logMAR (Snellen 6/9.5); and the presence of 
any ocular disease. Nine of the subjects had prior experience with the MPS. 
 
Five subjects (1 male, 4 females), aged 24 to 61, took part in an additional ‘intense intra-
session repeatability’ study. Four were familiar with the MPS, and three had participated 
in the main study. Refractive error (BVS) was between plano and -7.50 DS, and all 
participants had VAs of -0.1 logMAR (Snellen 6/4.8) or better in the eye being tested (the 
right eye). 
 
A further five subjects (2 males, 3 females), aged 21 to 47, took part in an additional 
‘intense inter-session repeatability’ study. Three were familiar with the MPS, two had 
participated in the main study, and three had participated in the ‘intense intra-session 
repeatability’ study. Refractive error (BVS) was between +3.00 DS and -7.50 DS, and all 
participants had VAs of -0.04 logMAR (Snellen 6/6+2) or better in the eye being tested 
(the right eye). 
 
Aston University’s Ethics Committee approved the studies. All subjects signed an 
informed consent form, and all procedures adhered to the tenets of the Declaration of 
Helsinki. 
 
MPS 9000 
The MPS is a small, portable device (figure 2.1). It was set up on a standard adjustable 
table, and participants were directed to rest their forehead on the upper part of the 
instrument’s eyepiece, such that the eye being tested was comfortably centred on the 
appropriate target. The central target of the MPS is a one-degree circular stimulus 
composed of blue (465 nm) and green (530 nm) light-emitting diodes (LEDs) on a thirty-
degree, white LED-generated background (van der Veen et al. 2009a) – see figure 2.2. 
For the foveal (‘central’) test, each subject looked directly at the stimulus while the 
alternation rate between the blue and green was automatically ramped down from 60 Hz. 
At the point when they first became aware of the stimulus flickering, the subject pressed a 
response button and this plotted a point on a graph that was visible to the investigator via 
a linked computer screen. The process then started again. The first five responses were 
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used to determine the flicker sensitivity of the subject. Based on this, the main part of the 
test began, with the subject responding to their first perception of flicker throughout a 
series of green-blue ratios, until a V-shaped curve was plotted on the screen (figure 2.3) 
– the minimum point on the curve corresponds to equiluminance of the blue and green 
lights (van der Veen et al. 2009a). For the central test the minimum point on the curve 
represents the amount of blue light absorption at the fovea. The process was then 
repeated for the perifoveal (‘peripheral’) test: the subject’s gaze was directed to a larger 
target (1.75), red in colour and eight degrees eccentric from the centre, but the task was 
still to respond to their first awareness of flicker in the central stimulus. Accordingly, the 
minimum point on the peripheral curve represents the amount of blue light absorption at 
an eccentric retinal area assumed to have negligible MP. 
 
 
Figure 2.1 The MPS 9000 (also known as M|POD or QuantifEYE), shown with a linked 
computer that reveals the resulting MPOD output. 
 
 
Figure 2.2 The stimuli setup of the MPS (not to scale). 
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Figure 2.3 Example central (right) and peripheral (left) curves, as generated by a subject 
using the MPS. 
 
The minimum point on the peripheral curve should always be at a lower dB luminance 
than the central curve. This is because the x-axis represents the attenuation of the green 
part of the green-blue ratio (Makridaki et al. 2009; van der Veen et al. 2009a), so as the 
numbers increase along the axis, the amount of blue in the stimulus is increasing, while 
the amount of green is decreasing. Since more blue light is absorbed at the fovea than 
the perifovea (due to the presence of MP), a greater amount of blue light is required to 
achieve equiluminance. The difference between the central and peripheral minima 
determines the MPOD – the larger the difference, the higher the MPOD. 
 
All subjects were tested by the same investigator (OH). An explanation of how to perform 
the MPS test was given verbally, using a prepared instruction sheet (see appendix 3). 
Subjects wore their habitual distance spectacles/contact lenses, if appropriate, and the 
eye not being measured was occluded to avoid distraction. The test room was occupied 
only by the operator and subject, providing a quiet, calm environment. 
 
For the main 25-subject study, each participant had their right eye (RE) and left eye (LE) 
assessed alternately, with three repeats per eye in a single session, i.e. R1, L1, R2, L2, 
R3, L3. Before the central and peripheral tests of R1 and L1, a short practice test was 
conducted (the practice option is part of the MPS software). The RE was always tested 
first. Because the MPS generates a visible curve as subjects respond to flicker, it 
provides a way for the operator to assess whether the curve adheres to the expected V-
shape, and hence gives an indication as to the accuracy of the MPOD value produced. In 
this study, if the operator thought that the curve was of very poor quality, the result was 
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discarded and repeated. The total procedure time, including regular, short breaks to help 
avoid fatigue, was approximately 45 minutes. The decision to investigate within-session 
MPOD data (rather than between-session) was made for two reasons. Firstly, at the time, 
all the future research projects were anticipated to be cross-sectional in nature, and as 
such the aim was to determine how best to acquire an accurate, one-off measure. 
Secondly, other members of the research group were already conducting a clinically-
driven, inter-session repeatability study on the MPS, with one central and one peripheral 
measure being taken in one eye per subject (Bartlett et al. 2010c). 
 
For the ancillary intra-session study, each participant’s MPOD was measured ten times 
consecutively, in the RE only. The total procedure time, including regular, short breaks to 
help avoid fatigue, was between 45 and 60 minutes. 
 
For the ancillary inter-session study, each participant’s MPOD was measured five times 
consecutively, in the RE only. The same method was repeated 7 to 14 days later. Again, 
the total procedure time was between 45 and 60 minutes. 
 
CENTRE-ONLY MPOD 
As mentioned earlier (section 2.1), the MPS also offers an MPOD calculation using the 
central flicker test alone. To recap from chapter 1, the main purpose of the peripheral test 
is to cancel out the effect of any blue light absorption by the crystalline lens, so that the 
final density value is a representation of MP alone, and not MP plus lens yellowing. With 
the MPS, a fixed peripheral minimum is offered in place of a subject actually undertaking 
the peripheral flicker test. It is estimated on the basis of the subject’s age and their 
subsequent expected level of lens yellowing, generated from the data of Pokorny et al. 
(1987) and van de Kraats and van Norren (2007). The amount of lens yellowing is known 
to increase with age, and therefore the central and peripheral curves are expected to shift 
rightwards, as a result of the extra blue light absorption by the lens (Makridaki et al. 
2009). (To illustrate this, figure 2.4 shows the curves of two subjects, one aged 25 and 
the other aged 82, both with MPOD values of 0.41.) Because the perifoveal area at eight 
degrees eccentricity is assumed to be free from MP, and is therefore just a measure of 
lens yellowing, the peripheral minimum point is potentially predictable from the 
aforementioned data on the aging lens. This is how the MPS can provide an MPOD value 
from the subject undertaking the central test alone. 
 
In this chapter, MPOD derived using the measured central and measured peripheral 
minima will be referred to as CP (central and peripheral), whereas MPOD derived using 
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the measured central minimum and the age-based peripheral estimate minimum will be 
referred to as C-only (central testing only). 
 
 
Figure 2.4 Central (filled symbols) and peripheral (unfilled symbols) curves of two 
subjects, MM and TG.  
The horizontal distance between the central and peripheral minima are the same for both 
subjects and equate to an MPOD of 0.41, but the curves of the older subject are shifted 
rightwards as a result of the higher amount of age-related lens yellowing in this subject. 
(It is also evident that the temporal frequencies at which the minima occur are lower for 
the older subject.) The arrows indicate the minima for subject TG. NB The temporal 
frequency unit ‘dB’ is incorrect and should read ‘Hz’. (Reprinted from Makridaki et al. 
2009.) 
 
SAMPLE SIZE 
A sample size of 25 is in line with many studies examining the repeatability of MP 
measuring devices (e.g., Hammond et al. 1995; Ciulla et al. 2001b; de Kinkelder et al. 
2011). For the ancillary studies, the objective was to gain a slightly more in-depth 
understanding of how many measures ought to be conducted in a single session for 
consistent results, and since it was intended that the data would be analysed on an 
individual basis, it was felt that five subjects per study were sufficient to achieve this. 
 
STATISTICS 
Microsoft Excel and IBM SPSS were used for data analysis. The means of the three 
repeated MPOD measures were compared using a one-way repeated measures ANOVA 
or its non-parametric equivalent, as appropriate in terms of normality. Simple calculations 
were used to work out mean individual standard deviations and coefficients of variation, 
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and repeatability was determined using Bland-Altman analysis and plots (Bland and 
Altman 1986). CP and C-only comparisons were made using paired-samples t-tests or 
the non-parametric equivalent (as appropriate), along with Pearson’s r or Spearman’s rho 
correlations and Bland-Altman analysis. Interocular MPOD comparisons were 
approached in the same way. 
 
NB In every study chapter (chapters 2 to 8), a p-value of less than 0.05 was considered 
statistically significant, and for all t-tests and correlations (and their non-parametric 
equivalents), the two-tailed significance level was used. 
 
2.3 Results 
MEAN MPOD AND WITHIN-SESSION REPEATABILITY 
Table 2.1 is a summary of the mean MPODs for the 25 participants under the various test 
conditions. Also shown are the results of the analyses conducted to assess whether any 
statistically significant differences existed between the means of the repeated MPOD 
measurements; there appeared to be no such differences, indicating an absence of any 
overall learning or fatigue effect throughout the measurements. 
 
Test condition 
Mean (±SD) MPOD Repeated measures analysis 
Measure 1 Measure 2 Measure 3 Statistic  Significance (p) 
CP RE 0.36 ± 0.17 0.31 ± 0.13 0.32 ± 0.14 2 = 3.098 0.213 
CP LE 0.33 ± 0.14 0.35 ± 0.15 0.32 ± 0.13 F = 2.943* 0.073 
C-only RE 0.39 ± 0.15 0.37 ± 0.13 0.36 ± 0.14 2 = 1.914 0.384 
C-only LE 0.37 ± 0.14 0.36 ± 0.13 0.36 ± 0.14 F = 0.390 0.679 
 
Table 2.1 Mean MPODs for 25 subjects (as determined using the MPS), plus information 
on whether the three means within each test condition were significantly different from 
one another.  
CP = central and peripheral testing derived MPOD. C-only = central testing only derived 
MPOD (peripheral estimate provided by the MPS, based on subject age). RE = right eye. 
LE = left eye. 
 ‘F’ refers to a one-way repeated measures ANOVA, which was used where each data 
set was normally distributed. Otherwise, Friedman’s ANOVA (‘2’) was used. 
*For CP LE, the assumption of sphericity was not met according to Mauchly’s test, so 
with the sample size in mind (n=25), multivariate test statistics were used for 
interpretation. 
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The mean individual standard deviations of the MPOD values are given in table 2.2 for 
each test condition. In other words – taking ‘CP RE’ as an example – the standard 
deviation of each individual’s three CP RE MPOD values was worked out, followed by 
calculation of the mean of all 25 standard deviations. Also shown are the mean individual 
coefficients of variation, calculated from the aforementioned individual standard 
deviations, and divided by the mean of an individual’s three MPOD values. Of note, the 
LE statistics were lower than those of the RE, and similarly, the C-only statistics were 
lower than the CP statistics. Paired-samples t-tests revealed that these differences were 
statistically significant (p<0.01) for all but CP RE versus CP LE, yet even these 
differences were approaching significance (p=0.055 for standard deviation and p=0.067 
for coefficient of variation) – see table A4.1 in appendix 4 for details. 
 
Test condition 
Mean SD (±SD) 
between measures 
1, 2 and 3 
Mean CV (±SD) 
between measures 
1, 2 and 3 (%) 
CP RE 0.063 ± 0.047 20.0 ± 12.6 
CP LE 0.047 ± 0.030 14.9 ± 9.3 
C-only RE 0.038 ± 0.027 11.0 ± 6.9 
C-only LE 0.024 ± 0.021 6.3 ± 5.4 
 
Table 2.2 The means of the individual standard deviations and the individual coefficients 
of variation (CV) of three repeated MPOD measurements in the 25 subjects, 
demonstrated for each of the four test conditions. 
 
Accurate analysis of test-retest data can be achieved using the coefficient of repeatability 
(CR) (Bland and Altman 1986), which gives the 95 percent confidence limits for the 
amount of difference between two sets of results. It is calculated as 1.96 multiplied by the 
standard deviation of the differences between two sets of data, and indicates the amount 
of change that can occur between readings and still be classed as measurement noise. 
The within-session CRs for MPOD values measured with the MPS are shown in table 2.3. 
Taking the first and second CP RE tests as an example, the data suggests that when the 
same operator is taking consecutive MPS readings within the same session, MPOD 
differences of less than or equal to 0.25 are not clinically significant (figure 2.5). 
Analogous to the mean individual standard deviations and coefficients of variation, the LE 
MPOD values had consistently better repeatability than the RE, and the C-only MPOD 
values had consistently better repeatability than the CP MPOD values.  
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Comparison Mean difference 
SD of mean 
difference 
Coefficient of 
repeatability 
CP R1 – R2 0.049 0.128 0.25 
CP R2 – R3 -0.008 0.085 0.17 
CP L1 – L2 -0.018 0.092 0.18 
CP L2 – L3 0.032 0.072 0.14 
C-only R1 – R2 0.022 0.068 0.13 
C-only R2 – R3 0.002 0.058 0.11 
C-only L1 – L2 0.008 0.043 0.08 
C-only L2 – L3 -0.002 0.046 0.09 
 
Table 2.3 Determination of coefficient of repeatability (CR) values for the MPS – see text 
for details.  
R1, L2, etc. = right eye measure 1, left eye measure 2, etc. 
 
 
Figure 2.5 Bland-Altman plot representing the difference in CP MPOD readings between 
measures R1 and R2, compared with the mean of both measures.  
The solid line represents the mean difference, and the dashed lines represent the 95% 
confidence limits. NB There are two overlapping points. 
 
CP MPOD VERSUS C-ONLY MPOD 
Looking at table 2.1, it appears that the mean CP MPOD was always lower than the C-
only MPOD. Paired-samples t-tests and Wilcoxon signed rank tests (as appropriate) 
comparing the CP and C-only mean MPODs did confirm this in most cases (see table 
2.4). Regardless of these differences, however, the two methods were, unsurprisingly 
(given that the central reading was common to both measures), highly correlated in all 
cases (table 2.4), thus suggesting a possible systematic difference. This was investigated 
further by calculating the 95 percent limits of agreement for CP and C-only MPOD (table 
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2.5), as per Bland-Altman analysis (Bland and Altman 1986), i.e., 95 percent of CP/C-
only differences are expected to lie between these limits. While the mean differences 
show that CP MPOD is consistently lower than C-only MPOD, the limits of agreement 
indicate that one cannot dismiss the fact that some individuals’ MPODs were actually 
higher with the CP strategy (see figure 2.6 for details). That said, these limits of 
agreement should be regarded with caution, particularly for R1, as they are likely to be 
influenced by the weaker repeatability of the CP strategy. To help overcome this potential 
problem, the same analyses were conducted using the averages of the three CP and the 
three C-only MPOD values. The results are presented in table 2.6 and figure 2.7, and 
confirm a statistically significant difference between the means, along with a highly 
significant correlation, for both the RE and LE MPOD. Moreover, the Bland-Altman 
analyses emphasize the bias toward lower CP values, but indicate a good level of 
agreement (as determined by the 95 percent limits of agreement), hence indicating that a 
correction factor could possibly be made to determine actual MPOD (CP) when using the 
C-only test strategy. Nevertheless, these findings are only truly relevant if it is intended 
for participants in future studies to always complete three measurements. 
 
Comparison Difference (significance, p) Correlation (significance, p) 
CP and C-only R1 z = -1.856 (p = 0.063) r = 0.904 (p<0.0005) 
CP and C-only R2 t = -3.927 (p = 0.001) rho = 0.806 (p<0.0005) 
CP and C-only R3 z = -3.067 (p = 0.002) rho = 0.866 (p<0.0005) 
CP and C-only L1 z = -2.840 (p = 0.005) r = 0.895 (p<0.0005) 
CP and C-only L2 z = -1.07 (p = 0.285) r = 0.919 (p<0.0005) 
CP and C-only L3 z = -3.464 (p = 0.001) r = 0.929 (p<0.0005) 
 
Table 2.4 Comparisons of the mean CP MPOD with the mean C-only MPOD, along with 
the correlations between CP and C-only MPOD.  
‘t’ refers to a paired-samples t-test, which was used where the differences between each 
data set were normally distributed. Otherwise, the Wilcoxon signed rank test (‘z’) was 
used. ‘r’ refers to Pearson’s r, which was used where both data sets were normally 
distributed. Otherwise, Spearman’s rho was used. 
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Comparison 
Mean 
difference 
SD of mean 
difference 
SD x 1.96* 
95% limits of 
agreement^ 
CP – C-only R1 -0.027 0.072 0.141 -0.17 to 0.11 
CP – C-only R2 -0.055 0.070 0.137 -0.19 to 0.08 
CP – C-only R3 -0.045 0.059 0.116 -0.16 to 0.07 
CP – C-only L1 -0.037 0.064 0.126 -0.16 to 0.09 
CP – C-only L2 -0.012 0.058 0.114 -0.13 to 0.10 
CP – C-only L3 -0.045 0.051 0.099 -0.14 to 0.05 
 
Table 2.5 Determination of the 95% ‘limits of agreement’ for CP versus C-only MPOD. 
*This represents the 95% confidence limit, and means that 95% of the CP/C-only 
differences are expected to lie within the value calculated here. NB This is the same 
calculation as used to determine the CR, but with the CR, the mean difference should be 
close to zero, and so there is no need for any further arithmetic. 
^The limits of agreement are calculated as: mean difference ± (SD x 1.96), and reflect the 
mean difference bias, e.g., for CP – C-only L3, the CP MPOD is expected to be no more 
than 0.14 below the C-only MPOD, and no more than 0.05 above it (in 95% of cases). 
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Figure 2.6 Bland-Altman plots representing the difference between CP and C-only 
MPOD readings, compared with the mean of both measures.  
The solid line represents the mean difference, the short dashed lines represent the 95% 
limits of agreement, and the long dashed line is set to zero in order to aid visualization of 
how many CP readings were lower than C-only readings. NB There are several 
overlapping points in each plot. 
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 CP – C-only RE CP – C-only LE 
Difference (significance, p) t = -4.224 (p<0.0005) t = -3.632 (p = 0.001) 
Correlation (significance, p) r = 0.925 (p<0.0005) r = 0.947 (p<0.0005) 
Mean difference -0.045 -0.032 
SD of mean difference 0.053 0.044 
SD x 1.96 0.103 0.085 
95% limits of agreement -0.15 to 0.06 -0.12 to 0.05 
 
Table 2.6 Statistical analyses of CP versus C-only MPOD, using the averages of the 
three CP and the three C-only MPOD values. 
 
  
 
Figure 2.7 Bland-Altman plots representing the difference against mean for the combined 
CP and C-only MPOD readings. 
 
INTEROCULAR COMPARISONS 
Paired-samples t-tests and Wilcoxon signed rank tests (as appropriate) comparing right 
and left mean MPODs showed no statistically significant interocular differences (see table 
A4.2 in appendix 4 for details). Interocular correlations were also high, with Pearson’s 
r/Spearman’s rho values ranging from 0.66 to 0.85 for the CP data, and from 0.87 to 0.92 
for the C-only data (p<0.0005 in all cases – see table A4.2 in appendix 4). The slightly 
weaker correlations for the CP interocular MPOD are probably a manifestation of the 
poorer repeatability of the CP data in general. Indeed, Bland-Altman constructions 
revealed a similar pattern; C-only interocular agreement was better than CP, with both 
methods showing increasing interocular agreement for the later measurements (see table 
2.7). To help remove some of the possible repeatability bias, the same analyses were 
conducted using the averages of the three RE and the three LE values. The results are 
presented in table 2.8 and figure 2.8, and confirm the lack of statistical difference 
between the right and left means, combined with a very high correlation, and a good level 
of interocular agreement as determined by the 95 percent confidence limits, for the CP 
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and C-only MPOD. The confidence limits also appear to be within the expected variation 
for repeated measurements (table 2.3), so taken together with the other statistics, it 
would appear that an MPS MPOD measurement in one eye alone should accurately 
reflect MPOD in the opposite eye too (but see discussion). 
 
Comparison 
Mean 
difference 
SD of mean 
difference 
SD x 1.96 
CP R1 – L1 0.026 0.123 0.241 
CP R2 – L2 -0.041 0.101 0.198 
CP R3 – L3 -0.001 0.076 0.149 
C-only R1 – L1 0.016 0.076 0.150 
C-only R2 – L2 0.002 0.053 0.104 
C-only R3 – L3 -0.002 0.050 0.098 
 
Table 2.7 Determination of the 95% confidence limits (i.e., SD x 1.96) for RE versus LE 
MPOD, i.e., 95% of R/L differences are expected to lie within the calculated value. 
 
 CP RE – LE  C-only RE – LE 
Difference (significance, p) t = -0.637 (p = 0.530) t = 0.651 (p = 0.521) 
Correlation (significance, p) r = 0.911 (p<0.0005) r = 0.947 (p<0.0005) 
Mean difference -0.008 0.006 
SD of mean difference 0.057 0.044 
SD x 1.96 0.111 0.087 
 
Table 2.8 Statistical analyses of RE versus LE MPOD, using the averages of the three 
RE and the three LE MPOD values. 
 
  
 
Figure 2.8 Bland-Altman plots representing the difference against mean for the combined 
RE and LE MPOD readings. 
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ANCILLARY INTRA-SESSION STUDY 
The aim of this smaller study was to investigate the variation in results of ten intra-
session MPOD measurements in a row, in an attempt to provide some further insight into 
how many repeat measures need to be carried out on the MPS before consistent data is 
obtained. For each of the five participants, running means, standard deviations and 
coefficients of variation were calculated over the course of the ten measures (table 2.9). 
 
Observation of the resulting data showed no clear set pattern for when the above-
mentioned consistent data was achieved. Only one participant’s MPOD standard 
deviation and coefficient of variation decreased throughout the ten measures (subject 1). 
For the rest the figures seemed reasonably stable by two to four measures. For one 
subject there was a considerable amount of CP MPOD inconsistency all the way through, 
but nevertheless, the standard deviations and coefficients of variation still reached a 
plateau early on (subject 4). As per the earlier studies, CP MPOD was subject to more 
disparity than C-only MPOD. For the most part, this was probably just a consequence of 
having two variables in play (i.e., C and P) rather than one (see discussion), but for 
subject four it would seem that it was a specific difficulty with the peripheral task, since 
their C-only data is as good as the other subjects. 
 
Despite the standard deviation and coefficient of variation calculations, it was probably 
the simplest marker that proved to be the most informative, namely the running MPOD 
mean. For all subjects, i.e., including one and four, the running mean was within 0.05 
units of the final MPOD mean (at measure ten) by measure three of the CP data, and by 
measure two of the C-only data. 
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 MEASURE 
1 2 3 4 5 6 7 8 9 10 
  CENTRE AND PERIPHERAL 
S
u
b
je
c
t 
1
 
MPOD 0.55 0.26 0.36 0.46 0.46 0.36 0.41 0.31 0.41 0.41 
Running mean MPOD N/A 0.41 0.39 0.41 0.42 0.41 0.41 0.40 0.40 0.40 
Running SD N/A 0.21 0.15 0.13 0.11 0.10 0.09 0.09 0.09 0.08 
Running CV (%) N/A 50.6 37.8 30.7 26.6 25.0 22.8 23.5 21.9 20.6 
S
u
b
je
c
t 
2
 
MPOD 0.26 0.26 0.22 0.26 0.26 0.26 0.26 0.31 0.31 0.26 
Running mean MPOD N/A 0.26 0.25 0.25 0.25 0.25 0.25 0.26 0.27 0.27 
Running SD N/A 0 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 
Running CV (%) N/A 0 9.4 8.0 7.1 6.4 5.9 9.2 10.4 9.9 
S
u
b
je
c
t 
3
 
MPOD 0.50 0.46 0.41 0.46 0.41 0.41 0.36 0.46 0.36 0.41 
Running mean MPOD N/A 0.48 0.46 0.46 0.45 0.44 0.43 0.43 0.43 0.42 
Running SD N/A 0.03 0.05 0.04 0.04 0.04 0.05 0.04 0.05 0.05 
Running CV (%) N/A 5.9 9.9 8.1 8.6 8.5 10.7 10.2 11.3 10.7 
S
u
b
je
c
t 
4
 
MPOD 0.26 0.12 0.22 0.36 0.26 0.07 0.31 0.07 0.22 0.02 
Running mean MPOD N/A 0.19 0.20 0.24 0.24 0.22 0.23 0.21 0.21 0.19 
Running SD N/A 0.10 0.07 0.10 0.09 0.11 0.10 0.11 0.10 0.11 
Running CV (%) N/A 52.1 36.1 41.4 35.4 48.8 44.8 52.8 49.1 59.8 
S
u
b
je
c
t 
5
 
MPOD 0.36 0.26 0.31 0.31 0.26 0.22 0.26 0.26 0.31 0.26 
Running mean MPOD N/A 0.31 0.31 0.31 0.30 0.29 0.28 0.28 0.28 0.28 
Running SD N/A 0.07 0.05 0.04 0.04 0.05 0.05 0.04 0.04 0.04 
Running CV (%) N/A 22.8 16.1 13.2 13.9 17.3 16.4 15.6 14.9 14.4 
  CENTRE-ONLY 
S
u
b
je
c
t 
1
 
MPOD 0.53 0.38 0.38 0.43 0.48 0.38 0.43 0.38 0.43 0.43 
Running mean MPOD N/A 0.46 0.43 0.43 0.44 0.43 0.43 0.42 0.42 0.43 
Running SD N/A 0.11 0.09 0.07 0.07 0.06 0.06 0.06 0.05 0.05 
Running CV (%) N/A 23.3 20.1 16.4 14.8 14.7 13.4 13.3 12.4 11.7 
S
u
b
je
c
t 
2
 
MPOD 0.24 0.24 0.19 0.24 0.24 0.24 0.24 0.24 0.24 0.24 
Running mean MPOD N/A 0.24 0.22 0.23 0.23 0.23 0.23 0.23 0.23 0.24 
Running SD N/A 0 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 
Running CV (%) N/A 0 12.9 11.0 9.7 8.8 8.1 7.6 7.1 6.7 
S
u
b
je
c
t 
3
 
MPOD 0.53 0.53 0.48 0.48 0.43 0.48 0.43 0.48 0.43 0.48 
Running mean MPOD N/A 0.53 0.51 0.51 0.49 0.49 0.48 0.48 0.47 0.48 
Running SD N/A 0 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04 
Running CV (%) N/A 0 5.6 5.7 8.5 7.7 8.5 7.9 8.2 7.8 
S
u
b
je
c
t 
4
 
MPOD 0.24 0.24 0.24 0.29 0.29 0.29 0.29 0.24 0.29 0.24 
Running mean MPOD N/A 0.24 0.24 0.25 0.26 0.27 0.27 0.27 0.27 0.27 
Running SD N/A 0 0 0.03 0.03 0.03 0.03 0.03 0.03 0.03 
Running CV (%) N/A 0 0 9.9 10.5 10.3 10.0 10.1 9.8 9.9 
S
u
b
je
c
t 
5
 
MPOD 0.24 0.29 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 
Running mean MPOD N/A 0.27 0.26 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
Running SD N/A 0.04 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
Running CV (%) N/A 13.3 11.2 9.9 8.9 8.2 7.6 7.2 6.8 6.5 
 
Table 2.9 Intra-session MPOD values for five subjects performing ten measurements in a 
row, along with a running mean, standard deviation and coefficient of variation. 
Example: Running mean at measure 3 = mean MPOD of measures 1-3. Running SD at 
measure 3 = SD of measures 1-3. Running CV = Running SD at measure 3/Running 
mean at measure 3 (x100 for percentage). 
 
ANCILLARY INTER-SESSION STUDY 
It was suggested that a small inter-session repeatability study would be an additional 
helpful way of determining how many repeat readings ought to be taken for reliable 
MPOD data. Inter-session CRs were calculated based on: (1) just the first MPOD reading 
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at each visit, (2) the average of the first two readings at each visit, (3) the average of the 
first three readings at each visit, and so on up to the average of all five readings (table 
2.10). For CP and C-only MPOD, it appears that by three measures, the CR is low and 
stable. 
 
 Mean difference 
visit 1 – visit 2 
SD of mean 
difference 
Coefficient of 
repeatability 
C
P
 
Measure 1 only -0.040 0.085 0.17 
Average of measures 1-2 -0.035 0.048 0.09 
Average of measures 1-3 -0.020 0.030 0.06 
Average of measures 1-4 -0.032 0.034 0.07 
Average of measures 1-5 -0.029 0.033 0.07 
C
-o
n
ly
 
Measure 1 only -0.010 0.065 0.13 
Average of measures 1-2 -0.010 0.029 0.06 
Average of measures 1-3 -0.013 0.014 0.03 
Average of measures 1-4 -0.022 0.015 0.03 
Average of measures 1-5 -0.022 0.016 0.03 
 
Table 2.10 Determination of inter-session CR values (calculated as 1.96 multiplied by the 
standard deviation of the mean difference) for the MPS (n=5) – see text for details. 
 
2.4 Discussion 
The exploratory investigations described in this chapter were designed to find out how to 
use the MPS to its full potential, in order that meaningful, reliable results on an 
individual’s MPOD would be achievable for future studies. 
 
With the CP MPS testing strategy, the mean MPOD for 25 subjects ranged from 
0.31±0.13 (R2) to 0.36±0.17 (R1). These values are largely in line with previously 
reported MPS means: 0.34±0.17 (n=5616 – Makridaki et al. 2009), 0.40±0.15 (n=26 – 
van der Veen et al. 2009a), 0.40±0.17 (n=40 – van der Veen et al. 2009c), 0.35±0.14 
(n=40 – Bartlett et al. 2010c), 0.39±0.17 (n=23 – de Kinkelder et al. 2011). With the C-
only strategy, the mean MPOD ranged from 0.36±0.14 (R3 and L3) to 0.39±0.15 (R1). 
This is in line with the only other reported C-only mean of 0.35 (SD unknown) (Makridaki 
et al. 2009). 
 
In a study by van der Veen et al. (2009a), 26 subjects repeated MPS measurements (CP) 
five times in a single session, and the mean individual standard deviation was 
0.067±0.033. The results of the present investigation are not directly comparable 
because there were only three repeats per eye, and the same eye was not tested 
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consecutively. Nevertheless, the figures are very similar, with the CP RE mean individual 
standard deviation being 0.063±0.047. Nolan et al. (2004), using another HFP device, 
took six MPOD readings in a single session. Their 100 participants produced a mean 
coefficient of variation of 16.14%, which is slightly lower than the CP RE variation in this 
study (20.0%), but again the results are not directly comparable.  
 
In the other test conditions (CP LE, C-only RE, C-only LE), the mean individual standard 
deviations and coefficients of variation decreased (see table 2.2), which seems to 
indicate, firstly, that subjects were better (or at least more consistent) at completing the 
MPS task after the first measure, and secondly, that the C-only strategy produces more 
repeatable MPOD results than the CP strategy. The latter of these findings may be the 
result of the C-only MPOD having just one variable in play (i.e., the central minimum) 
rather than the two variables of CP MPOD (i.e., the central and peripheral minimum), or it 
could be that participants found the central test less demanding – and hence more 
repeatable – than the peripheral test, or it might be a combination of both these things. To 
assess these possibilities, the original central and peripheral minimum values were 
considered separately. The resulting mean individual standard deviations and coefficients 
of variation are given in table 2.11. It appears that the peripheral values are more variable 
than the central values. On comparing the means statistically, though, the differences 
were significant only for the LE coefficients of variation (t(24) = -2.563, p=0.017). This 
would seem to suggest that it is probably the combined effect of the C-only MPOD having 
just the one variable involved, and the central test giving slightly more consistent results, 
that leads to its overall better repeatability.  
 
Test condition Mean (±SD), dB 
Mean SD (±SD) between 
measures 1, 2 and 3 
Mean CV (±SD) between 
measures 1, 2 and 3 (%) 
Minimum C RE 6.13 ± 0.54 0.16 ± 0.11 2.6 ± 1.7 
Minimum P RE 4.77 ± 0.28 0.18 ± 0.12 3.7 ± 2.5 
Minimum C LE 6.11 ± 0.52 0.10 ± 0.08 1.6 ± 1.4 
Minimum P LE 4.72 ± 0.24 0.15 ± 0.14 3.1 ± 2.7 
 
Table 2.11 The means of the individual standard deviations and the individual coefficients 
of variation of three repeated central (C) and peripheral (P) minimum measures, 
demonstrated for the RE and LE. The means of the minimum values are also provided 
(second column) to help put the subsequent standard deviations and coefficients of 
variation into context. 
 
 56 
The within-session CRs determined in this study are not directly comparable with any 
previously published HFP data. Three studies have reported a within-session CR for non-
MPS HFP instruments, but these have been calculated on the basis of all repeat tests 
rather than concentrating on only two tests at a time. The reported formulae for these 
CRs vary slightly, or are not provided at all in one case (Nolan et al. 2004). Koh et al. 
(2004) took five consecutive MPOD readings, and the CR was 0.035±0.016 (RE) and 
0.041±0.014 (LE), calculated as 1.96.√2.SD2. Nolan et al. (2004) took six readings, and 
the CR was 0.025±0.011 (calculation not provided). Berendschot and van Norren (2005) 
took five readings, and the CR was 0.19, calculated as 2.√2.SD. In an attempt to 
compare the present study’s results, a formula advised by Bland and Altman (1999) for 
determining repeatability on replicate measures has been used: 1.96.√2.√variance. In 
other words, this means working out the variance of each subject’s three MPOD values, 
then calculating the mean within-subject variance and the square root of this, followed by 
multiplying by 2.77 (i.e., 1.96√2). Note that this formula is subtly different from that used 
by Berendschot and van Norren (2005), in so much as the mean within-subject standard 
deviation does not automatically equal the square root of the mean within-subject 
variance. The resulting CRs in the present study of 25 subjects were 0.22, 0.15, 0.13 and 
0.09 for CP RE, CP LE, C-only RE and C-only LE, respectively. (For the purposes of 
comparison, in table 2.12 these CR values are shown alongside the original CRs.) The 
figures are most similar to the CR of 0.19 obtained by Berendschot and van Norren, and 
given that the formulas are very similar, it seems that the MPS is as good as other HFP 
devices when it comes to within-session repeatability. 
 
Comparison 
Coefficient of 
repeatability 
CP R1 – R2 0.25 
CP R2 – R3 0.17 
CP R1 to R3 0.22 
CP L1 – L2 0.18 
CP L2 – L3 0.14 
CP L1 to L3 0.15 
C-only R1 – R2 0.13 
C-only R2 – R3 0.11 
C-only R1 to R3 0.13 
C-only L1 – L2 0.08 
C-only L2 – L3 0.09 
C-only L1 to L3 0.09 
 
Table 2.12 Coefficient of repeatability values for the MPS (n=25). 
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For the purpose of a one-off measurement, the CR values as found here (tables 2.3 and 
2.12) are probably acceptable. Given that the CR reduced with the later measurements, 
though, it would seem wise to take three consecutive measures, discarding the first of 
these and using the average of the last two to give the final MPOD value. However, this 
does seem a waste, particularly as the raw data showed that for many subjects the first 
MPOD value was very consistent with the following two. This requires further evaluation 
(see chapter 3). 
 
As explained above, there was no question that the C-only test strategy provided more 
consistent MPOD data than the CP strategy, so completing the central test alone would 
be ideal if it produces the same – or a reliably correctable – MPOD as using the central 
and peripheral tests. Unfortunately, this was not necessarily the case. C-only MPOD was 
a little higher than CP MPOD for most, but by no means all, individuals, and while there 
was certainly a good level of agreement between the two, the mean bias towards higher 
C-only values was not consistent (see table 2.5). The research group who developed the 
MPS provided MPS data on 5616 eyes and reported a CP/C-only correlation of 0.92 
(Makridaki et al. 2009), which is very similar to the correlations found in the current study, 
particularly when using the average of all three measurements (table 2.6). They also 
reported that the 95 percent limits of agreement were ±0.13, which are also very similar 
to those found here. There was a slight bias towards higher C-only MPOD in the 
Makridaki study, but not as much. This may be a reflection of the far greater number of 
eyes tested. Overall, the results are very alike, and the same conclusions are drawn; the 
C-only strategy is useful but should not replace the CP strategy unless a patient has 
trouble with the peripheral test. By completing both elements, any pessimist/optimist 
variations should be largely accounted for. For example, if a subject likes to be absolutely 
sure of flicker before pressing the response button, they are likely to do this for the central 
and the peripheral test. If only the central test is completed, though, this would result in a 
different MPOD than if they were to do both parts of the test, on account of their more 
conservative than normal approach. That said, for the purposes of monitoring MPOD over 
time, in response to supplementation for example, the central test alone could suffice, 
because the emphasis is on whether there is any change in MPOD, rather than whether 
the MPOD is a completely accurate representation of the subject’s actual MP. 
 
The statistical analyses looking at interocular MPOD for the 25 participants suggested 
that right and left MPOD were similar enough to be interchangeable, therefore negating 
the need to measure MPOD in both eyes of an individual. This confirms the findings from 
several earlier studies using other HFP instruments (Hammond and Fuld 1992; Beatty et 
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al. 2001; Lam et al. 2005; Neelam et al. 2006; Iannaccone et al. 2007; Schalch et al. 
2007). While most studies comparing right-left MPOD have used paired t-tests and/or 
Pearson correlations to look at a group as a whole, two have used independent t-tests to 
look at individual subject differences (Hammond and Fuld 1992; Landrum et al. 1997). 
They report finding one or two individuals with interocular MPOD differences, so although 
the vast majority of individuals appear to have similar MPOD in each eye, there are 
exceptions. With this in mind, in the preliminary analyses done early on in the research 
period, independent t-tests were conducted for every subject using their three right and 
left eye MPOD measurements. In hindsight, this was probably an inappropriate choice of 
analysis considering the paucity of measures. Nevertheless, the results were interesting; 
only two subjects had a statistically significant interocular difference and both of these 
subjects were anisomyopic, with a right-left BVS refractive error difference of at least 1.50 
DS. Moreover, each eye with the lower MPOD had the higher degree of myopia. Two 
other subjects had a refractive error difference of 1.50 DS (both myopic), and it seemed 
interesting to note that while not reaching statistical significance, the eyes with the lower 
MPOD again had the higher degree of myopia. 
 
The ancillary studies provided some further interesting information, although it should 
perhaps be acknowledged that the low subject numbers – which also included some 
individuals who were already familiar with the MPS – were a limitation for these studies, 
although similar numbers of subjects have been used in other HFP repeatability 
investigations (e.g., Wooten et al. 1999; Hammond and Caruso-Avery 2000; Mellerio et 
al. 2002; Koh et al. 2004; Tang et al. 2004; Hammond and Wooten 2005). For the first 
ancillary study, the overall finding was that no more than three consecutive measures are 
necessary for CP MPOD, and no more than two for C-only MPOD. Interestingly, this 
applied even to a subject who clearly found the peripheral test difficult (evident from the 
subject’s comments on the task and from several of their generated curves), thus 
implying that even when a patient’s data seems particularly variable, there is little point in 
attempting lots of repeat measures, provided that they do fully comprehend the task in 
hand. The second ancillary study found that for CP and C-only MPOD, the inter-session 
CR reached its lowest level by the time the average of three repeat readings had been 
taken.  
 
In conclusion, it appears that for accurate MPS-based MPOD values in a single session, 
measurements should be repeated three times, with either the average of all three 
readings being calculated or the average of the last two. Doing the latter may result in the 
dismissal of perfectly acceptable data, however. The C-only MPOD should not ordinarily 
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be a replacement for CP MPOD, but only one eye need be assessed, although both eyes 
may be necessary if the subject has an anisometropic refractive error.  
 
2.5 Summary 
This chapter has introduced a novel MPOD measuring instrument, the MPS 9000. 
Information on how to use it to its full potential has been established, showing that three 
measures of the central and peripheral tests are needed. However, the problem with 
having to repeat the test three times, albeit in only one eye, is that it is not particularly 
practical, especially in a time-pressured clinical setting. In the next chapter, an attempt is 
made to address this drawback, while also improving the overall reliability of the 
technique. 
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CHAPTER 3: IMPROVING THE REPEATABILITY OF THE MPS 9000  
 
From the exploratory studies described in the previous chapter, it seemed that three 
within-session measurements were required on the MPS for consistent MPOD values to 
be achieved, but following this procedure on everyone would be undeniably time-
consuming, especially where MPOD values in both eyes are required (approximately 20 
minutes per eye, on average). In this chapter, the curves and MPOD values from the 
original 25-subject study are re-examined to find out whether repeatability of the MPS can 
be improved further, and preferably with a shorter average test time.  
 
3.1 Background and rationale  
The MPS is predominantly marketed towards clinicians working in optometric practice. 
However, the studies described in chapter 2 demonstrated that three measurements 
were required for an accurate one-off MP measure, which may be too time-consuming for 
many clinicians and patients, even if technical support staff (e.g., optical assistants) are 
assigned to oversee the tests. In this secondary analysis of the original data, the aim was 
to determine if the repeatability of the MPS could be stabilised in fewer than three 
measures, thus making it more suitable for observing MPOD in the clinical (and research) 
environment. 
 
3.2 Methods 
SUBJECTS 
The data from the twenty-five subjects described in the earlier main repeatability study 
(section 2.2 in chapter 2) was reanalysed; no new subjects were recruited. 
 
POST DATA COLLECTION SECONDARY ANALYSIS 
As described in chapter 2, as subjects respond to flicker, the MPS generates a curve that 
is visible on a computer screen. It therefore provides a way for the operator to assess 
whether curves adhere to the expected V-shape (figure 3.1), and thus gives an indication 
as to the accuracy of the MPOD value produced. Many of the curves generated by the 
participants did not produce a perfect V-shape with a clearly defined minimum, but they 
were considered acceptable by the operator at the time, based on knowledge acquired 
from the product manual (‘MPOD QuantifEYE Reference Guide and Technician 
Training’). In this study the influence on repeatability of data from these less than optimal 
curves was assessed. Hence, further careful observation of all subjects’ curves took 
place; MPOD values generated from curves without a clear-cut minimum area were 
removed (see figure 3.2 for an example), and MPOD values generated from curves with 
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questionable minima were adjusted (see figures 3.2 to 3.4 and table 3.1). It should be 
noted that the product literature advises that MPOD values from graphs that are 
“scattered significantly” should not be relied upon as accurate, but the visual examples of 
unacceptable graphs are far removed from anything resembling a V-curve, and therefore 
it was difficult to know what the cut-off point for significant scatter was, particularly as very 
few subjects exhibited consistently ‘perfect’ curves. During collection of the data, the 
operator did discard and repeat any tests that were judged (subjectively) to be of 
unacceptable quality at the time. 
 
 
Figure 3.1 Example of an optimal central curve and an optimal peripheral curve – both V-
shaped with well-defined minima. 
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Figure 3.2 Example of a less than optimal central curve (diamond points – right curve) 
and a peripheral curve (square points – left curve) with two possible minima.  
The central curve is less than optimal because it has several points all with similar flicker 
frequencies to the computer-chosen exact minimum at 6.80 dB, rather than an isolated, 
definite minimum. An MPOD value generated by a curve such as this would be removed 
from the repeatability analysis. The peripheral curve has an exact minimum at 4.50 dB 
but, judging by eye, its right adjacent point has a very similar flicker frequency that could 
also be argued to be a minimum (at 4.70 dB). An MPOD value generated by a curve such 
as this would be adjusted, by recalculation using a peripheral minimum of 4.60 dB, i.e., 
the mean of these two points. 
 
 
Figure 3.3 Example of a central and peripheral curve, both with two possible minimum 
points (see figure 3.2 for details).  
The dashed lines indicate the adjusted minima (dB): 4.70 for the peripheral curve and 
6.40 for the central curve. 
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Figure 3.4 Example of a central curve with a questionable minimum.  
There is a larger than usual drop in flicker frequency between the minimum and the 
previous point. On repeat testing, experience dictates that points like this normally prove 
to be anomalies resulting from a subject’s lapse in concentration, with the true minimum 
occurring at the next point (5.50 dB in this case). The adjustments, however, would be 
cautious, with the dashed line indicating an adjustment to 5.40 dB and not 5.50 dB. 
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Difference:  
C min – P min 
MPOD 
Difference:  
C min – P min 
MPOD 
0.1 0.02 2.1 0.5 
0.2 0.05 2.2 0.53 
0.3 0.07 2.3 0.55 
0.4 0.1 2.4 0.58 
0.5 0.12 2.5 0.6 
0.6 0.14 2.6 0.62 
0.7 0.17 2.7 0.65 
0.8 0.19 2.8 0.67 
0.9 0.22 2.9 0.7 
1.0 0.24 3.0 0.72 
1.1 0.26 3.1 0.74 
1.2 0.29 3.2 0.77 
1.3 0.31 3.3 0.79 
1.4 0.34 3.4 0.82 
1.5 0.36 3.5 0.84 
1.6 0.38 3.6 0.86 
1.7 0.41 3.7 0.89 
1.8 0.43 3.8 0.91 
1.9 0.46 3.9 0.94 
2.0 0.48 4.0 0.96 
 
Table 3.1 Conversion table for MPS-based MPOD.  
New MPOD values, following adjustment (by eye) of minimum points on the curves, were 
calculated as follows: 
Difference between central (C) minimum and peripheral (P) minimum = X 
X = MPOD, found by referring to the table above. 
Example: C min = 6.1 dB, P min = 4.7 dB; 6.1 – 4.7 = 1.4; 1.4 = MPOD value of 0.34. 
This conversion table was produced after much practice on the MPS. 
 
MASKING 
To avoid any potential bias, each curve was considered separately without looking at the 
same participant’s other MPOD values. 
 
STATISTICS 
Microsoft Excel and IBM SPSS were used for data analysis. Simple calculations were 
used to work out mean individual standard deviations and coefficients of variation, and 
repeatability was determined using Bland-Altman analysis and plots (Bland and Altman 
1986). The differences between the resulting CRs before and after data 
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removal/adjustment were assessed by a one-way repeated measures ANOVA (each data 
set was normally distributed). 
 
3.3 Results 
The mean individual standard deviations of the MPOD values are given in table 3.2 for 
each test condition. In other words – taking ‘CP RE’ as an example – the standard 
deviation of each individual’s three CP RE MPOD values was worked out, followed by 
calculation of the mean of all 25 standard deviations. After adjustment of MPOD values 
as appropriate (minima adjustment), the standard deviations were slightly lower in all 
categories. Note that three MPOD values were obtained for each test condition and no 
data was removed for this analysis. Also shown are the mean individual coefficients of 
variation, calculated from the aforementioned individual standard deviations, and divided 
by the mean of an individual’s three MPOD values. Again, the figures were lower after 
data adjustment. 
 
Test 
condition 
Mean SD between 
measures 1, 2 and 3 
Mean SD after 
minima adjustment 
Mean CV between 
measures 1, 2 and 3  
Mean CV after 
minima adjustment 
CP RE 0.063 ± 0.047 0.060 ± 0.045 20.0 ± 12.6 18.6 ± 11.7 
CP LE 0.047 ± 0.030 0.041 ± 0.028 14.9 ± 9.3 13.2 ± 8.6 
C-only RE 0.038 ± 0.027 0.034 ± 0.027 11.0 ± 6.9 9.8 ± 6.9 
C-only LE 0.024 ± 0.021 0.023 ± 0.019 6.3 ± 5.4 6.1 ± 4.9 
 
Table 3.2 The means of the individual standard deviations and the individual coefficients 
of variation (%) of three repeated MPOD measurements in the 25 subjects, before and 
after minima adjustment, demonstrated for each of the four test conditions. 
 
The within-session CR values for MPOD, before and after data removal and minima 
adjustment, are shown in table 3.3. A one-way repeated measures ANOVA was 
conducted to analyse the original CR values (O), the CR values after data removal (R), 
and the CR values after data removal and adjustment (RA). Mauchly’s test indicated that 
the assumption of sphericity was not met, and as a result, degrees of freedom were 
corrected using the Greenhouse-Geisser estimate of sphericity. There was a statistically 
significant improvement in repeatability (F(1.2,8.4) = 11.09, p=0.008). Pairwise 
comparisons (Bonferroni corrected) indicated a statistically significant difference between 
O and RA (p=0.017), and between R and RA (p=0.045), but not between O and R 
(p=0.095). Figures 3.5 and 3.6 illustrate in graphical format (Bland-Altman plots) the 
repeatability for the various data sets. 
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Comparison 
Coefficient of repeatability 
Number of 
MPOD values 
from a total of 
50 removed  
Remainder of 
MPOD values 
with minima 
adjusted  
Original (O) 
After data 
removal (R) 
After data 
removal & 
adjustment of 
minima (RA) 
CP R1, R2 0.25 0.16 0.16 11 (n=10) 7 (n=7) 
CP R2, R3 0.17 0.15 0.12 7 (n=5) 17 (n=15) 
CP L1, L2 0.18 0.15 0.13 6 (n=5) 18 (n=16) 
CP L2, L3 0.14 0.13 0.12 4 (n=3) 18 (n=16) 
C-only R1, R2 0.13 0.11 0.10 3 (n=3) 5 (n=4) 
C-only R2, R3 0.11 0.08 0.07 5 (n=5) 9 (n=7) 
C-only L1, L2 0.08 0.08 0.08 2 (n=2) 6 (n=5) 
C-only L2, L3 0.09 0.08 0.07 1 (n=1) 9 (n=8) 
 
Table 3.3 Coefficients of repeatability for the various data sets, before and after data 
removal and minima adjustment.  
n = number of subjects (out of 25). 
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ORIGINAL AFTER DATA REMOVAL AND ADJUSTMENT 
  
  
  
  
Figure 3.5 Bland-Altman plots representing the difference in CP MPOD readings 
between measures, compared with the mean of both measures.  
The solid line represents the mean difference, and the dashed lines represent the 95% 
confidence limits. NB There are several overlapping points in each plot. 
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ORIGINAL AFTER DATA REMOVAL AND ADJUSTMENT 
  
  
  
  
Figure 3.6 Bland-Altman plots representing the difference in C-only MPOD readings 
between measures, compared with the mean of both measures.  
The solid line represents the mean difference, and the dashed lines represent the 95% 
confidence limits. NB There are several overlapping points in each plot. 
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The original raw MPOD difference data was also considered. It was calculated that with 
the CP MPOD data, between 64 percent (R1 vs R2) and 80 percent (L2 vs L3) of 
participants’ MPOD values were within 0.09 of each other from one test to the next. With 
the C-only MPOD data, between 84 percent (R1 vs R2) and 92 percent (R2 vs R3, L1 vs 
L2, and L2 vs L3) were within 0.09 of each other from one test to the next. These 
reasonably high percentages imply that the CR values may be influenced by individuals 
who simply struggle to perform the flicker test well. Indeed, taking into account the 
removed MPOD values, plus the adjusted values, the above percentages increased to 
80-91% and 86-100%, for CP MPOD and C-only MPOD respectively. To explore this a 
little further, table 3.4 is a more subject-specific breakdown of where and how much data 
was removed. It shows that few subjects had more than one central minimum value or 
one peripheral minimum value removed, thus indicating that most subjects achieved at 
least two optimal central and peripheral curves per eye (albeit with some later 
adjustments), and this was seemingly irrespective of whether subjects had some previous 
experience of using the MPS or not. One subject, in particular, clearly struggled with the 
peripheral MPS task, resulting in the removal of five of their six peripheral curves. 
 
Number of minimum values removed: 0 1 2 3 4 5 6 
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) 
Total number of subjects 18 5 2 0 0 0 0 
Number/percentage subjects with 
previous experience 
7/78 1/11 1/11 0/0 0/0 0/0 0/0 
Number/percentage subjects with 
NO previous experience 
11/69 4/25 1/6 0/0 0/0 0/0 0/0 
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e
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Total number of subjects 15 7 2 0 0 1 0 
Number/percentage subjects with 
previous experience 
4/44 3/33 2/22 0/0 0/0 0/0 0/0 
Number/percentage subjects with 
NO previous experience 
11/69 4/25 0/0 0/0 0/0 1/6 0/0 
T
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Total number of subjects 12 7 3 2 0 0 1 
Number/percentage subjects with 
previous experience 
4/44 2/22 1/11 2/22 0/0 0/0 0/0 
Number/percentage subjects with 
NO previous experience 
8/50 5/31 2/13 0/0 0/0 0/0 1/6 
 
Table 3.4 The breakdown of how many minimum values were removed in the secondary 
analysis, and how many subjects were involved in these removals.  
Note that for the three central and peripheral tests carried out on each subject in each 
eye, there were six central and six peripheral minimum values per subject. 
 
 70 
3.4 Discussion 
This second-look study aimed to find ways of improving the repeatability of the MPS, as 
well as the time required to achieve any such improved repeatability, by examining in 
detail all the MPOD data curves generated by the 25 subjects from the original 
exploratory study (chapter 2). Subsequent removal and adjustment of certain curves took 
place, and the effect of doing so was assessed by means of various statistical indicators. 
 
In all four test conditions, minima adjustment alone successfully improved (i.e., reduced) 
the mean individual standard deviations and coefficients of variation of the three repeated 
MPOD measurements. This was encouraging, as it demonstrated that the adjustment 
technique (described in figures 3.2 to 3.4) could be beneficial. 
 
Accurate analysis of test-retest data is achieved using the CR, and in this respect, the 
results indicated that a statistically significant improvement in the CR could be obtained 
through the removal and adjustment technique. The weakest CR was between the first 
and second RE tests (0.25), using the central plus peripheral-based MPOD. The CR was 
reduced to 0.16 following removal of less than optimal data, although this involved a fairly 
high number of such removals (11 out of 50 MPOD values). Nevertheless, the techniques 
of removal and adjustment did improve the within-session repeatability of the MPS. 
 
Further examination of the data revealed that the majority of participants actually 
produced serial MPOD values within 0.09 of each other and, moreover, that after 
adjustment (if appropriate), all but a few subjects produced at least two optimal central 
and peripheral curves per eye. From all the data and experience gathered so far, an 
MPOD reading that is repeatable to within 0.09 seems like an acceptable limit of 
accuracy for a psychophysical task of this nature. Combined with the points already 
discussed, this leads to the following protocol suggestion for use in future studies: For 
reliable results, each subject should perform the central and peripheral test twice, even if 
the first curves are considered to be ‘perfect’. If there is a ≥0.4 dB difference between 
equivalent minimum readings (central or peripheral), or if one or more of the generated 
curves are less than optimal in appearance (and not amenable to adjustment), then a 
third central and/or peripheral test (as appropriate) should be completed. When a curve 
exhibits a poorly defined minimum (see figure 3.2), it should not be included in the final 
calculation of MPOD, but adjustment of a computer-produced minimum reading is 
acceptable when a curve has two or three very similar minimum points, or an anomalous 
minimum (see figures 3.2 to 3.4). This method will lead to most subjects having at least 
two good quality central and peripheral curves, and from these the accepted minima can 
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be averaged, followed by calculation of MPOD using the earlier established table (table 
3.1). At first glance this protocol may appear confusing. It is therefore explained in more 
detail, with examples, below. 
 
The reason for choosing a difference of 0.4 dB as the cut-off point at which a repeat test 
should be completed is because this equates to a 0.09 or 0.1 difference in MPOD (see 
table 3.1). It could have been decided to use a ≥0.1 difference in MPOD readings as the 
point at which to repeat a test. The problem with this, however, is that it requires both 
tests to be repeated (central and peripheral), which may be unnecessary. By 
concentrating on the individual curves (and their minimum values), the testing time can 
be reduced. 
 
Example 1. Subject A 
Test 
Minimum C 
(dB) 
Minimum P 
(dB) 
MPOD Quality of curves Removals/Adjustments 
1 6.1 4.7 0.34 Good C. Good P. None. 
2 6.6 4.7 0.46 Good C. Good P. None. 
3 6.2 - - Good C. None. 
 
Here, the first four curves from tests 1 and 2 are all of good quality, but the MPOD results 
show a difference of 0.12. However, as the two peripheral (P) minima are identical, 
repeating the peripheral test seems unnecessary. The MPOD difference originates from 
the 0.5 dB difference between the two central (C) minima. Therefore, only the central test 
need be repeated a third time. MPOD is then calculated as follows: 
Average minimum C = (6.1+6.6+6.2)/3 = 6.3. Average minimum P = 4.7. 
6.3 – 4.7 = 1.6, which corresponds to an MPOD of 0.38 (using table 3.1). 
 
Example 2. Subject B 
Test 
Minimum C 
(dB) 
Minimum P 
(dB) 
MPOD Quality of curves Removals/Adjustments 
1 6.6 4.7 0.46 Good C. Good P. Adjust C to 6.5 (2 mins). 
2 6.4 4.9 0.36 Good C. Poor P. Remove P. 
3 - 4.5 - Good P. None. 
 
Here, the second P curve is of poor quality and is therefore removed and repeated. The 
first C curve has two possible minima and is therefore adjusted to 6.5, but it does not 
require repeating a third time. MPOD is then calculated as follows: 
Average minimum C = (6.5+6.4)/2 = 6.45. Average minimum P = (4.7+4.5)/2 = 4.6. 
6.45 – 4.6 = 1.85, which corresponds to an MPOD of 0.445 (using table 3.1). 
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Example 3. Subject C 
Test 
Minimum C 
(dB) 
Minimum P 
(dB) 
MPOD Quality of curves Removals/Adjustments 
1 5.8 4.4 0.34 Good C. Good P. None. 
2 5.5 4.6 0.22 Good C. Good P. Adjust C to 5.6 (2 mins). 
 
Here, the MPOD results show a difference of 0.12. However, observation of the two C 
and two P minima reveals that they are within 0.4 dB of each other; the difference in 
MPOD stems from the fact that in test 2, the C minimum decreased by 0.3 dB (and by 0.2 
dB with adjustment), while the P minimum increased by 0.2 dB, so in truth (given that all 
four curves are of good quality) there is no need to repeat the tests a third time. MPOD is 
calculated as follows: 
Average minimum C = (5.8+5.6)/2 = 5.7. Average minimum P = (4.4+4.6)/2 = 4.5. 
5.7 – 4.5 = 1.2, which corresponds to an MPOD of 0.29 (using table 3.1). 
Note that even with adjustment of the second C minimum to 5.6 (resulting in an MPOD of 
0.24), the MPOD difference would still have been 0.1. Without paying attention to the 
individual C and P minima, this would have dictated that a third test be completed. This 
therefore emphasizes the importance of observing the C and P minima separately. 
 
In a clinical setting, this protocol, regardless of any improved patient test time, would 
probably be considered too convoluted, and the calculations themselves too time-
consuming. It might therefore be more appropriate to use a slightly different protocol, 
albeit resulting in one or two unnecessary tests: Each patient should perform the central 
and peripheral test twice, even if the first curves are considered to be ‘perfect’. If there is 
a ≥0.1 difference between MPOD readings, or if one or more of the generated curves are 
less than optimal in appearance, then a third central and peripheral test should be 
completed. The average of the two or three MPOD values should give an accurate one-
off measure of MP, unless many of the curves are poor or the MPOD values constantly 
variable, in which case it would be worth paying attention to the central curves and C-only 
MPOD readings to see whether the results are more consistent.  
 
In conclusion, although there is still an element of examiner subjectivity involved, 
following either of these protocols, the first one in particular, will improve within-session 
repeatability, and should in turn mean that smaller MPOD changes over time (estimated 
at ≥0.09) can be classed as clinically significant, unless the curves of a patient are 
especially poor or their MPOD values variable. It will also make the testing time quicker, 
because the originally suggested ‘three central and three peripheral tests for all’ (see 
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section 2.5 in chapter 2) will be unnecessary for many individuals. For an optometrist 
practice or similar, the time required will be akin to that of a comprehensive visual field 
test. 
 
3.5 Summary 
This chapter has provided further information on using the MPS to its optimal capability, 
repeatability-wise and time-wise, and evidence-based testing protocols have 
subsequently been introduced that will make the instrument more useful in the clinical 
and research environment. In the chapters that follow, the more research-suitable 
protocol will be used to study MPOD in a variety of subject groups and situations. 
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CHAPTER 4: ANISOMETROPIA AND MACULAR PIGMENT OPTICAL DENSITY 
 
Over the course of the preliminary work aimed at establishing how best to use the MPS 
(chapters 2 and 3), it was noted that the two subjects with the largest interocular MPOD 
difference were also considerably anisometropic; both were myopic with the higher 
refractive error eye having the lower MPOD. In this chapter, this potentially interesting 
finding is explored in detail. 
 
4.1 Background and rationale 
Anisometropia, the condition in which one eye has a different refractive error from the 
other eye, has not been examined with respect to interocular MP levels in any published 
research. Refractive error in general has been mentioned briefly (Ciulla et al. 2001a; 
Curran-Celentano et al. 2001), but no link with MP appears to have been found, and 
Neelam et al. (2006) looked in detail at a number of ocular biometric parameters (e.g., 
axial length, anterior chamber depth), but again there were no associations with MPOD. 
In an exploratory study for the present research, though, there was an indication that a 
link between anisometropia and MPOD may exist (see section 2.4 in chapter 2); while the 
vast majority of participants showed no statistically significant difference between right 
and left eye MPOD, two did, and of the background details recorded (age, gender, 
refractive error, race), it was noted that the only apparent distinguishing factor for these 
two individuals was an interocular refractive error difference of at least 1.50 DS. Both 
were myopic, and each subject’s eye with the lower MPOD had the higher level of 
myopia. Two other participants were anisometropic to the same degree, and they also 
showed a difference in right-left MPOD, and followed the same higher myopia, lower 
MPOD pattern, but the differences did not reach statistical significance.  
 
The investigation described here aimed to explore this potential anisometropia-MPOD 
link, with two main purposes in mind. Firstly, to establish whether MPOD ought to be 
measured in both eyes of an individual with a sizeable amount of anisometropia, and 
secondly, to see whether an association of lower MPOD with higher myopia (or lower 
hyperopia) exists beyond the two subjects discussed above. Such a result would perhaps 
be unexpected given the proposed protective effect of MP against AMD; if a hypothesis 
were to be suggested, it would likely anticipate a higher MPOD being associated with a 
higher level of myopia (or lower hyperopia), because AMD has been linked (albeit 
weakly) to hyperopia, not myopia, in many studies (Maltzman et al. 1979; Delaney and 
Oates 1982; Hyman et al. 1983; Sandberg et al. 1993; Chaine et al. 1998; AREDS 2000; 
Ikram et al. 2003; Xu et al. 2006; Fraser-Bell et al. 2010; Lavanya et al. 2010; Tao and 
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Jonas 2010; Xu et al. 2010). However, if the opposite were to be found, it could simply be 
that in a longer (i.e., more myopic) eye, the MP is stretched further apart, meaning that 
the foveal area of MPOD measured with the MPS is not a true reflection of the amount of 
MP in the central retina for these subjects. That said, the aforementioned study by 
Neelam et al. (2006) used an HFP device with a target the same size as used with the 
MPS, but they found no axial length association with MPOD. Nevertheless, observing 
MPOD in both eyes of a group of anisometropic individuals offered a unique opportunity, 
in that any between-subject variables that could unwittingly influence a study looking at 
MPOD and refractive error in general (e.g., diet, smoking, iris colour) were controlled for 
because the comparison was made within the same subject.  
 
4.2 Methods 
SUBJECTS 
Participants were predominantly identified by stored autorefraction data of undergraduate 
optometry students. Permission to view the clinical eye records (held within the 
university’s optometry clinic) of potential subjects was granted, and from these the 
individuals considered most suitable for the study were contacted by email. Suitable 
subjects were those with an interocular BVS difference of greater than 1.00 DS, 
astigmatism only up to a level that would be correctable by a daily disposable toric 
contact lens (CL), and VA better than 6/9.5, i.e., only mild amblyopia, if any. Ten subjects 
(5 males, 5 females) were eventually recruited. They were all in good general and ocular 
health, with ages ranging from 19 to 42 years (mean±SD: 27.2±6.9 years). Two of the 
subjects were those mentioned above as having demonstrated interocular MPOD 
differences in the MPS exploration study. The other two subjects with an appropriate level 
of anisometropia (from that study) were unavailable to take part in the current 
investigation.  
 
Aston University’s Ethics Committee approved the study. All subjects signed an informed 
consent form, and all procedures adhered to the tenets of the Declaration of Helsinki. 
 
REFRACTIVE STATUS 
Refractive error was determined with an open view autorefractor, the Shin-Nippon SRW-
5000 (Ryusyo Industrial Co. Ltd., Osaka, Japan), which has been shown to have very 
good validity and repeatability (Mallen et al. 2001). Five measures per eye were taken 
and averaged, with the resulting prescription being used to calculate the BVS (spherical 
power plus half the cylindrical power), which was between +4.00 DS and -10.50 DS (all 
eyes together) for the ten participants.  
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OCULAR DIMENSIONS 
Axial length (AL), corneal curvature (i.e., keratometry – K) and anterior chamber depth 
(ACD) were determined with a partial coherence laser interferometer, the Zeiss 
IOLMaster (Carl Zeiss, Jena, Germany), which is a non-contact technique that has been 
shown to have very good validity and repeatability (Vogel et al. 2001; Connors et al. 
2002; Santodomingo-Rubido et al. 2002; Kielhorn et al. 2003; Sheng et al. 2004). The 
averages of five AL measures, three K measures, and one ACD measure (five readings 
taken automatically in one measure) were calculated. 
 
CONTACT LENSES 
To avoid any interocular magnification differences caused by spectacle lenses, CLs were 
worn for measurement of MPOD. Experienced CL wearers inserted either their own 
lenses or daily disposable lenses of appropriate power. The investigator (OH) inserted 
daily disposable lenses of appropriate power for inexperienced CL wearers. Visual acuity 
was then measured under standard testing conditions using a logMAR letter chart; all 
eyes had VAs of 0.1 logMAR (Snellen 6/7.5) or better, except for one eye of one subject 
(VA 0.2, 6/9.5). 
 
MPS 9000 
For measurement of MPOD using the MPS, each subject received verbal instructions and 
completed a short practice test, after which the prior established protocol was used 
(chapter 3). Right and left eyes were assessed alternately; the right eye was always 
tested first. The averages of the central minima and peripheral minima were used to 
calculate MPOD. Using this technique, all subjects (and eyes) had two to three good 
quality central and peripheral curves to derive MPOD from. 
 
The total procedure time was between 45 and 60 minutes. 
 
SAMPLE SIZE 
A sample size of seven to twelve subjects was chosen on the basis of G*Power 3.1 
power analysis comparing two dependent means (two-tailed) and looking for 80 percent 
power at the five percent alpha significance level. An effect size of 1.3 was calculated on 
the basis of an estimated significant mean difference in MPOD of 0.08 between groups, a 
correlation of 0.9, and a standard deviation of 0.14 in both groups. This led to a sample 
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size of seven. Adjusting the potential correlation to 0.8, the effect size was 0.9, resulting 
in a sample size of 12. 
 
STATISTICS 
Microsoft Excel and IBM SPSS were used for data analysis. Mean values were compared 
using paired-samples t-tests (all data sets – including their differences – were normally 
distributed). Pearson’s r correlations were used to quantify the associations between 
MPOD, BVS, AL, ACD and K. 
 
4.3 Results 
Table 4.1 is a summary of means for MPOD and the refractive parameters assessed in 
this study of ten anisometropic individuals. The means of the right and left eyes are 
shown, along with the means of the most myopic(/least hyperopic) and least 
myopic(/most hyperopic) eyes. The table also shows the significance results of paired-
samples t-tests comparing the means. As expected, when comparing the most myopic 
eye with the least myopic eye, there were statistically significant differences in BVS and 
AL. In addition, there was a statistically significant difference for ACD, but not for K 
readings. It is clear from the table that interocular MPOD was not significantly different 
despite the interocular refractive error differences. Table 4.2 shows the mean differences 
for MPOD, BVS, AL, etc., along with the maximum and minimum differences. It can be 
seen that the averaged autorefractor results confirmed the anisometropic nature of the 
participants, with the mean anisometropic difference being 2.38 DS, and the minimum 
difference being 1.25 DS. All subjects met the refractive error criteria set out in the 
original recruitment process. 
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Variable 
Mean (±SD) 
RE 
Mean (±SD) 
LE 
Significance 
(p-value) 
Mean (±SD) 
‘myopic’ eye 
Mean (±SD) 
‘hyperopic’ 
eye 
Significance 
(p-value) 
MPOD 0.45 ± 0.18 0.43 ± 0.16 0.584 0.44 ± 0.17 0.44 ± 0.17 0.901 
BVS (DS) -2.68 ± 4.54 -2.80 ± 4.71 0.882 -3.93 ± 4.42 -1.55 ± 4.49 <0.0005 
AL (mm) 24.6 ± 1.73 24.7 ± 1.80 0.960 25.0 ± 1.72 24.3 ± 1.72 <0.0005 
ACD (mm) 3.60 ± 0.31 3.57 ± 0.33 0.284 3.62 ± 0.30 3.55 ± 0.34 0.012 
K (mm) 7.78 ± 0.27 7.77 ± 0.26 0.797 7.75 ± 0.26 7.79 ± 0.27 0.137 
 
Table 4.1 Interocular comparisons of mean MPOD and various refractive variables for ten 
anisometropic subjects.  
Paired-samples t-tests were used to assess the statistical significance of the differences 
between eyes. 
BVS = best vision sphere. AL = axial length. ACD = anterior chamber depth. K = corneal 
curvature (the average of the two principle meridians). ‘Myopic’ eye = the eye with the 
highest level of myopia or the lowest level of hyperopia. ‘Hyperopic’ eye = the eye with 
the lowest level of myopia or the highest level of hyperopia. 
 
Variable 
Mean difference (±SD) ‘myopic’ 
versus ‘hyperopic’ eye 
Maximum 
difference 
Minimum 
difference 
MPOD 0.003 ± 0.062 0.1 0.0 
BVS (DS) -2.38 ± 0.68 3.75 1.25 
AL (mm) 0.76 ± 0.29 1.13 0.35 
ACD (mm) 0.067 ± 0.068 0.220 0.010 
K (mm) -0.038 ± 0.074 0.155 0.010 
 
Table 4.2 The average, maximum and minimum differences for MPOD and the various 
refractive variables for the ten participants. 
 
The relationships between all the variables were also analysed (table 4.3). 
Unsurprisingly, the most myopic and least myopic eyes were all highly correlated in terms 
of MPOD, BVS, AL, ACD and K (p<0.0005 in all cases), and statistically significant inter-
relationships between BVS, AL and ACD were demonstrated. With respect to MPOD, 
there appeared to be a link with BVS and AL; increasing myopia and axial length were 
positively correlated with MPOD (figure 4.1). However, it should be borne in mind that 
with so few study subjects, the latter finding may be a misleading coincidence or may be 
influenced by some confounding variable(s). 
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 MPOD 
myo 
MPOD 
hyp 
BVS 
myo 
BVS hyp AL  
myo 
AL  
hyp 
ACD 
myo 
ACD 
hyp 
K  
myo 
K  
hyp 
MPOD 
myo 
 0.936* -0.675^  0.672^  0.485  0.026  
MPOD 
hyp 
0.936*   -0.657^  0.788*  0.566  0.114 
BVS 
myo 
-0.675^   0.988* -0.909*  -0.852*  0.476  
BVS  
hyp 
 -0.657^ 0.988*   -0.912*  -0.754^  0.517 
AL  
myo 
0.672^  0.909*   0.986* 0.881*  -0.131  
AL  
hyp 
 0.788*  -0.912* 0.986*   0.811*  -0.218 
ACD 
myo 
0.485  -0.852*  0.881*   0.984* -0.408  
ACD 
hyp 
 0.566  -0.754^  0.811* 0.984*   -0.481 
K  
myo 
0.026  0.476  -0.131  -0.408   0.964* 
K  
hyp 
 0.114  0.517  -0.218  -0.481 0.964*  
 
Table 4.3 Pearson correlation matrix analysing the relationships between MPOD, BVS, 
AL, ACD and K. Grey cells = correlations not applicable for analysis. 
*p<0.01 ^p<0.05  
myo = the eye with the highest level of myopia or the lowest level of hyperopia. 
hyp = the eye with the lowest level of myopia or the highest level of hyperopia. 
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Figure 4.1 The relationship between MPOD and best vision sphere (DS), and between 
MPOD and axial length (mm). ‘r’ = Pearson’s r. 
 
4.4 Discussion 
This study of anisometropia and MPOD was designed to explore whether an earlier 
finding of a right-left MPOD difference in two subjects with anisometropia, was merely an 
unusual result, or if the pattern would carry through to a group of anisometropic 
individuals. 
 
The mean MPOD for ten subjects with anisometropia was 0.45±0.18 in the right eye and 
0.43±0.16 in the left eye (p>0.05). These values are higher than the means determined in 
an earlier study (see table 2.1 in chapter 2), and may reflect differences in the sample 
characteristics. For instance, there were a higher proportion of males in the present study 
(50% vs 16%), and a higher proportion of Asian, as opposed to Caucasian, subjects 
(50% vs 14%). Males have been found to have significantly higher (p<0.05) MPOD than 
females in nine MP studies (Hammond et al. 1996a; Wooten et al. 1999; Hammond and 
Caruso-Avery 2000; Berendschot et al. 2002a; Broekmans et al. 2002; Mellerio et al. 
2002; Lam et al. 2005; Nolan et al. 2007b; Bartlett et al. 2010c), whereas the opposite 
has been found in only one MP study (Nolan et al. 2010), although it is worth pointing out 
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that no statistical difference has been found in the majority of studies (see table 1.1 in 
chapter 1). The mean MPOD for males in this study was 0.46±0.18, and for females was 
0.42±0.16 (using both eyes in the analysis), but the difference was not statistically 
significant (Mann-Whitney U test, p>0.05). In terms of race and MPOD, no studies have 
explored a (South) Asian population sample, but there have been findings of other non-
white subjects having higher mean MPODs than white subjects (Wolf-Schnurrbusch et al. 
2007; Nolan et al. 2008; Sasamoto et al. 2010). The mean MPOD for Asians in this study 
was 0.47±0.14, and for Caucasians was 0.41±0.20 (using both eyes in the analysis), but 
the difference was not statistically significant (independent t-test, p>0.05). However, in 
both cases (gender and race) it is likely that the sample size was too small to have 
sufficient power to reach statistical significance, so the results do not necessarily rule 
these factors out as possible contributors to the higher mean MPOD. 
 
Comparing MPOD in the more myopic (or less hyperopic) eyes with MPOD in the less 
myopic (or more hyperopic) eyes, resulted in means of 0.44±0.17 for both, so there was 
no overall significant interocular MPOD difference (p>0.05), despite significant 
differences in BVS, AL and ACD. It would therefore seem that the original reason for 
performing this study was driven by a purely coincidental finding in the earlier study; while 
the two anisometropic subjects from that study maintained interocular MPOD differences 
of 0.08 and 0.09 in the present one, all but one of the eight previously untested subjects 
did not have differences as big as this, and the one individual that did followed an 
opposite pattern – they were hyperopic and the more hyperopic eye had a lower MPOD 
by 0.1. 
 
Although a conclusion of no relation between MPOD and anisometropia has been made, 
there was a statistically significant correlation between BVS and MPOD, and between AL 
and MPOD. Against the original preliminary finding of lower MPOD in the more myopic 
eye, the results suggested that increasing myopia is associated with higher MPOD. 
However, in light of the much larger (n=180) study by Neelam et al. (2006), who found no 
link at all between AL and MPOD, this result should be interpreted with caution. With only 
ten subjects, the present finding may well be influenced by other unknown variables, as 
per the higher mean MPOD discussed above. Nonetheless, it might be interesting to 
explore MPOD in two groups of opposite refractive error, such as subjects with myopic 
refractive errors greater than -5.00 DS, and subjects with hyperopic refractive errors 
greater than +2.00 DS. Only 14 (16.5%) of Neelam and colleagues’ study population had 
myopic refractive errors greater than -5.00 DS, and although 46 (25.8%) were hyperopic 
by more than +0.50 DS, no further information on the levels of hyperopia was reported. 
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As a result, any MPOD differences between two opposite refractive error groups (such as 
≤-5.00 vs ≥+2.00) may have been missed. Unfortunately, after examining all the gathered 
data from this current body of research (i.e., not just data from the anisometropia study), 
there are too few subjects meeting the hyperopic criteria (even if reducing the criteria to 
≥+1.00 DS) to make any meaningful statistical comparisons at this stage. 
 
If it were to be concluded that some level of association between MPOD and refractive 
error exists, what might be the cause of that? Myopia is well documented as being 
associated with accelerated nuclear sclerosis and yellowing of the crystalline lens (e.g., 
Wensor et al. 1999; Wong et al. 2000; Wong et al. 2001; Chen et al. 2003; Chang et al. 
2005; Praveen et al. 2008). Therefore the lens of someone with myopia might be 
expected to absorb more blue light than the lens of an emmetropic or hyperopic 
individual. Consequently, the MP in the retina might have a lighter workload, with L and Z 
being depleted less readily than in the retina of the emmetropic/hyperopic eye. However, 
if this were the case, then one might expect to see an increase in MPOD with age, on 
account of the increase in lens yellowing that occurs with age (Pokorny et al. 1987; van 
de Kraats and van Norren 2007), but so far there is no consistent proof of an age-MPOD 
relationship (see table 1.1 in chapter 1). Nolan et al. (2009), though, postulated that the 
increased oxidant load that occurs in the retina with age (Beatty et al. 2000b) might 
counteract any potential advantage of increased blue light absorption by the yellowing 
lens, so the myopia-higher MPOD theory is not necessarily ruled out. All the same, it is 
perhaps unlikely that lens yellowing would have had such a big influence in the fairly 
young cohort of subjects from the present study. Indeed, observation of the peripheral 
minimum values for each subject – the peripheral minimum essentially being a basic 
measure of lens yellowing – does not reveal any apparent refractive error based 
differences between subjects. Moreover, if the opposite had been found, i.e., if increasing 
myopia was associated with lower MPOD, it could be argued that a thinner retina, the 
result of a longer eye (AL), leads to lower MPOD, either because the MP is stretched 
further apart, meaning that the measured foveal area is not a true reflection of MPOD in 
the central retina, or because of previous findings of foveal thickness correlating 
positively with MPOD (Aleman et al. 2001; Duncan et al. 2002; Liew et al. 2006; Aleman 
et al. 2007; van der Veen et al. 2009c; Sandberg et al. 2010; Sasamoto et al. 2010). 
 
In conclusion, firstly, no relationship between anisometropia and MPOD was found. This 
negative finding is helpful in that it confirms the need to only measure MPOD in one eye, 
even when there is a considerable interocular refractive error difference. Rarely, there will 
be interocular MPOD differences, but these are not predictable from any information 
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gathered so far (in this study or otherwise), and the right-left difference is unlikely to be 
more than 0.1 ‘density units’. Secondly, a positive and statistically significant correlation 
was found between MPOD and increasing myopia/AL, but this result may have been 
inadvertently caused by other variables influencing MPOD in the small study population. 
 
4.5 Summary 
This chapter has described an assessment of MPS-based MPOD in both eyes of 
individuals with considerable anisometropia. An earlier theory of anisometropia-induced 
interocular MPOD differences was disproved, but a link between refractive error and 
MPOD could not be ruled out altogether. The possibility of other factors, such as gender 
and race, influencing MPOD was raised, and it was noted that no studies have examined 
MPOD in South Asians. This leads onto the next chapter, in which MPOD in a group of 
adults of South Asian origin is explored for the first time. 
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CHAPTER 5: MACULAR PIGMENT OPTICAL DENSITY IN YOUNG ADULTS OF 
SOUTH ASIAN ORIGIN 
 
In the preceding chapter it was confirmed that an MPOD measurement in one eye is a 
good reflection of MPOD in the other eye, even when there is a marked difference in 
refractive error. As a result, measurement of MPOD in one eye alone will be the norm in 
the studies that follow, unless there is a particular reason for measurement in both eyes. 
In this next chapter, an aspect of the rarely mentioned issue of ethnicity and MPOD is 
dealt with, by examination of MPOD in a group of young adults of South Asian origin. 
 
Please note that in this chapter, the words ethnicity, ethnic group and race are used 
synonymously, though it is recognized that their definitions are not entirely the same. 
Similarly, the term ‘South Asian’ is generally shortened to ‘Asian’, and is not intended to 
encompass any other Asian groups, such as East Asians or South-East Asians. Finally, 
the terms ‘Caucasian’ and ‘white’ are used interchangeably. 
 
5.1 Background and rationale 
Evidence suggests that ethnicity has a role to play in AMD, with white people having the 
highest prevalence of the disease, and black people the lowest prevalence (Sommer et 
al. 1991; Rahmani et al. 1996; Klein et al. 1999; Frank et al. 2000; Muñoz et al. 2000; 
Klein et al. 2003; Congdon et al. 2004; Friedman et al. 2004a; Friedman et al. 2004b; 
Leske et al. 2006; Duan et al. 2007; Klein et al. 2011; VanderBeek et al. 2011). Other 
ethnic groups that have been studied include East Asians (Chinese/Japanese), South-
East Asians (Malays), Hispanics, and Latinos (Chang et al. 1999; Rodriguez et al. 2002; 
Iwase et al. 2006; Li et al. 2006; Sivaprasad et al. 2006; Yasuda M et al. 2009; Varma et 
al. 2010), and in general the AMD prevalence in these groups has been found to lie 
somewhere between blacks and whites, i.e., lower than in white people but higher than in 
black people. A North Indian and South Indian population has also been studied, and the 
prevalence was reported as being comparable to Western countries (Krishnaiah et. al. 
2005; Gupta et al. 2007; Krishnaiah et al. 2009). However, there have been no direct 
comparisons with other ethnicities, although a study is underway in Singapore that will 
compare the epidemiology of eye diseases in South Asians, Chinese and Malays 
(Lavanye et al. 2009). In a meta-analysis study, Kawasaki et al. (2010) pooled prevalence 
data from studies on Japanese, Chinese, Malay and Indian populations. On combining 
these four Asian groups, their findings were that early AMD prevalence was lower than in 
white populations, but late AMD prevalence was similar. 
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In the effort to find out whether MP, in high levels, can protect against AMD, it has been 
common practice in many studies to explore MPOD with respect to factors that are 
believed to have some level of involvement with the development and progression of 
AMD (see table 1.1 in chapter 1). Yet the relationship, if any, between race and MPOD 
has rarely been mentioned, largely because the vast majority of participants in MPOD 
studies have been Caucasian. The only dedicated study to examine racial differences 
and MPOD was by Wolf-Schnurrbusch et al. (2007), who compared MPOD (using fundus 
AF) in a group of 51 African and 67 white non-Hispanic subjects, aged 35 to 49 years. 
The mean MPOD for the African subjects (0.59±0.14) was significantly higher than for the 
white subjects (0.36±0.13, p<0.0001). Conversely, Iannaccone et al. (2007), in an older 
group (69-86 years) of 35 black and 148 white subjects, reported MPOD means (using 
HFP) of 0.22±0.23 and 0.37±0.19, for the black and white subjects respectively. These 
differences were also statistically significant (p=0.0002). Nolan et al. (2008), though, 
agreed with Wolf-Schnurrbusch and colleagues, with their HFP-based MPOD study 
comprising 18 non-white (Indian, ‘Asian’, Hispanic and black) and 41 white subjects, aged 
18 to 60 years. Mean MPOD was significantly higher in the non-white group (0.55±0.28) 
than the white group (0.34±0.13, p<0.01). Two other studies found no statistically 
significant MPOD ethnicity differences (Hammond et al. 1996b; Bernstein et al. 2002), but 
the numbers of non-white subjects (7-8% of total samples) were very low compared with 
white subjects so there may well have been a lack of statistical power involved. 
 
Outside of ethnic comparisons, there have been MP investigations on non-Caucasian 
population samples, but they are few in number, and variations in instrumentation 
(including within the same technique), methods and population backgrounds make 
comparisons between ethnicities inappropriate. Chen et al. (2001) used FR to measure 
MPOD in a group of East Asians; Tang et al. (2004) and Lam et al. (2005) used two 
different HFP devices to measure MPOD in separate Chinese groups; Obana et al. 
(2008) used RRS to measure MPOD in a group of Japanese subjects; and Sasamoto et 
al. (2010) used AF to measure MPOD in another group of Japanese subjects.  
 
Similar to AMD prevalence studies, there is an absence of South Asian ethnicity in all 
prior MPOD work, which was therefore the motivation behind the present investigation. 
The aims here were to assess the distribution of MPOD in a healthy group of young 
adults of South Asian origin, to investigate whether any dietary factors or personal 
characteristics were related to inter-subject variations in MPOD, and to compare mean 
MPOD in the Asian group with mean MPOD in a Caucasian group. 
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5.2 Methods 
SUBJECTS 
One hundred and twenty Asian subjects were recruited by email and by word-of-mouth, 
and consisted mainly of undergraduate optometry students from Aston University. There 
were 104 British Asians, 14 Canadian Asians, and two African Asians. They were all in 
good health, with ages ranging from 18 to 30 years (mean±SD: 21.3±2.6 years). Visual 
acuity was measured under standard testing conditions using a logMAR letter chart; all 
participants had VAs of 0.14 logMAR (Snellen 6/7.5–2) or better in the eye being tested. 
Exclusion criteria were: age younger than 18 years; VA worse than 0.2 logMAR (Snellen 
6/9.5); and the presence of any ocular disease in the eye being tested.  
 
In addition to the Asian subjects, MPOD data was collected on 53 Caucasian subjects. 
Most of this data was taken from the other studies in this body of research, but 19 
subjects were recruited specifically for the present study. There were 47 British 
Caucasians, two Canadian Caucasians, one Australian Caucasian, one German 
Caucasian, one Irish Caucasian, and one Polish Caucasian. All 53 participants were in 
good health, with ages ranging from 18 to 61 years (mean±SD: 27.6±9.3 years). Visual 
acuity was measured under standard testing conditions using a logMAR letter chart; all 
participants had VAs of 0.14 logMAR (Snellen 6/7.5–2) or better in the eye being tested. 
 
Aston University’s Ethics Committee approved the study. All subjects signed an informed 
consent form, and all procedures adhered to the tenets of the Declaration of Helsinki. 
 
LIFESTYLE QUESTIONNAIRE 
A questionnaire was constructed for the Asian participants to complete. Questions were 
primarily focused on the various physical, ocular, lifestyle, dietary and environmental 
factors that may be associated with MPOD or AMD. For example, height and weight (for 
body mass index calculation), iris colour, smoking history, fruit and vegetable 
consumption, sunlight exposure. A copy of the questionnaire is provided in appendix 5. 
 
FOOD DIARY 
The Asian participants were also asked to complete a three-day food diary, in which they 
recorded everything they ate and drank over the course of three days (two weekdays and 
one weekend day). A copy of the food diary is provided in appendix 6. A nutritional 
database and analysis package (WISP, Tinuviel Software, UK) was used to assess the 
nutritional content of each subject’s three-day food intake. The database did not include L 
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or Z values, but it did allow for additional ‘custom’ nutrients. Information on L/Z 
(combined) was therefore obtained from the USDA (United States Department of 
Agriculture) national nutrient database (USDA 2010). A careful, systematic approach was 
taken. To start, the basic foods in each diary were searched for their L/Z content (e.g., 
fruits, vegetables, cereals, breads, pastas, meats, dairy products, confectionaries, 
beverages), followed by a L/Z search for the breakdown of extra food components 
making up a meal recipe (e.g., herbs, spices, salt, sauces, flour). Nothing was presumed 
to have zero L/Z so every food was searched for. The L/Z levels were entered into the 
WISP database under the appropriate heading, e.g., boiled, raw (see figure 5.1). During 
this process, standard recipes for certain meals were created (e.g., pasta dishes, soups, 
curries, pasties). Not all of these were needed specifically, because the WISP database 
contained many pre-entered standard meals, but recipes did need to be created in order 
to establish L/Z contents. Finally, the food intakes for each subject were entered (see 
figure 5.2). 
 
 
Figure 5.1 An example of manually-entered L and Z content into the WISP nutrient 
database. 
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Figure 5.2 An example of a daily food intake record for one subject, using the WISP 
nutritional analysis software. 
 
MPS 9000 
For measurement of MPOD using the MPS, each subject received verbal instructions and 
completed a short practice test, after which the prior established protocol was used 
(chapter 3) to measure MPOD in one eye (the right eye unless it was unsuitable, e.g., 
due to amblyopia). The averages of the central minima and peripheral minima were used 
to calculate MPOD. Using this technique, the vast majority of participants had two to 
three good quality central and peripheral curves to derive MPOD from. Three Asian 
subjects and one Caucasian subject were removed from the analyses due to continually 
poor curve quality and/or highly variable MPOD readings.  
 
All subjects were tested by the same investigator (OH). The total MPS testing time was 
between 15 and 30 minutes (includes time taken to go through any questionnaire/food 
diary queries). 
 
SAMPLE SIZE 
Originally, the aim was to recruit approximately 200 Asian subjects, which would be 
similar to other studies examining MPOD in population samples (e.g., Hammond and 
Caruso-Avery 2000; Iannaccone et al. 2007). This target was not reached, but the final 
numbers were still in line with a number of other MPOD studies that each examined a 
host of variables and their possible associations with MPOD (e.g., Mellerio et al. 2002; 
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Burke et al. 2005; Wolf-Schnurrbusch et al. 2007; Nolan et al. 2010). In addition, 
G*Power 3.1 was used. An effect size of 0.57 was calculated on the basis of an 
estimated significant mean difference in MPOD of 0.08 between two groups, both with 
standard deviations of 0.14. For a two-tailed independent-samples t-test, this 
corresponded to a sample size of 100, with 50 subjects per group, for 80 percent power 
at the five percent alpha significance level. 
 
STATISTICS 
Microsoft Excel, IBM SPSS and the WISP nutritional analysis package (Tinuviel 
Software) were used for data analysis. Mean values were mainly compared using 
independent-samples t-tests or a non-parametric equivalent, as appropriate in terms of 
normality. Pearson’s r or Spearman’s rho correlations were used to quantify associations 
between continuous variables. 
 
5.3 Results 
LIFESTYLE QUESTIONNAIRE 
Of the 117 Asian participants with successful MPOD measurements, 100 fully completed 
the lifestyle questionnaire, and one subject partially completed it. Macular pigment 
measurements had been taken on ten Asian subjects in the other MPOD studies, so 
these measurements were included in the analyses where applicable, but as they had not 
been required to complete the questionnaire, only limited information was available. The 
same was true for the remaining six subjects who failed to complete the questionnaire. 
Table 5.1 is a summary of the information gathered for the Asian sample. 
 
Continuous data  Categorical data 
Variable Mean ± SD  Variable N (%) 
Age (years) 21.3 ± 2.6 (n=117) 
 Gender  
(n=117) 
Male: 44 (37.6%) 
Female: 73 (62.4%) 
Body mass index 
All: 21.9 ± 4.0 (n=100) 
Male: 23.8 ± 4.6 (n=38) 
Female: 20.8 ± 3.1 (n=62) 
 
Asian background 
(n=106) 
Indian: 75 (70.8%) 
Pakistani: 22 (20.8%) 
Bangladeshi: 3 (2.8%) 
Sri Lankan: 4 (3.8%) 
Other: 2 (1.9%) 
Vegetable 
servings per 
week 
7.0 ± 5.2 (n=100) 
 
Iris colour  
(n=106) 
Dark brown: 61 (57.5%) 
Brown: 37 (34.9%) 
Light brown: 1 (0.9%) 
Hazel: 5 (4.7%) 
Green: 2 (1.9%) 
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Fruit servings per 
week 
6.6 ± 5.8 (n=100) 
 
Smoking status  
(n=102) 
Current: 7 (6.9%) 
Former: 3 (2.9%) 
Never: 92 (90.2%) 
Eggs (including 
yolks) per week 
All: 1.8 ± 2.1 (n=100) 
Yes group: 2.6 ± 2.0 
 Dietary 
background  
(n=101) 
Meat-eater: 72 (71.3%) 
Part-vegetarian: 8 (7.9%) 
Vegetarian: 21 (20.8%) 
Oily fish servings 
per week 
All: 0.7 ± 1.1 (n=101) 
Yes group: 1.7 ± 1.1 
 Egg intake 
(n=100) 
Yes: 71 (71%) 
No: 29 (29%) 
Alcohol units per 
week 
All: 3.8 ± 8.2 (n=101) 
Yes group: 9.9 ± 10.7 
 Oily fish intake  
(n=101) 
Yes: 41 (40.6%) 
No: 60 (59.4%) 
Hours spent 
outside per week 
A/W: 8.7 ± 5.8 (n=100) 
S/S: 17.0 ± 10.0 (n=100) 
 Alcohol intake  
(n=101) 
Yes: 39 (38.6%) 
No: 62 (61.4%) 
BVS (spectacle 
prescription) 
-2.08 ± 2.82 DS (n=110) 
 Regular exercise 
(n=101) 
Yes: 44 (43.6%) 
No: 57 (56.4%) 
  
 Strong sunlight 
exposure(n=101) 
Yes: 24 (23.8%) 
No: 77 (76.2%) 
  
 Sunbed use  
(n=101) 
Yes: 1 (1.0%) 
No: 100 (99.0%) 
  
 Skin sun 
sensitivity(n=101) 
Yes: 12 (11.9%) 
No: 89 (88.1%) 
  
 
Sunglasses use  
(n=101) 
Yes: 19 (18.8%) 
Part-time: 39 (38.6%) 
No: 43 (42.6%) 
  
 
Glasses and CL 
wear (n=105)* 
Glasses/UV CLs: 39 (37.1%) 
None/non-UV CLs: 62 (59.0%) 
Mixture: 4 (3.8%) 
  
 Family history of 
AMD (n=101) 
Yes: 2 (2.0%) 
No: 99 (98.0%) 
 
Table 5.1 A summary of the physical, ocular, lifestyle, dietary and environmental data 
collected on the Asian subject group. 
n/N = number of subjects. A/W = autumn/winter. S/S = spring/summer. CL = contact lens. 
UV CLs = ultraviolet-filtering CLs. AMD = age-related macular degeneration.  
‘Part-vegetarian’ refers to someone who eats one form of meat only, e.g., fish.  
For sunglasses use, yes = always or most of the time, part-time = sometimes or 
occasionally, and no = very rarely or never. 
*Glasses and UV-filtering CLs were grouped together because of their UV protection – all 
plastic spectacle lens materials absorb up to at least 370 nm (Wilkinson 1999).  
Information on vitamin and supplement use was also acquired from the questionnaire, but 
it is not included here as very few subjects took either, and of those that did, no 
vitamins/supplements included L or Z. 
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The mean MPOD of all 117 Asian subjects was 0.43±0.14. Table 5.2 is a summary table 
of the analyses conducted to assess whether any MPOD differences existed for the 
various physical, ocular, lifestyle, dietary and environmental factors examined in the 
questionnaire. Some variables were not analysed because of the very low subject 
numbers in one or more of the groups involved. These variables were: Asian 
backgrounds other than Indian and Pakistani, smoking status, sunbed use, and family 
history of AMD. For the same reason, some variables were adjusted: iris colours other 
than dark brown were combined together to make a larger group size that could then be 
compared with dark brown; part-vegetarians were excluded from the dietary background 
analysis; and the ‘mixture’ group was excluded from the glasses and CL wear analysis.  
 
Variable Mean (±SD) MPOD Statistic value 
Significance (p) 
value 
Gender 
Male: 0.47 ± 0.13 
Female: 0.41 ± 0.14 
U = 1134.5 0.008 
Asian background 
Indian: 0.44 ± 0.15 
Pakistani: 0.42 ± 0.12 
t = 0.806 0.422 
Iris colour 
Dark brown: 0.46 ± 0.15 
Other (n=45): 0.41 ± 0.13  
t = 1.778 0.078 
Dietary background 
Meat-eater: 0.43 ± 0.13 
Vegetarian: 0.46 ± 0.16 
t = -1.001 0.319 
Egg intake 
Yes: 0.43 ± 0.13 
No: 0.46 ± 0.17 
t = -1.101 0.273 
Vegetable + Fruit + Egg 
intake per week 
≤15 servings (n=59): 0.44 ± 0.13  
>15 servings (n=41): 0.44 ± 0.15 
t = 0.023 0.982 
Oily fish intake^ 
Yes: 0.44 ± 0.14 
No: 0.43 ± 0.14 
t = 0.356 0.723 
Alcohol intake 
Yes: 0.47 ± 0.16 
No: 0.42 ± 0.13 
t = 1.845 0.068 
Regular exercise 
Yes: 0.43 ± 0.13 
No: 0.44 ± 0.15 
t = -0.368 0.714 
Outdoor daylight 
exposure – A/W 
≤7 hours (n=56): 0.43 ± 0.14 
>7 hours (n=44): 0.44 ± 0.15 
t = -0.219 0.827 
Outdoor daylight 
exposure – S/S 
≤15 hours (n=52): 0.43 ± 0.13 
>15 hours (n=48): 0.44 ± 0.15 
t = -0.332 0.740 
Strong sunlight exposure 
Yes: 0.43 ± 0.13 
No: 0.44 ± 0.15 
t = -0.400 0.690 
Skin sun sensitivity 
Yes: 0.46 ± 0.11 
No: 0.43 ± 0.14 
t = 0.562 0.575 
Light exposure score* 
Minimal (0, n=35): 0.43 ± 0.14 
Moderate (1-2, n=57): 0.44 ± 0.14 
Heavy (3-4, n=8): 0.39 ± 0.14 
F = 0.500 0.608 
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Light exposure score (2 
groups)* 
Minimum (0-1, n=58): 0.43 ± 0.14 
Maximum (2-4, n=42): 0.45 ±0.14 
t = -0.853 0.396 
Sunglasses use 
Yes: 0.40 ± 0.16 
Part-time: 0.43 ± 0.13 
No: 0.45 ± 0.14 
F = 0.858 0.427 
Sunglasses use (2 
groups) 
Yes/part time (n=58): 0.42 ± 0.14 
No: 0.45 ± 0.14 
t = -1.025 0.308 
Glasses and CL wear 
Glasses/UV CLs: 0.47 ± 0.15 
None/non-UV CLs: 0.42 ± 0.14 
t = 1.911 0.059 
 
Table 5.2 Mean MPODs and comparisons for the variables examined in the Asian 
subject group. 
Unless stated in the table here, please refer to table 5.1 for subject numbers. 
‘t’ refers to an independent-samples t-test, which was used when each data set was 
normally distributed. Otherwise, the Mann-Whitney U test (‘U’) was used. For variables 
containing three groups, a one-way between-groups ANOVA (‘F’) was used (each data 
set was normally distributed). For all t-tests and ANOVAs, the assumption of 
homogeneity of variance was met. 
^Oily fish intake was also analysed by including in the ‘yes’ group subjects who took fish 
oil supplements; there was no difference in the overall outcome. 
*The light exposure score was based on an idea from Mellerio et al. (2002), in which 
points were assigned for various aspects of light exposure. Here, the points were 
assigned as follows. Zero points for: ≤7 hours autumn/winter outdoor daylight exposure; 
≤15 hours spring/summer outdoor daylight exposure; an answer of ‘no’ to strong sunlight 
exposure; an answer of ‘no’ to sunbed use. One point for: >7 hours autumn/winter 
outdoor daylight exposure; >15 hours spring/summer outdoor daylight exposure; an 
answer of ‘yes’ to strong sunlight exposure; an answer of ‘yes’ to sunbed use. The results 
were categorized into minimal (0 points), moderate (1-2 points) and heavy (3-4 points) 
light exposure. Because of the small subject numbers in the latter group, subjects were 
also re-assigned into one of two groups, minimum (0-1 points) and maximum (2-4 points). 
 
Of all the variables examined, only gender demonstrated a statistically significant 
difference in MPOD, with the males having a higher average MPOD than the females 
(p=0.008). Figure 5.3 is a frequency distribution of MP densities for both gender groups. It 
illustrates the high proportion of males that had MPODs of 0.41 or higher (72% compared 
with 50% of females). The possible influence of the differing sample sizes (44 males vs 
73 females) was also explored; a random sample of 44 females was selected (using the 
website ‘random.org’); the male-female difference remained highly significant (U=613.0, 
p=0.003). 
 93 
 
 
Figure 5.3 The frequency distribution of MPOD for males and females in the Asian 
subject group. 
 
In addition to looking for differences in mean MPOD between the various groups, the 
possibility of any MPOD associations was explored for the continuous data. Using 
Pearson’s r or Spearman’s rho (dependent on normality), and scatter graph observations, 
virtually no statistically significant correlations between MPOD and any variable (body 
mass index, vegetable intake, fruit intake, vegetables/fruits combined, egg intake, 
vegetables/fruits/eggs combined, oily fish intake, alcohol intake, hours spent outside, and 
best vision sphere) were found, even when analysing males and females separately (in 
view of the MPOD gender difference). The only significant correlation to emerge was a 
positive association between MPOD and alcohol intake (rho=0.229, p=0.021). This 
association remained significant for females (rho=0.330, p=0.009) but not for males 
(rho=0.108, p=0.511). However, observation of the scatter graphs indicated that the large 
proportion of subjects who did not drink alcohol (see table 5.1) might have influenced the 
correlations. Indeed, separating the group as a whole into drinkers of alcohol and non-
drinkers resulted in no relationship for alcohol units and MPOD (rho=0.045, p=0.782). 
With the same reasoning, this method was applied to egg intake and oily fish intake. 
Removing the individuals who did not consume any oily fish did not alter the 
(insignificant) outcome. Removing the individuals who did not consume any eggs, though, 
did alter the outcome, and a statistically significant positive correlation between egg 
intake and MPOD emerged (rho=0.287, p=0.015; see figure 5.4). 
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Figure 5.4 The relationship between MPOD and the number of eggs consumed per week 
(Spearman’s rho=0.287, p=0.015). 
 
FOOD DIARY 
Of the 100 participants who fully completed the questionnaire, 50 also completed the 
three-day food diary. Four out of the remaining 50 subjects failed to produce the food 
diary on request, but the other 46 were not asked to complete the diary for three reasons. 
Firstly, their MPOD measurements were made at the beginning of an academic year, so 
the student volunteers had just returned to university from their family homes, and in view 
of the anticipated change in their diets, it was felt that their food diaries may not be an 
accurate reflection of any nutrient-MPOD associations (or lack thereof), given that the 
rate of L and Z turnover in the retina has not been conclusively established – 
supplementation and dietary modification studies have shown a lot of variability with 
respect to how quickly or slowly MPOD changes occur in response to dietary modification 
or supplement use (e.g., Landrum et al. 1997; Bone et al. 2003; Stringham and 
Hammond 2008; Connolly et al. 2010; Nolan et al. 2011). Secondly, the food diary aspect 
of the study had proved something of a barrier to subject recruitment so far, and by 
removing this requirement, it was hoped that more individuals would be willing to 
participate, thus offering a better chance (power-wise) of establishing some statistically 
significant MPOD links with the variables examined in the questionnaire. Finally, a total of 
45 food diaries had already been received, and from observation it seemed highly 
unlikely that MPOD in the Asian subjects was going to be related to their dietary intakes. 
Further to these reasons, two previous studies have obtained nutrient intakes for 45 and 
50 subjects, and both of them reported statistically significant relationships with MPOD 
(Werner et al. 2000; Wenzel et al. 2007a), so the lower numbers here (compared with the 
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questionnaire data) should not have been a barrier to establishing such relationships if 
they existed. 
 
Table 5.3 is a summary of questionnaire-collected and food diary-collected information 
that was considered pertinent to the ensuing analyses. Gender, Asian background and 
dietary background were reconsidered with respect to MPOD in this smaller group of 
subjects. The same results were encountered, namely, a higher mean MPOD in males 
than females (p=0.027), but no significant differences for Indian Asians compared with 
Pakistani Asians, or for meat-eaters compared with vegetarians (p>0.05). These same 
three variables were also taken into account for body mass index (BMI) and 
vegetable/fruit/egg intake, because it seemed reasonable to expect that their diets may 
be different from one another, with subsequently differing BMI and so on. The results 
revealed a higher mean BMI for males than females (p=0.001), but no other statistically 
significant differences. Consequently, Asian and dietary background was not considered 
in some of the specifically-chosen food diary variables given in the lower half of the table. 
Of these variables, energy, carbohydrates and total fat showed statistically significant 
differences between males and females, thus instilling some confidence in the credibility 
of the food diary data, given the BMI gender differences. Dietary L (combined with Z) was 
selected because of its assumed and reported association with MP (see table 1.1 in 
chapter 1); it was compared by gender (because of the differences in MPOD and energy 
values), by Asian background (because of potentially different types of vegetable intake 
etc.), by dietary background, and by vegetable/fruit/egg combined intake. Despite the 
male-female difference in MPOD, no such difference existed for L/Z intake. Conversely, 
vegetarians had a higher L/Z intake than meat-eaters (p=0.023), despite there being no 
difference in their mean MPOD values. No other significant differences were identified. 
 
Continuous data  Categorical data 
Variable Mean ± SD  Variable N (%) 
From questionnaire/MPOD measurements 
 
From questionnaire 
 
MPOD 
All: 0.44 ± 0.14 
Male: 0.50 ± 0.10 
Female: 0.41 ± 0.15* 
Indian: 0.44 ± 0.16 
Pakistani: 0.43 ± 0.12 
Meat-eater: 0.44 ± 0.12 
Vegetarian: 0.45 ± 0.20 
 Gender 
Male: 17 (34%) 
Female: 33 (66%) 
Body mass index 
All: 21.6 ± 4.0 
Male: 24.8 ± 4.6 
 Asian background 
Indian: 32 (64%) 
Pakistani: 14 (28%) 
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Female: 20.0 ± 2.5* 
Indian: 21.1 ± 3.5 
Pakistani: 23.5 ± 5.1 
Meat-eater: 22.1 ± 4.1 
Vegetarian: 21.3 ± 3.7 
Bangladeshi: 1 (2%) 
Sri Lankan: 2 (4%) 
Other: 1 (2%) 
Vegetable + Fruit + 
Egg intake per week 
All: 15.1 ± 8.5 
Male: 16.1 ± 10.5 
Female: 14.5 ± 7.3 
Indian: 15.8 ± 9.7 
Pakistani: 14.1 ± 5.3 
Meat-eater: 14.5 ± 6.7 
Vegetarian: 19.9 ± 11.8 
 
Dietary 
background 
Meat-eater: 35 (70%) 
Part-vegetarian: 4 (8%) 
Vegetarian: 11 (22%) 
From food diary (nutrients per day)  VFE group 
≤15 servings: 29 (58%)  
>15 servings: 21 (42%) 
Energy (kilocalories) 
All: 1950 ± 615 
Male: 2435 ± 659 
Female: 1699 ± 414* 
   
Carbohydrate 
(grams) 
All: 248.4 ± 80.3 
Male: 298.6 ± 97.5 
Female: 222.5 ± 55.6* 
   
Total fat (grams) 
All: 78.2 ± 29.6 
Male: 98.7 ± 27.6 
Female: 67.7 ± 25.0* 
   
Lutein + Zeaxanthin 
(milligrams) 
All: 1.31 ± 2.46 
Male: 0.63 ± 0.34 
Female: 1.66 ± 2.97 
Indian: 1.51 ± 2.97 
Pakistani: 1.12 ± 1.19 
Meat-eater: 0.94 ± 0.97 
Vegetarian: 2.76 ± 4.84* 
VFE ≤15: 0.99 ± 1.05 
VFE >15: 1.74 ± 3.59 
   
 
Table 5.3 Summary data for the 50 Asian subjects with completed questionnaires and 
food diaries. 
VFE = vegetable+fruit+egg. 
*p<0.03 (Comparison by independent-samples t-tests or Mann-Whitney U tests, e.g., 
male vs female mean MPOD: t=2.285, p=0.027 – see table A7.1 in appendix 7 for full 
details.) 
 
Besides the food diary nutrients listed in table 5.3, the food diary analysis software 
provided data on many other nutrients. All these nutrients and their means are listed in 
appendix 7 (table A7.2), but the nutrients that are commonly labelled on food and drink 
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items in the UK are given in table 5.4, alongside the means found in the subject group 
here, and the guideline daily amounts as recommended by the Food and Drink 
Federation (FDF 2010). With the exception of protein, the averages for the subjects 
appear to compare well with the guideline amounts (which is to be expected given the 
healthy BMI average of this Asian sample), therefore implying that the food diary analysis 
was an accurate method of assessing nutrient intake. 
 
Nutrient 
Mean (±SD) from 
food diaries 
Guideline daily 
amount 
Energy (kilocalories) 1950 ± 615 2000 
Protein (grams) 75.8 ± 32.9 45  
Carbohydrate (grams) 248.4 ± 80.3 270  
Sugars (grams) 96.9 ± 42.4 90  
Fat (grams) 78.2 ± 29.6 70  
Saturated fat (grams) 26.5 ± 10.5 20  
Fibre (grams) 17.1 ± 7.1 24 
Sodium (grams) 2.66 ± 1.03 2.4  
 
Table 5.4 Mean nutrient values per day, derived from analysis of the 50 food diaries, plus 
the recommended daily allowances for each nutrient.  
 
Correlation analysis was used to explore the possibility of any MPOD-nutrient 
associations. Using Pearson’s r or Spearman’s rho (dependent on normality), and scatter 
graph observations, no significant correlations between MPOD and any nutrient were 
found, including L and Z. In view of the gender difference in MPOD, the correlations were 
repeated for males and females separately. The only significant correlation to emerge 
was between male MPOD and both sodium (r=-0.609, p=0.01) and chloride (r =-0.690, 
p=0.002), i.e., sodium chloride (salt). In other words, as sodium chloride intake increases, 
MPOD decreases (figure 5.5). 
 
 
 98 
  
Figure 5.5 The relationship between MPOD and sodium chloride intake per day in male 
subjects (r=-0.609, p=0.01 for sodium, and r=-0.690, p=0.002 for chloride).  
 
The possibility of any BMI-nutrient associations was also explored via Pearson and 
Spearman correlations, and scatter graph observation; no significant correlations were 
found, even when comparing males and females separately (on account of the BMI 
gender difference). 
 
ASIAN VERSUS CAUCASIAN MPOD COMPARISONS 
The total number of Caucasian subjects was 52, and their mean MPOD was 0.33±0.13. 
As established earlier, there were 117 Asian subjects in total, and their mean MPOD was 
0.43±0.14. These means are significantly different (p<0.0005), as demonstrated in table 
5.5, which is a breakdown of the information that was available for both study groups, and 
the results of all subsequent analyses. Figure 5.6 is a frequency distribution of MP 
densities for both racial groups. Because the number of Asian subjects was more than 
double that of the Caucasian subjects, the possible influence of differing sample sizes 
was explored by a random selection of 52 Asian participants (using the website 
‘random.org’); the mean Asian MPOD remained higher than the Caucasian mean, and 
the difference was still highly significant (see table 5.5). However, it was also confirmed 
that the Caucasian group was older than the Asian group, on average, and moreover, 
that a significant decline in MPOD with age was present in this particular sample (figure 
5.7), which could therefore be the cause of the differing MPOD means between the two 
races. Although there was still a difference in the mean ages (p=0.01), limiting the 
Caucasian subjects to the same age range as the Asian subjects (18-30 years) removed 
the MPOD-age correlation, yet a statistically significant difference between the two 
MPOD means (p=0.002) was maintained. The age range limitation gave rise to an even 
bigger difference in sample size, though, so a further random selection of the Asian 
participants took place. Again, the MPOD means remained significantly different 
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(p=0.007). Finally, MPOD in the Caucasian subject group was examined for any gender 
differences. In contrast to the Asian subject group, the mean MPOD in males was lower 
than the mean MPOD in females, but this difference was not statistically significant. 
 
Variable Group (n) Mean ± SD Statistic 
MPOD (full samples) 
Asian (117) 
Caucasian (52) 
0.43 ± 0.14 
0.33 ± 0.13 
U = 1705, p < 0.0005 
MPOD (equal sample sizes) 
Asian (52) 
Caucasian (52) 
0.45 ± 0.13 
0.33 ± 0.13 
U = 661, p < 0.0005 
Age, years (full samples) 
Asian (117) 
Caucasian (52) 
21.3 ± 2.6 
27.6 ± 9.3 
U = 1657, p < 0.0005 
MPOD & Age (full samples) 
Asian (117) 
Caucasian (52) 
N/A 
N/A 
rho = -0.105, p = 0.260 
rho = -0.357, p = 0.009 
MPOD & Age (18-30 years) 
Asian (117) 
Caucasian (39) 
N/A 
N/A 
rho = -0.105, p = 0.260 
rho = -0.135, p = 0.413 
Age (18-30 years) 
Asian (117) 
Caucasian (39) 
21.3 ± 2.6 
23.2 ± 3.6 
U = 1657, p = 0.01 
MPOD (18-30 years) 
Asian (117) 
Caucasian (39) 
0.43 ± 0.14 
0.35 ± 0.14 
t = 3.175, p = 0.002 
MPOD (18-30 years, equal 
sample sizes) 
Asian (39) 
Caucasian (39) 
0.43 ± 0.12 
0.35 ± 0.14 
t = 2.785, p = 0.007 
Caucasian MPOD 
Male (15) 
Female (37) 
0.30 ± 0.14 
0.34 ± 0.13 
U = 234.5, p = 0.385 
 
Table 5.5 Comparisons between the Asian and Caucasian subject groups. 
‘U’ refers to a Mann-Whitney U test, which was used when one or both data sets were not 
normally distributed. Otherwise, an independent-samples t-test was used (the assumption 
of homogeneity of variance was met in both cases). ‘rho’ refers to a Spearman’s rho 
correlation, which was used because one or both data sets were not normally distributed. 
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Figure 5.6 The frequency distribution of MPOD in the Asian and Caucasian subjects. 
 
Figure 5.7 The relationship between age and MPOD for the Caucasian subjects 
(Spearman’s rho=-0.357, p=0.009). 
 
5.4 Discussion 
With no previously published research on South Asians, current knowledge regarding 
MPOD in this particular racial group was negligible at best. The present investigation 
addressed this issue by obtaining MPOD measurements in a South Asian population 
sample, evaluating those measurements against a variety of personal and dietary 
characteristics obtained from a purposely-designed questionnaire and a three-day food 
diary, and finally, comparing them with mean MPOD measurements from a Caucasian 
group. 
0%
5%
10%
15%
20%
25%
30%
35%
P
e
rc
e
n
ta
g
e
 o
f 
s
u
b
je
c
ts
 
MPOD range 
Asians (n=117)
Caucasians (n=44)
 101 
 
For 117 young Asian subjects, the mean MPOD was 0.43±0.14, which is higher than all 
previously published MPS-based MP averages (Makridaki et al. 2009; van der Veen et al. 
2009a; van der Veen et al. 2009c; Bartlett et al. 2010c; de Kinkelder et al. 2011). The 
male subjects averaged a higher mean MPOD than the female subjects, and the 
difference was statistically significant. As stated in chapter 4, this finding is in common 
with nine other MPOD studies (Hammond et al. 1996a; Wooten et al. 1999; Hammond 
and Caruso-Avery 2000; Berendschot et al. 2002a; Broekmans et al. 2002; Mellerio et al. 
2002; Lam et al. 2005; Nolan et al. 2007b; Bartlett et al. 2010c), while the opposite has 
been reported in only one study to date (Nolan et al. 2010). Several reasons have been 
put forward for why this difference may exist. Firstly, L in adipose tissue has been shown 
to correlate positively with MPOD in men, but negatively or not at all in women (Johnson 
et al. 2000; Broekmans et al. 2002). In another study, a female group of volunteers had 
statistically significant higher adipose L levels than a male group, while the males had 
statistically significant higher MP levels than the females (Berendschot et al. 2002a). It 
therefore seems sensible to suggest that competition between adipose tissue and retinal 
tissue may exist in females, and indeed this has been the opinion of others (Johnson et 
al. 2000; Broekmans et al. 2002). Hammond et al. (1996a) also hypothesized that retinal 
L and Z are metabolized differently between sexes, Berendschot et al. (2002a) proposed 
that gender differences might arise as a result of differences in the transport of L and Z to 
the retina, while Curran-Celentano et al. (2001) and Nolan et al. (2007b) thought that 
hormonal differences could be the cause. Nolan and colleagues also suggested that the 
higher body fat of women might also be a reason. Nevertheless, and whatever the reason 
might be, it should not be forgotten that the majority of studies have not found any gender 
differences (see table 1.1 in chapter 1), and even in the present study, the effect size (r-
value 0.25) was only small to medium, thus suggesting that there is still a great deal of 
unexplained variation in what determines an individual’s MPOD. 
 
Aside from the gender-related difference, MPOD in the present study was unrelated to 
virtually all of the physical, ocular, lifestyle, dietary and environmental factors determined 
from the questionnaire. Most notably lacking any association – in the context of findings 
from other MPOD investigations – was fruit and vegetable intake, and BMI. In view of the 
dietary sources of L and Z (Sommerburg et al. 1998; Perry et al. 2009; USDA 2010), it 
would not be unexpected for there to be a positive relationship between MPOD and 
consumption of fruits and vegetables, and two (out of six) previous studies have found 
such a relationship (Mellerio et al. 2002; Burke et al. 2005). One of these obtained their 
significance between a ‘low consumer’ fruit and vegetable group, and a ‘very high 
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consumer’ fruit and vegetable group (Burke et al. 2005) (there were four groups in total). 
The low group averaged less than three servings per day, while the very high group 
averaged more than five servings per day. Considering that the average combined 
consumption of fruits and vegetables in this study was less than two servings per day, it 
is perhaps unsurprising that no link with MPOD was found. On the other hand, Mellerio et 
al. (2002) combined fruit and vegetable intake with egg intake, and compared MPOD 
between a group of subjects consuming 16 or more servings per week (n=62) and a 
group of subjects consuming 15 or less servings per week (n=62). Despite these two 
groups being extremely similar to the present investigation in terms of servings and 
subject numbers, and notwithstanding the fact that both studies equate to a considerably 
lower average intake than the low consumer group in Burke et al.’s study (even with eggs 
included), Mellerio et al. obtained a highly significant difference in mean MPOD between 
the two categories (p<0.001). Nevertheless, it could be that the contrasting finding of the 
current study with that of Mellerio’s was to do with the types of fruit and vegetable being 
eaten (and hence the levels of L/Z being consumed). 
 
Although there have been several studies, like the current one, that have not found any 
association between BMI and MPOD, an equal number of studies have reported a 
statistically significant relationship (see table 1.1 in chapter 1), with increasing BMI being 
linked to decreasing MPOD. However, not all of these significant relationships have 
stemmed from correlation analysis. For example, there wasn’t a significant linear 
correlation for subjects in the above-mentioned study by Burke et al. (2005), but there 
was a significant difference when the subjects were split into two BMI groups (<27 and 
≥27). Similarly, Hammond et al. (2002) reported that their correlation was led by 
participants with BMIs greater than 29; the correlation became insignificant after 
removing these individuals. As a result, it could be that the lack of any significant 
relationship in the present study reflects the fact that very few subjects were overweight 
or obese (n=15 [15%] with a BMI ≥25, and n=4 [4%] with a BMI ≥30). Still, splitting the 
Asian study group as per Burke et al. did not reveal any statistically significant MPOD 
differences. In fact, the mean MPOD of the group with BMIs greater than 27 was higher 
than the mean MPOD of the group with BMIs less than 27, although this was probably 
because 75 percent of the former group were male (with their accompanying higher MP 
levels), compared with 33 percent in the latter group. 
 
Of the many other variables that were unrelated to MPOD in this study, it is noteworthy 
that although there was a weak correlation between increasing hyperopia and decreasing 
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MPOD (Spearman’s rho=-0.114), this correlation was not statistically significant 
(p=0.235), unlike the anisometropia study described in the preceding chapter. 
 
After delving a little deeper, a significant correlation did come to light between MPOD and 
the number of eggs consumed per week (Spearman’s rho=0.287, p=0.015). This is a 
plausible relationship because eggs are known to be a highly bioavailable source of L 
(Handelman et al. 1999; Chung et al. 2004) and have also been shown to increase 
MPOD in a fairly modest (six eggs per week) intervention study (Wenzel et al. 2006b). 
 
The final observation for the questionnaire was an approaching-significance (p=0.059) 
MPOD difference between individuals who wore spectacles or ultraviolet (UV)-filtering 
CLs full time (MPOD 0.47±0.15) and those who wore no spectacles or non-UV-filtering 
CLs (MPOD 0.42±0.14). Unlike BMI, the differences in the means here were not 
apparently driven by a higher proportion of males in the spectacle/UV CL group (36% 
males vs 64% females) than in the opposite group (42% males vs 58% females). This 
appears to be the first MPOD study to explore these refractive correction variables, so 
there are no comparisons to be drawn in this case, although the reasoning behind any 
association, should it truly exist, would presumably have something to do with UV light. 
Light exposure, particularly UV and blue light, is damaging to the retina (e.g., Ham et al. 
1976; Ham et al. 1978; Ham et al. 1980; Ham et al. 1982), and it has been shown to 
cause the production of free-radicals, thus leading to oxidative stress and possibly AMD 
(Algvere et al. 2006). From population-based studies, there is some evidence to suggest 
that chronic light exposure is a risk factor for AMD (e.g., Taylor et al. 1992; Tomany et al. 
2004; Hirakawa et al. 2008). So, taking all this into account, with less UV light reaching 
the retina as a result of absorption by spectacles (see note under table 5.1) or UV CLs, 
there may be less light-induced oxidative stress occurring in the retina, thus permitting an 
augmentation of MP by reducing its antioxidant-function workload. That said, there was 
no sign of any MPOD relationship with questionnaire-reported sunglasses use or light 
exposure, but this is not particularly surprising. With respect to sunglasses, they are 
mostly limited to wear in bright conditions (and the questionnaire only asked about their 
use in bright conditions) so the UV protection is intermittent. Spectacles and CLs, though, 
would be worn far more often because of the need to see clearly (and the questionnaire 
asked specifically about the frequency of spectacle/CL wear and their use in public), so 
chronic exposure to UV light would be less than with sunglasses. For light exposure, an 
approach similar to Mellerio et al. (2002) was chosen, because they found a significant 
(negative) correlation between MPOD and light. However, in the present study, the 
questions on time spent outdoors were far and above the ones that participants struggled 
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with the most, so the lack of any significant correlation may in part be a reflection of the 
overall difficulties in establishing an individual’s light exposure. 
 
For the 50 Asian subjects with completed three-day food diaries, the WISP nutritional 
analysis package produced daily nutrient averages that were in agreement with 
recommended daily intakes (table 5.4), so in view of the healthy average BMI of the 
participants, it seems reasonable to assume that the food diary inputs were accurate. 
Furthermore, published L and Z mean daily intakes from MPOD studies have varied from 
1.1 mg (Ciulla et al. 2001a) up to 3.7 mg (Beatty et al. 2001), so the average of 1.3 mg 
per day in this study lends support to the reliability and accuracy of manually inputting L/Z 
levels using the USDA nutrient database (USDA 2010). 
 
On average, the vegetarians in this part of the study had a statistically significant higher 
average intake of L/Z than the meat-eaters. This was not altogether unexpected, but it 
was interesting that there was no concurrent higher average MPOD for the vegetarians. 
In the same vein, the males in this part of the study did not have a higher intake of L/Z 
despite maintaining a higher average MPOD than the females. In fact, although not 
statistically significant, the female L/Z mean was more than double that of the male. This 
kind of outcome has been reported before (Hammond et al. 1996a; Curran-Celentano et 
al. 2001; Burke et al. 2005), and it ties in with the theories for male-female MPOD 
differences discussed earlier. However, the L/Z-MPOD insignificance for dietary 
background and gender was more likely driven by the lack of any overall correlations 
between MPOD and L/Z, which was against the findings of some investigations (e.g., 
Bone et al. 2000; Werner et al. 2000; Ciulla et al. 2001a; Curran-Celentano et al. 2001; 
Mares et al. 2006; Wenzel et al. 2007a), and in accordance with several others (e.g., 
Hammond et al. 1996a; Beatty et al. 2001; Kirby et al. 2010). Aside from a genuine lack 
of any L/Z-MPOD correlation, it is possible that the cause was rooted in a problem with 
the method used to collect dietary information; in the life of a student, a three-day food 
diary may not be very representative of overall diet, so in hindsight a detailed food 
frequency questionnaire would probably have been a better option. This theory is in part 
supported by the fact that BMI was unrelated to any of the major dietary components that 
might be expected to influence it (i.e., energy, fat, carbohydrate). 
 
The only nutrients that did demonstrate a relationship with MPOD were sodium and 
chloride (i.e., salt) in males. The correlation was inverse and strong (see figure 5.5), but 
in view of the food diary issue mentioned in the previous paragraph, this result should 
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probably be interpreted with caution, particularly as salt has never been mentioned before 
in terms of MP. 
 
Nutrients aside from L and Z that have been noted to have some level of association with 
MPOD in earlier studies are fat, fibre and iron. Positive and significant associations have 
been reported between dietary fat intake and MPOD in males, and the exact opposite for 
females (Hammond et al. 1996a), although in most other studies (Hammond et al. 1995; 
Werner et al. 2000; Ciulla et al. 2001a; Curran-Celentano et al. 2001; Nolan et al. 2004; 
Nolan et al. 2007b), including an all-female one (Mares et al. 2006), there have been no 
significant associations. Mares et al. (2006) did find, however, that polyunsaturated fat 
intake, in combination with dietary L/Z and fibre, accounted for three percent of the 
variation in MPOD in their study of 1698 women; higher intakes of these nutrients 
resulted in higher MPOD. Ciulla et al. (2001a) also reported a positive and significant link 
with fibre, while Hammond et al. (1996a) obtained a significant, positive relationship 
between MPOD and iron intake in men. 
 
Comparing the Asian MPOD mean with the Caucasian MPOD mean revealed highly 
significant differences; MPOD in the Asian participants was higher than in the Caucasian 
participants, and this was the case regardless of various sample size and age restrictions 
(table 5.5). Even though there was still a lot of MP overlap between the two races (figure 
5.6), and hence a lot of variation left unexplained by ethnicity (the effect size, r, was 0.35, 
i.e., a medium effect), the difference was clear. So what might be the cause? Going by 
the low fruit and vegetable consumption of the Asian group, it seems unlikely that this 
difference would be the result of dietary factors. It also seems unlikely that gender 
differences between the groups would be a factor, because the ratio of males to females 
in each group was similar, and comparison tests demonstrated significant MPOD 
differences even when each gender was considered separately (U=120, p<0.0005 for 
males, and U=890, p=0.004 for females). It therefore seems reasonable to assume that 
the cause lies elsewhere. 
 
Various aspects of foveal architecture have been associated with MPOD (see table 1.1 in 
chapter 1). For instance, Nolan et al. (2008) found MPOD to be positively and 
significantly correlated with foveal width (r=0.41, p=0.001), and moreover, that the foveas 
of their non-white subjects (Indian/Asian/Hispanic/black) were significantly wider than the 
foveas of their white subjects (p<0.05). Consequently, it is possible that ethnic variations 
in foveal architecture could be a reason for the disparity in MPOD, at least in part. From 
this point of view, it would have been useful to know the spatial profile of MP for the study 
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participants, something that is becoming increasingly popular and beneficial in MP 
studies (Chen et al. 2001; Robson et al. 2003; Berendschot and van Norren 2006; 
Wenzel et al. 2007b; Trieschmann et al. 2008), including race-related ones (Wolf-
Schnurrbusch et al. 2007; Nolan et al. 2008). 
 
Another likely candidate for what might cause differences in MPOD between these two 
races is iris colour, or more specifically, melanin. Like MP, melanin absorbs short-
wavelength light (mainly UV rather than blue) and has antioxidant properties. In the iris, 
its function is predominantly the former, and in the RPE and choroid its function is 
predominantly the latter (Hu et al. 2008). Returning to parallels between AMD and 
MPOD, light irides, which by virtue of their colour contain less melanin than dark irides, 
have frequently been identified as a risk factor for AMD (e.g., Hyman et al. 1983; Weiter 
et al. 1985; Sandberg et al. 1994; Mitchell et al. 1998; Frank et al. 2000; Nicolas et al. 
2003) and a risk factor for low MP (Hammond et al. 1996b; Wooten et al. 1999; 
Hammond and Caruso-Avery 2000; Ciulla et al. 2001a; Mellerio et al. 2002; Kirby et al. 
2010; Sandberg et al. 2010), so in an ethnic group where the vast majority of irides are 
dark, it seems logical that they might have higher levels of MP (and a lower risk for AMD) 
than an ethnic group with a mixture of light and dark iris colours. On account of the 
expected high propensity of dark irides in the Asian sample, an eye colour related MPOD 
difference was not anticipated. All the same, the group were split into a ‘dark brown’ and 
an ‘other’ category, and although not reaching statistical significance, there did appear to 
be a trend towards the darker brown eyes having higher MPODs (p=0.078). The spread 
of MPOD in both groups is illustrated in figure 5.8. Iris colour in this study, as in others 
(Hammond and Caruso-Avery 2000; Ciulla et al. 2001a; Mellerio et al. 2002), was self-
reported and not verified, so the fact that a difference may exist between two such subtle 
iris colour groups lends support to the theory of melanin, or indeed a genetic unknown 
that has a common inheritance with melanin, being a cause of MPOD differences 
between racial groups. In order to rule out the possibility of a greater male dominance in 
the dark brown than the ‘other’ iris group (with subsequent higher MPOD being the result 
of gender rather than eye colour), the means were compared separately by independent 
t-tests (the assumption of normality was met by all groups). For males, the difference 
became more insignificant – dark brown mean (n=24): 0.47±0.12, ‘other’ mean (n=16): 
0.48±0.13 (t=-0.379, p=0.707). For females, however, the difference became statistically 
significant – dark brown mean (n=37): 0.45±0.16, ‘other’ mean (n=29): 0.37±0.12 
(t=2.365, p=0.021). To investigate this further, table 5.6 shows the individual MPOD 
breakdown of the more unusual iris colours in the ‘other’ category (unusual, that is, for an 
Asian population), so brown irides, which accounted for the largest percentage eye colour 
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in this group, have been omitted. Although the small numbers are probably unsuitable for 
statistical analysis, it is striking that all but one MPOD value is well below the overall 
average of 0.43±0.14 and below the ‘other’ iris colour group’s average of 0.41±0.13. The 
exception to the rule is one of only two males in this subgroup, so it is possible that the 
higher MPOD is related to his gender. It therefore seems highly plausible that iris colour 
is a cause of the racial differences in mean MPOD observed in this study. By filtering out 
more light than lighter coloured eyes, dark eyes could reduce the amount of harmful 
wavelengths reaching the retina (Hammond et al 1996b; Hu et al. 2008), and as a result, 
there might be a lowering of oxidative stress and less depletion of MP than in lighter eyes 
(by removing some of the antioxidant workload). Furthermore, an additional benefit might 
come from the choroid, whose melanin levels are correlated with iris melanin 
(Wakamatsu et al. 2008) and are known to vary between races (Weiter et al. 1986). As 
stated above, choroidal melanin is an antioxidant, so with higher levels of it, there may 
again be less work for MP, although the antioxidant activity of melanin in the choroid is 
clearly in a different location to MP. Another possibility, as suggested by Hammond et al. 
(1996b), is that melanin and MP deposition are co-inherited traits. An interesting 
investigation that could truly establish whether MPOD is related to iris colour/melanin 
would be a study that measured MPOD in individuals with simple iris heterochromia. 
 
 
 
Figure 5.8 The frequency distribution of MPOD for individuals with dark brown eyes and 
other-coloured eyes (brown, light brown, hazel, green) in the Asian subject group. 
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Iris colour MPOD Gender 
Light brown 0.36 Male 
Hazel 0.58 Male 
Hazel 0.26 Female 
Hazel 0.30 Female 
Hazel 0.35 Female 
Hazel 0.38 Female 
Green 0.31 Female 
Green 0.36 Female 
 
Table 5.6 The individual MPOD values of the eight Asian subjects with iris colours other 
than dark brown or brown. 
 
A final rationale for racial differences in MPOD could lie in ethnicity-variant genetics 
besides melanin, but the possibilities in this respect are highly diverse. For example, 
there might be ethnic variations in how effectively L and Z are absorbed, transported or 
deposited, or there could be specific genes/alleles that lead to higher or lower MPOD, or 
indeed the first example could be the result of the second example. Twin studies on 
MPOD have demonstrated that there is definitely a genetic component to individual MP 
levels (Hammond et al. 1995; Liew et al. 2005), and a spousal-based MPOD study 
appeared to confirm this also – despite statistically significant correlations for dietary and 
blood serum levels of L and Z between married couples, MPOD between husbands and 
wives was not correlated at all (Wenzel et al. 2007a). Recently, and for the first time, a 
specific gene and its respective genotypes were examined as part of an MPOD study; 
Loane et al. (2010a) compared MPOD in three different genotype groups of the 
apolipoprotein E gene, a gene that codes for lipoproteins that may carry L and Z in 
serum. It was found that subjects in one of the genotype groups – which contained at 
least one specific allele – had significantly higher MPOD than subjects in the other two 
groups – which were both without the specific allele. (As described by Loane et al., the 
allele in question, Apo ε4, has also been shown to reduce the risk for AMD.) This 
confirms again the genetic aspect of MP, which is not unexpected given the still large 
amount of unexplained inter-subject MPOD variation in the current study and many 
previous ones. 
 
In conclusion, MPOD in a group of young adults of South Asian origin was largely 
unrelated to any physical, ocular, lifestyle, dietary or environmental factors. Males and 
females, however, did have significantly different MP levels, and compared with a 
Caucasian group of adults, MPOD was significantly higher in the Asian group, which in 
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turn could mean a decreased risk for AMD in this race. As discussed in the introduction, 
though, current information on AMD prevalence in South Asians, particularly with respect 
to comparisons with Caucasians, is limited.  
 
5.5 Summary 
This chapter has explored for the first time the range of MP in a South Asian population 
sample. In the next chapter, observation turns to intervention, with a novel attempt to 
increase MPOD. 
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CHAPTER 6: THE EFFECT OF BLUE-LIGHT-FILTERING CONTACT LENSES ON 
MACULAR PIGMENT OPTICAL DENSITY: AN EXPLORATORY STUDY 
 
In each of the earlier chapters, the MPOD measurements have been a one-visit 
assessment, because that was all that was required for the nature of the research being 
conducted. However, the key findings from the previous chapter were that, in general, 
South Asians have higher MPOD values than Caucasians, and that male Asians have 
higher MPOD values than female Asians. In other research a number of additional 
variables have been associated with differences in MPOD. So what can be done for 
those individuals who have reduced MPOD compared with others, and thus a potentially 
increased risk for AMD? Dietary intervention is the standard method by which 
researchers have aimed to increase MPOD, but the study described in this chapter steps 
away from convention and introduces a fresh attempt at increasing MPOD. 
 
6.1 Background and rationale 
In the preceding chapter, cumulative exposure to sunlight as a risk factor for AMD was 
mentioned briefly. Like many of the proposed causes of AMD, the reasoning behind the 
hypothesis is interwoven with several other hypotheses as well. Firstly there is the widely 
quoted work of Ham and colleagues who reported a series of monkey-based experiments 
that showed a harmful effect to the retina of short-wavelength light (UV, violet and blue) 
compared with longer wavelengths of light (Ham et al. 1976; Ham et al. 1978; Ham et al. 
1980; Ham et al. 1982). As a result, there might be a directly damaging effect of this type 
of light over time in the human eye. In combination with this reason, or unaccompanied, it 
could be that light in general (and short-wavelength light in particular) contributes to 
oxidative stress in the retina (Beatty et al. 2000b; Algvere et al. 2006), oxidative stress 
being one of the major pathogenesis theories of AMD (Beatty et al. 2000b). Both these 
theories then go hand in hand with the next thread in the AMD-light exposure story, 
whereby cataract surgery (and lens replacement with a UV-filtering intraocular lens) has 
been connected on some level with the development or progression of AMD (Bockelbrink 
et al. 2008), the theory being that after cataract surgery, the blue light absorption 
previously carried out by the aging, yellowing crystalline lens can no longer happen, so 
the retina experiences an influx of blue light (Bockelbrink et al. 2008) and everything that 
may or may not go along with that as described above. Add to all this the potential 
contribution of MP, and things become even more interesting, which is what led to the 
original idea for the current study.  
 
 111 
There has been a great deal of interest surrounding the use of yellow (i.e., blue-light-
filtering) intraocular lenses (IOLs), and the possibility that they may confer some 
protection against AMD by filtering out blue light in addition to UV light (Cuthbertson et al. 
2009; Edwards and Gibson 2010; Henderson and Grimes 2010; Davison et al. 2011). 
Several thorough, contemporary reviews have advocated the use of these IOLs, 
concluding that there are no clinically-significant disadvantages over UV-only IOLs 
(Cuthbertson et al. 2009; Henderson and Grimes 2010; Davison et al. 2011), and that 
besides the potential for AMD protection, they may actually offer other advantages, such 
as improvements to glare disability (Hammond et al. 2010; Gray et al. 2011). Although at 
the present time there have been no clinical studies examining whether yellow IOLs 
decrease the risk for, or slow the progression of, AMD, Davison et al. made the 
seemingly valid statement that the large number and range of studies conducted are 
enough to support the use of yellow IOLs, in the same way that UV-blocking IOLs were 
introduced ‘without definitive clinical trial’ (Davison et al. 2011).  
 
With a yellowing natural lens or a yellow artificial lens filtering out some of the blue light 
before it reaches the retina, there could be an expected augmentation in MP, or at least 
less depletion of MP, because it is being assisted by either lens type. This was alluded to 
in a previous chapter when discussing the possibility of myopic refractive error being 
associated with higher MPOD (section 4.4 in chapter 4). In that chapter it was also 
pointed out the relationship between age and MP is unresolved. This might well be down 
to a complicated balance between increased lens yellowing with age (and the subsequent 
possibility of an augmentation in MP), and increased oxidative stress with age (Nolan et 
al. 2009; Beatty et al. 2000b) (and the subsequent possibility of a reduction in MP), both 
of which would be expected to vary to some degree from person to person. So what if a 
blue filter was introduced to a younger, less lens-yellowed eye, such that it would mimic 
the absorption characteristics of an older, more lens-yellowed eye? Without the 
equivalent oxidant load of an older eye, it is theoretically plausible that the MP of that 
younger eye would increase. However, in the absence of any pathology or refractive 
requirement, clear lens exchange for a blue-filtering IOL would be improbable and 
unethical. The wearing of yellow spectacle lenses is an option, but they would perhaps be 
considered cosmetically unappealing. Yellow CLs, on the other hand, would be more 
discreet than spectacles, and they could offer further protection to the retina by filtering 
light from all directions (Kwok et al. 2003; Walsh and Bergmanson 2011), assuming, that 
is, that any spectacles worn would be of a non-wraparound style. 
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The aim of this exploratory study was to examine the effect, if any, on MPOD of wearing 
a yellow (blue-light-filtering) CL over the course of one year. If found to increase MPOD 
(or even if not), more extensive trials could see these lenses eventually being offered as 
a protective measure to individuals most at risk of AMD, such as those with a family 
history of the disease. 
 
6.2 Methods 
SUBJECTS 
A university-wide recruitment email was sent to staff at Aston, and a separate email was 
sent to all current undergraduate optometry students at Aston. The emails specified that 
the study was for experienced soft CL wearers only. Interest from 22 people was 
received. The exclusion criteria for this study included toric and multifocal CL wearers, so 
six of the 22 potential volunteers were unsuitable on these grounds. In addition, two 
volunteers anticipated being unable to attend all the appointments, one did not wish to 
wear non-daily disposable CLs, one developed an eye infection before the first planned 
appointment and consequently decided against participating, and four failed to reply to 
follow-up emails. Further exclusion criteria (besides toric and multifocal lenses) were: age 
younger than 18 years or older than 60 years; VA worse than 0.2 logMAR (Snellen 6/9.5); 
and the presence of any relevant ocular disease. Eight individuals attended an initial 
appointment with investigator 1 – an eye and CL examination, and an MPOD assessment 
on the MPS. All were deemed suitable for inclusion and consented to take part in the 
study, but one volunteer (for reasons unknown) dropped out before the next appointment. 
The remaining seven subjects (1 male, 6 females) took part for the whole duration of the 
study. They were all in good general and ocular health, with a spectacle and CL VA of 
0.14 logMAR (Snellen 6/7.5–2) or better in each eye (except for one subject’s CL VA, 
which was corrected for her near vision). 
 
Aston University’s Ethics Committee approved the study. All subjects signed an informed 
consent form, and all procedures adhered to the tenets of the Declaration of Helsinki. 
 
CHOICE OF CONTACT LENS AND YELLOW TINT 
Several factors were taken into consideration when choosing which CL to use, including 
type, frequency of replacement, and whether or not have a lens with a high level of UV 
absorption. The decision was made to use a two-weekly disposable, daily wear silicone 
hydrogel lens with high UV-blocking properties (Acuvue Oasys). The UV element meant 
that the yellow CLs would be comparable to yellow IOLs, with UV light being absorbed as 
well as blue.  
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Several sample lenses were sent for tinting to an independent CL manufacturer with 
expertise in specialist CLs (Cantor and Nissel Ltd, Brackley, Northamptonshire, UK). The 
samples were returned with corresponding transmission curves. Two types of yellow tint 
were supplied. According to the curves provided in a review article by Cuthbertson et al. 
(2009) (figure 6.1), the transmission of the lighter tint approximated well to the 
transmission of a 50-year-old crystalline lens for the wavelength range 430 nm to 500 nm. 
This included a virtually identical transmission (48% and 50%) at 460 nm, i.e., the peak of 
MP absorption. Beyond 500 nm, the transmission of the CL increased rapidly, reaching 
80 percent transmission by 505 nm, compared with approximately 73, 65 and 56 percent 
at 505 nm for a 30, 50 and 70-year-old crystalline lens respectively. The deeper tint 
transmitted less than 20 percent of light up to 490 nm, then transmission increased 
rapidly, reaching 80 percent by 530 nm (figure 6.2), which equated well to 80, 73 and 65 
percent at 530 nm for a 30, 50 and 70-year-old crystalline lens respectively. Although it 
was recognized that most blue-light-filtering IOLs attempt to mimic the transmission of an 
eye with a lens age somewhere between 30 and 50 years old (see figure 6.1), because 
the subjects taking part in this study were anticipated to be a range of ages (up to 60 
years old), there seemed to be little advantage in choosing the lighter tint with 
transmission characteristics equivalent to a reasonably young lens. The darker yellow tint 
was thus selected (see figure 6.2). Thought was given to the possibility of disruption to 
visual function, but preliminary investigations showed no differences in terms of contrast 
sensitivity (Pelli-Robson), colour vision (City and Ishihara tests, plus traffic light colour 
recognition), stereopsis or VA. There has been some debate as to whether yellow IOLs 
reduce scotopic sensitivity and/or disrupt circadian rhythm (Mainster and Turner 2010), 
but the abovementioned reviews of the literature, particularly the later ones with access to 
the most recent data, have overwhelmingly come to the conclusion that any effects are 
clinically insignificant (Cuthbertson et al. 2009; Henderson and Grimes 2010; Davison et 
al. 2011). Admittedly, the chosen tint did suppress more light than a blue-filtering IOL, but 
the decision had already been taken to fit only one eye with a yellow CL, so any effects 
would be reduced by this approach, and moreover, the CLs were unlikely to be worn for 
all waking hours. Fitting the contralateral eye with an untinted lens of the same brand and 
type also offered a simple way of controlling for any within or between subject variables 
that could influence MPOD, such as dietary changes over time. 
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Figure 6.1 The average light transmission of the human crystalline lens at age 30, 50 and 
70 (demonstrated on every graph), compared with the light transmission of a variety of 
intraocular lenses, divided by category. (Reprinted from Cuthbertson et al. 2009.) 
 
 
 
 
Figure 6.2 The transmission curve of the chosen yellow (blue-filtering) CL (top), and its 
appearance in situ (bottom). (Photograph courtesy of Miss Cecylia Jones.)  
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MPS 9000 AND CONTACT LENS CHECKS 
Visit 1: Investigator 1 (OH) performed an eye examination and a CL examination (with the 
subject’s current CLs), followed by a CL fitting with the new (Acuvue Oasys) CLs, and 
then an assessment of MPOD using the MPS. For the latter, each subject received verbal 
instructions and completed a short practice test, after which the prior established protocol 
was used (chapter 3). Right and left eyes were assessed alternately; the right eye was 
always tested first. The averages of the central minima and peripheral minima were used 
to calculate MPOD. For the purposes of masking (see below) and consistency, subjects 
wore their spectacles for MPOD measurements throughout the study period. 
 
After visit one, the appropriate CLs were ordered and sent on for yellow tinting. 
Unfortunately, some substantial delays in receiving the first batches of lenses meant that 
the length of the study had to be reduced to a total of nine months (eight months wear 
time and a one month post-study check-up). 
 
Visit 2: Investigator 2 (FE) carried out a CL collection with the clear and yellow-tinted CLs. 
With no problems evident, subjects were permitted to begin lens wear. They were 
instructed to wear their CLs at least five days a week, on a daily wear basis. 
 
Visit 3: After one month of CL wear, investigator 2 carried out a CL check. The lenses 
were removed and investigator 1 used the MPS to assess MPOD in both eyes of each 
subject. 
 
Visit 4: After three months of CL wear, a third MPOD assessment was performed 
(investigator 1). 
 
Visit 5: After five months of CL wear, investigator 2 carried out another CL check. The 
lenses were removed and a fourth MPOD assessment was performed (investigator 1). 
 
Visit 6: After eight months of CL wear, investigator 2 carried out a final CL check. The 
lenses were removed and a fifth MPOD assessment was performed (investigator 1). 
Subjects were asked to stop wearing the yellow CL from then on; any surplus yellow 
lenses were collected at this appointment. 
 
Visit 7: One month after ceasing yellow CL wear, a sixth and final MPOD assessment 
was performed (investigator 1). 
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The total time per visit was normally between 30 and 60 minutes. 
 
MASKING 
The study was single-masked. For all subjects, investigator 1 (operator for the MPOD 
measurements) was unaware of which eye was wearing the blue-light-filtering CL; 
investigator 2 was responsible for sending the appropriate lenses for yellow tinting. 
 
SAMPLE SIZE 
As an exploratory study, it was difficult to estimate the sample size required. 
Nevertheless, on the basis of G*Power 3.1 calculations for two dependent means (one-
tailed), a sample size of ten subjects was recommended for 80 percent power at the five 
percent alpha significance level. This was assuming an increase in mean MPOD of 0.08 
between the first and fifth MPOD measurements. 
 
STATISTICS 
Microsoft Excel and IBM SPSS were used for data analysis. Perhaps unsurprisingly for a 
small subject group, the data sets did not meet the assumption of normality, so mean 
MPOD values over time were compared by non-parametric repeated measures analysis. 
The differences between data sets were all normally distributed, though, so paired-
samples t-tests were used when comparing mean MPOD values between two visits.  
 
6.3 Results 
MEAN MPOD 
Table 6.1 shows the mean MPOD of the seven participants at each of the visits where 
MP was measured. Also shown is the mean C-only MPOD (peripheral estimate provided 
by the MPS, based on subject age), because for the purposes of monitoring change in 
MPOD over time, this test is acceptable, and the test-retest repeatability is better than it is 
for the standard (centre and peripheral derived) MPOD (see chapter 7).  
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Measure Time 
Mean (±SD) MPOD Mean (±SD) C-only MPOD 
Yellow CL 
eye 
Normal CL 
eye 
Yellow CL 
eye 
Normal CL 
eye 
1 Baseline 0.45 ± 0.20 0.40 ± 0.14 0.49 ± 0.19 0.48 ± 0.15 
2 One month of CL wear 0.45 ± 0.18 0.43 ± 0.18 0.50 ± 0.18 0.47 ± 0.18 
3 Three months of CL wear 0.43 ± 0.20 0.44 ± 0.19 0.49 ± 0.20 0.48 ± 0.19 
4 Five months of CL wear 0.45 ± 0.21 0.43 ± 0.18 0.50 ± 0.19 0.48 ± 0.19 
5 Eight months of CL wear 0.46 ± 0.21 0.42 ± 0.15 0.50 ± 0.21 0.46 ± 0.17 
6 One month post CL wear 0.45 ± 0.17 0.39 ± 0.12 0.50 ± 0.19 0.45 ± 0.13 
 
Table 6.1 Mean MPOD (and C-only MPOD) of the seven participants at each of the six 
MPS visits. 
 
By observation only, there did not appear to be any noticeable differences in the mean 
MPODs, and repeated measures analysis confirmed that there was no statistically 
significant change from baseline to the end of the wearing period for the eyes wearing the 
yellow CL or the eyes wearing the normal CL (table 6.2). The same was true for C-only 
MPOD. Paired-samples t-tests were used to compare two visits at a time. Only the results 
for measure one (baseline) versus measure five (end of the wearing period) are shown in 
table 6.2, but the results of all the other combinations can be found in appendix 8 (table 
A8.1). Again, there were no statistically significant differences, apart from a borderline 
difference between MPOD measures five and six for the eyes wearing the normal CL 
(p=0.047). Figure 6.3 clearly illustrates the lack of MPOD change over time in all 
categories. 
 
 Comparison Statistic value Significance (p) value 
Y
e
llo
w
 C
L
 
e
y
e
 
MPOD measure 1 to 5 
2
 = 2.928 0.570 
C-only MPOD measure 1 to 5 
2
 = 0.992 0.911 
MPOD measure 1 vs 5 t = -0.617 0.560 
C-only MPOD measure 1 vs 5 t = -0.634 0.549 
N
o
rm
a
l 
C
L
 
e
y
e
 
MPOD measure 1 to 5 
2
 = 4.571 0.334 
C-only MPOD measure 1 to 5 
2
 = 5.190 0.268 
MPOD measure 1 vs 5 t = -1.592 0.162 
C-only MPOD measure 1 vs 5 t = 1.641 0.152 
 
Table 6.2 Statistical comparisons of the mean MPOD across all of the MPS visits 
combined, except the last (i.e., measure 1 through to measure 5), and between visits one 
(measure 1 – baseline) and five (measure 5 – end of the wearing period) specifically.  
‘2’ refers to Friedman’s ANOVA test, and ‘t’ refers to a paired-samples t-test. Both tests 
were appropriate for the distribution of the data sets involved. 
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Figure 6.3 Mean MPOD (and C-only MPOD) at each MPS visit.  
The error bars are ± 1 SD. 
Measures: 1 = baseline; 2 = after one month of CL wear; 3 = after three months of CL 
wear; 4 = after five months of CL wear; 5 = after eight months of CL wear; 6 = one month 
post yellow CL wear.  
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INDIVIDUAL MPOD – SUBJECT 1 
Background: 23-year-old Asian female with brown eyes. 
Previous CLs: Silicone hydrogel, UV-blocking, two-weekly disposable, daily wear.  
Study CLs: RE -3.25 DS, LE -3.00 DS. Worn for 8½ months between August 2010 and 
May 2011.  
MPOD: See table 6.3 and figure 6.4. 
MPS proficiency: Excellent – consistently optimal curves produced throughout the study. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.33 0.34 0.38 0.38 
2 0.29 0.29 0.36 0.36 
3 0.30 0.34 0.37 0.38 
4 0.34 0.34 0.38 0.36 
5 0.36 0.31 0.38 0.35 
6 0.36 0.33 0.41 0.38 
 
Table 6.3 MPOD over time for subject 1. 
 
  
  
Figure 6.4 MPOD over time for subject 1. 
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INDIVIDUAL MPOD – SUBJECT 2 
Background: 19-year-old Asian female with brown eyes. 
Previous CLs: Non silicone hydrogel, non UV-blocking, monthly disposable, daily wear.  
Study CLs: RE -4.00 DS, LE -3.50 DS. Worn for 8½ months between August 2010 and 
May 2011.  
MPOD: See table 6.4 and figure 6.5. 
MPS proficiency: Slightly variable – central and peripheral curves were mostly optimal, 
but sometimes not. Three tests were required for at least one eye at every visit. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.39 0.30 0.42 0.45 
2 0.42 0.38 0.45 0.41 
3 0.34 0.40 0.40 0.41 
4 0.38 0.36 0.42 0.42 
5 0.47 0.35 0.49 0.37 
6 0.41 0.32 0.41 0.37 
 
Table 6.4 MPOD over time for subject 2. 
 
  
  
Figure 6.5 MPOD over time for subject 2. 
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INDIVIDUAL MPOD – SUBJECT 3 
Background: 25-year-old Caucasian female with blue eyes. 
Previous CLs: Non silicone hydrogel, non UV-blocking, daily disposable, daily wear.  
Study CLs: RE -5.50 DS, LE -6.00 DS. Worn for 8 months between October 2010 and 
July 2011.  
MPOD: See table 6.5 and figure 6.6. 
MPS proficiency: Very good – virtually all optimal curves throughout the study. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.46 0.42 0.53 0.45 
2 0.45 0.41 0.52 0.43 
3 0.47 0.38 0.52 0.41 
4 0.45 0.38 0.49 0.41 
5 0.42 0.45 0.47 0.46 
6 0.49 0.41 0.49 0.43 
 
Table 6.5 MPOD over time for subject 3. 
 
  
  
Figure 6.6 MPOD over time for subject 3. 
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INDIVIDUAL MPOD – SUBJECT 4 
Background: 28-year-old Caucasian female with blue eyes. 
Previous CLs: Non silicone hydrogel, part UV-blocking, daily disposable, intermittent daily 
wear.  
Study CLs: RE -1.75 DS, LE -1.75 DS. Worn for 8 months between October 2010 and 
July 2011.  
MPOD: See table 6.6 and figure 6.7. 
MPS proficiency: Very good – virtually all optimal curves throughout the study. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.34 0.35 0.37 0.41 
2 0.34 0.38 0.41 0.41 
3 0.33 0.39 0.35 0.42 
4 0.30 0.36 0.36 0.38 
5 0.30 0.35 0.37 0.41 
6 0.31 0.32 0.38 0.41 
 
Table 6.6 MPOD over time for subject 4. 
 
  
  
Figure 6.7 MPOD over time for subject 4. 
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INDIVIDUAL MPOD – SUBJECT 5 
Background: 28-year-old Caucasian female with blue eyes. 
Previous CLs: Non silicone hydrogel, non UV-blocking, monthly disposable, daily wear.  
Study CLs: RE -2.25 DS, LE -2.75 DS. Worn for 8 months between November 2010 and 
July 2011.  
MPOD: See table 6.7 and figure 6.8. 
MPS proficiency: Good – required three tests at a few visits but this normally resulted in 
at least two optimal central and peripheral curves. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.31 0.24 0.31 0.29 
2 0.37 0.25 0.37 0.29 
3 0.26 0.25 0.34 0.29 
4 0.28 0.23 0.33 0.29 
5 0.29 0.29 0.31 0.26 
6 0.30 0.29 0.33 0.31 
 
Table 6.7 MPOD over time for subject 5. 
 
  
  
Figure 6.8 MPOD over time for subject 5. 
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INDIVIDUAL MPOD – SUBJECT 6 
Background: 57-year-old Caucasian female with light brown eyes. 
Previous CLs: Silicone hydrogel, non UV-blocking, monthly disposable, daily wear 
(monovision).  
Study CLs: RE -0.50 DS (near), LE -2.75 DS (distance). Worn for 8 months between 
October 2010 and July 2011.  
MPOD: See table 6.8 and figure 6.9. 
MPS proficiency: Slightly variable – central and peripheral curves were sometimes 
optimal, sometimes not. Three tests were required for at least one eye at every visit. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.43 0.50 0.55 0.60 
2 0.43 0.50 0.53 0.57 
3 0.46 0.51 0.55 0.59 
4 0.51 0.59 0.61 0.64 
5 0.50 0.49 0.55 0.57 
6 0.50 0.44 0.58 0.52 
 
Table 6.8 MPOD over time for subject 6. 
  
  
Figure 6.9 MPOD over time for subject 6. 
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INDIVIDUAL MPOD – SUBJECT 7 
Background: 21-year-old Asian male with dark brown eyes. 
Previous CLs: Non silicone hydrogel, non UV-blocking, daily disposable, daily wear.  
Study CLs: RE -5.00 DS, LE -5.00 DS. Worn for 7½ months between November 2010 
and July 2011.  
MPOD: See table 6.9 and figure 6.10. 
MPS proficiency: Variable – concentration levels were low for this subject, which was not 
helped by his very high levels of MP making every test rather long. As a result, some but 
nowhere near all curves were optimal. Three tests were required for at least one eye at 
every visit. 
Outcome (taking MPS proficiency into account): No change in MPOD. 
 MPOD C-only MPOD 
Measure Yellow CL eye Normal CL eye Yellow CL eye Normal CL eye 
1 0.90 0.66 0.88 0.76 
2 0.84 0.79 0.89 0.82 
3 0.86 0.85 0.90 0.88 
4 0.89 0.77 0.88 0.84 
5 0.90 0.72 0.94 0.77 
6 0.81 0.63 0.89 0.71 
Table 6.9 MPOD over time for subject 7. 
  
  
Figure 6.10 MPOD over time for subject 7. 
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6.4 Discussion 
Cumulative exposure to light is a frequently cited but unsettled-upon risk factor for AMD 
(e.g., Taylor et al. 1992; Darzins et al. 1997; Tomany et al. 2004; Khan et al. 2006; 
Fletcher et al. 2008; Hirakawa et al. 2008). Any association is thought to arise more from 
damage caused by short-wavelength light such as UV and blue, rather than longer-
wavelength light, although out of UV and blue, the latter is probably more likely because 
in adults most UV light is absorbed by the crystalline lens before it reaches the retina 
(Margrain et al. 2004). As an absorber of blue light, and as an antioxidant, MP may also 
have a place in the AMD-light exposure story. It was for this reason that the present study 
investigated whether MPOD increases by wearing a blue-light-filtering CL. 
 
For eight (±0.3) months, seven subjects wore a yellow (UV and blue-filtering) CL in one of 
their eyes and a clear (UV-filtering) CL in their other eye. There was no apparent change 
in MPOD for the group as a whole or for any one individual. The hypothesis for this study 
was that there would be an increase in MPOD in the eye wearing the yellow CL, because 
the MP would have a reduced antioxidant and blue light absorption workload, and would 
therefore be depleted less, although the blue-filtering function of MP is probably a passive 
mechanism, so the lack of change in this respect is not unexpected. The results suggest 
that MP is stable in the retina, regardless of any change in the amount of light reaching it. 
This is in contrast to the results of Nolan et al. (2009), who published an interesting study 
during the planning stages of this experiment.  
 
In Nolan’s investigation MPOD was measured by HFP five times over the course of a 
year in a group of 24 (or 30 – contradictory numbers in the article) presbyopes (Nolan et 
al. 2009). All of the subjects were due to have cataract surgery at the time of the first 
measurement. Thirteen (or 16) of them had a standard IOL implanted and 11 (or 14) had 
a yellow IOL implanted. Measurements of MPOD were taken one week before surgery 
and one week after, followed by further measures three, six and twelve months later. The 
results indicated a statistically significant increase in MPOD over time for the yellow IOL 
group but not for the standard IOL group. This was against the hypothesis of the 
researchers involved, who expected to see no change in MPOD for the yellow IOL group, 
but rather a decrease in MPOD for the standard IOL group, on account of the anticipated 
increase in incident blue light for this group (Nolan et al. 2009). As stated in section 6.2, 
the implanted yellow IOL would be expected to absorb a lot more blue light than a 
standard IOL, but still considerably less than an age-yellowed cataractous lens (figure 
6.1). The authors conceded that their results were difficult to explain, but they did offer 
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some plausible theories. However, looking more closely at the actual MPOD values 
provided in the paper for each subject at each visit, the findings are perhaps not quite as 
remarkable as the overall results indicate. Four of the 11 yellow IOL subjects 
demonstrated an increase in MPOD at each visit, with an average increase of 0.24 (range 
0.1 to 0.33) from one week post-surgery to 12 months post-surgery. The remaining seven 
subjects’ MPOD values tended to go up and down by a small amount over the course of 
the visits, much like the subjects in the present study. For two of these subjects, the final 
comparison (visit 5 minus visit 2) indicated an increase, yet one subject’s MPOD 
appeared to have increased only because of an erroneous low reading at the second 
visit, to which all the other visits were then compared (subject 6 in table 2 of Nolan et al. 
2009). The other subject’s MPOD increase may also have been artificial, as their 
readings seemed rather variable and could therefore be the result of difficulties with the 
HFP task (subject 19 in table 2 of Nolan et al. 2009). Nevertheless, there does seem to 
have been a genuine rise in MPOD for some subjects in the yellow IOL group, and it is 
hard to reconcile the statistically significant results of Nolan et al. with the not statistically 
significant results of the present study, considering that here a filter was used that 
blocked out more blue light than that of a yellow IOL. Possible reasons for the 
discrepancy are now discussed. 
 
There were a reasonably good variety of volunteers in this investigation, but ideally there 
would have been a few more males and a slightly wider age range; apart from one 57-
year-old subject, the age range was limited to between 19 and 28 years old. Notably, it 
was only for this older subject that MPOD showed any consistent and sustained increase 
(top left graph of figure 6.9). While not wishing to draw any invented conclusions, this was 
in the eye wearing the yellow CL, so it is tempting to speculate that the results of this 
study might have been different with a sample of subjects closer in age to the subjects in 
Nolan et al.’s sample (Nolan et al. 2009). Given that any anticipated change in MPOD 
rested largely on the antioxidant function of MP, it might simply be that in a twenty-
something adult, the oxidant load isn’t yet enough to require any major contribution from 
MP, and for that reason there was no possibility of reducing its depletion. In chapter 1 
(section 1.2) it was reported that MP has been located in the polyunsaturated fatty acid 
rich membranes of human perifoveal rods (Rapp et al. 2000), and also that these 
polyunsaturated fatty acids are highly susceptible to lipid peroxidation (and hence cell 
damage) by free radicals (Beatty et al. 2000b). However, lipid peroxidation in the central 
human retina is strongly correlated with age (De La Paz and Anderson 1992; Beatty et al. 
2000b), which supports the reasoning for why there was no augmentation of MP in this 
particular group of subjects. 
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In dietary intervention studies, it has been noted several times that subjects with the 
lowest baseline MPOD often show the greatest rise in MPOD (Wenzel et al. 2006b; 
Aleman et al. 2007; Richer et al. 2007; Borel et al. 2011). With this in mind, it is 
interesting to note that the four subjects who appeared to demonstrated a real increase in 
MP in Nolan and colleagues’ yellow IOL study had starting MPODs (the mean of one 
week pre-surgery to one week post-surgery) between 0.11 and 0.29, whereas the starting 
MPODs in the present study were between 0.31 and 0.90. It is therefore possible that an 
individual with a blue-light-filtering IOL or CL who has a low baseline MPOD may be more 
likely to see an increase in MP than someone with a higher baseline MPOD. This might 
then offer another explanation as to why there was no increase in the current 
investigation. That said, six of the remaining seven subjects in the IOL study had similar 
starting MPODs to the other four (between 0.03 and 0.29), so one could argue otherwise. 
 
Other possible reasons come down to limitations of the study. Firstly, the frequency of CL 
wear could not be closely monitored. Secondly, the study duration may not have been 
long enough to produce a change in MPOD. Thirdly, the MPS is not able to assess the 
spatial distribution of MP. Addressing the first of these limitations, it should be noted that 
before beginning the study, all but one of the volunteers wore their regular CLs for at 
least six days of the week. The other volunteer had observed that in recent months she 
had been wearing her daily disposable lenses most days, and had therefore been 
planning on changing to a monthly CL. Consequently, this limitation is unlikely to be a 
reason for the insignificant findings. Study duration is a credible reason, particularly in 
view of the proposed lower age-related need for MP in an antioxidant capacity. All the 
same, the four subjects that demonstrated a realistic increase in MPOD in the yellow IOL 
study (Nolan et al. 2009) did so by the six-month check. With respect to the third 
limitation, it is worth returning again to Nolan and colleagues, who were able to measure 
the MP spatial distribution of their participants; the rise in MP was only significant in the 
central one degree of the fovea. As a result, it does not seem likely that any increases in 
MP were missed by not extending the area over which MP was measured. Furthermore, 
any augmentation of MP in the perifovea (where the peripheral ‘control’ test is carried 
out), which might have caused an underestimation of MP in the fovea, was negated by 
observing the C-only MPOD values as well as the actual MPOD values. 
 
In conclusion, there was no increase in MPOD in this group of mainly young adults 
wearing a blue-light-filtering CL for eight months, but the possibility that such an increase 
might occur in an older group of adults cannot be excluded. If, in time, MP is proven to be 
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a true player in the defence against AMD, blue-blocking CLs could be an added option for 
a CL-wearing presbyope who, for example, has a close family history of this disease. The 
subjects in this study reported no problems specific to the yellow CL, and they adapted 
quickly to the altered appearance of their environment, so from this point of view there is 
no reason why this kind of lens could not be worn in place of a standard CL. 
 
6.5 Summary 
The study described in this chapter attempted to increase MPOD by an innovative CL 
method, and the results were a little disappointing. It is possible that variation in the 
abilities of individuals to accurately complete the psychophysical task of the MPS may in 
some small way have contributed to the insignificant findings, so having an objective 
MPOD measuring device would have been a welcome addition to the investigation. One 
such objective device did become available after beginning this study, but before it could 
be used as a possible replacement for the MPS, it needed to be evaluated in terms of its 
repeatability. The next chapter describes this evaluation of the new device, and in doing 
so, it also allows for an inter-session repeatability assessment of the MPS, using the 
protocol that has been used throughout the main studies described so far (chapters 4 to 
6). 
 
 
 130 
CHAPTER 7: CLINICAL ASSESSMENT OF THE MACULAR PIGMENT 
REFLECTOMETER 
 
Macular pigment measurement in the preceding studies has been carried out using only 
the MPS, and as previous chapters have described, this instrument requires a 
considerable amount of time, as well as good concentration from the subject, to produce 
accurate and consistent results. However, over the course of the research period, 
another MPOD device was purchased, called the Macular Pigment Reflectometer (MPR), 
which provided the opportunity for fast, objective measurements. In this chapter, an 
assessment of the MPR is described. 
 
7.1 Background and rationale 
As the name suggests, the MPR is an MP device that employs the FR (fundus 
reflectometry) method of measurement. As such, it offers the advantages of objectivity 
(on the part of the subject) and speed, and unlike most reflectometry equipment, it does 
not require pupil dilation (van de Kraats et al. 2006). Furthermore, it is the first MPOD 
instrument to provide individual measures of L and Z, in addition to their combined value 
(van de Kraats et al. 2008). 
 
To recap, FR is the quantitative measurement of light reflected from the fundus. In terms 
of MP measurement, there are two main approaches: comparison and spectral analysis. 
The comparison technique is akin to the HFP method; light reflected from the fovea is 
compared with light reflected from a non-foveal retinal area, using two wavelengths (one 
absorbed by MP and one not) or a spectrum of wavelengths (Berendschot and van 
Norren 2004). A spectral analysis, which is the method used by the MPR, uses a detailed 
optical model of the pathways of light in the eye (e.g., van de Kraats et al. 1996) to 
analyse a spectrum of light reflected from the retina.  
 
So far, only the research group who developed the MPR has published data on its 
reliability. The aim of this study was therefore to provide an independent assessment of 
the MPR, by determining inter-session repeatability and inter-operator reproducibility, as 
well as comparing it with the MPS. This also allowed for an assessment of MPS inter-
session repeatability, using the proposed protocol described in chapter 3. 
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7.2 Methods 
SUBJECTS 
Twenty-five subjects (10 males, 15 females) were recruited by email and by word-of-
mouth, and consisted of staff and students from Aston University. They were all in good 
general health, with ages ranging from 19 to 52 years (mean±SD: 29.9±10.1 years). 
Refractive error (BVS) was between +3.00 DS and -8.75 DS (mean±SD: -1.50±3.00 DS). 
Visual acuity was measured under standard testing conditions using a logMAR letter 
chart; all participants had VAs of 0.14 logMAR (Snellen 6/7.5–2) or better in the eye being 
tested (the right eye for all but one of the participants). Exclusion criteria were: age 
younger than 18 years; VA worse than 0.2 logMAR (Snellen 6/9.5); and the presence of 
any ocular disease. A further two subjects (one male and one female, aged 24 and 28) 
took part in the MPS part of the study only. Thirteen of the subjects had prior experience 
with the MPS, and one with the MPR. 
 
Aston University’s Ethics Committee approved the study. All subjects signed an informed 
consent form, and all procedures adhered to the tenets of the Declaration of Helsinki. 
 
MPS 9000 
Due to the high light levels of the MPR producing bright afterimages, measurement of 
MPOD with the MPS was completed first, followed by measurement with the MPR. Each 
subject received verbal instructions and completed a short practice test, after which the 
prior established protocol was used (chapter 3). The averages of the central minima and 
peripheral minima were used to calculate MPOD. Using this technique, all subjects had 
two to three good quality central and peripheral curves to derive MPOD from, and no 
subjects needed to be removed from the analysis. Only one operator (OH) took the 
measurements on the MPS, with each subject repeating the test 7 to 14 days after the 
first session. 
 
MACULAR PIGMENT REFLECTOMETER 
The MPR (figure 7.1) is currently a research-based instrument produced in the 
Netherlands (University Medical Centre Utrecht). It uses a series of optical relay systems 
to focus a 30W halogen lamp onto a one-degree spot on the retina (figure 7.2). The 
reflected light is received by an optical fibre and sent to a spectrometer, which produces a 
spectral reflection output that is visible via a computer with the appropriate software 
(figure 7.3). Training was provided by one of the developers of the MPR, and the 
recommended protocol was adhered to throughout. 
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Figure 7.1 The Macular Pigment Reflectometer (MPR). 
 
 
Figure 7.2 Schematic diagram of the MPR.  
L1-L8 = lenses 1-8. M = mirror. Also shown (left) is the configuration of the illumination 
and detection beams. The semicircular illumination beam must be positioned in the upper 
half of a subject’s pupil. This is to ensure that the detection beam, which is invisible, stays 
within the pupil. (Reprinted from van de Kraats et al. 2006.) 
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Figure 7.3 A typical spectral reflection output, with corresponding MPOD values to the 
upper right. It shows a high level of reflection in the long-wavelength region, with a 
gradual reduction due to absorption by blood and melanin, followed by further absorption 
(and lower reflection) by MP from around 520 to 440 nm. The lowest reflection from 440 
to 400 nm is due to increasing absorption by the crystalline lens. The output is actually 
the mean of two successive one-second measurements, with the vertical error bars 
representing their standard deviations at the numerous wavelengths; the error bars are 
generally larger in the short-wavelength region than in the longer-wavelength region. The 
operators in this study saved outputs according to the following criteria: error bars that 
were as small as possible from about 500 nm upwards; reflections that looked high from 
about 550 nm upwards; and reflections that looked low from about 450 nm downwards. 
 
At the beginning of each data collection session, the MPR was switched on and left to run 
for at least ten minutes, to ensure the lamp reached its maximum brightness. The rest of 
the procedure took place in a darkened room. 
 
Firstly, the machine was calibrated using a 230 mm black, anodized tube with an inner 
white surface at the end of it (‘white calibration’). This involved mounting the tube onto the 
device, setting a lens focusing dial to ‘R’ (reference, +2.00 DS), and using the computer 
software to begin measuring (30x1-second measurements). A single measurement was 
then taken, with the expectation of a one percent reflection (figure 7.4). 
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Figure 7.4 Single measure output following a white calibration. It shows a uniform one 
percent reflection. 
 
After this initial setup (carried out once at the start of each data collection session), a 
‘dark calibration’ was done, using a shorter, completely black tube, and with the lens 
focusing dial set to the individual subject’s BVS distance refraction. In the dark calibration 
mode, a further 30x1-second measurements were automatically taken, followed by a 
single measurement. Each subject (without spectacles or CLs) was directed to place their 
chin onto a rest and their forehead onto a brow bar; they were asked to remain as still as 
possible. The light beam was aligned (using a joystick) into the upper half of their pupil, at 
a distance of one to two cm from the eye. The subject looked directly into the centre of 
the light spot while the operator monitored the continuously-produced reflection output 
and the light spot position in the pupil, making small joystick adjustments as necessary 
for a good output (see figure 7.3 for details). Five or six such outputs were saved by each 
operator for later analysis. This analysis involved choosing and averaging the best 
reflections according to the criteria given in figure 7.3. As a result, a minimum of two 
reflection outputs were accepted per subject. Two subjects were removed from the MPR 
analysis altogether, due to consistently poor outputs (one male, aged 19, with a BVS of  
-6.25 DS; one female, aged 35, with a BVS of -8.75 DS). 
 
Data from the MPR was collected by two operators, PV and OH, in two sessions 
separated by 7 to 14 days. In the first session, PV took the measurements first (PV1), 
followed by OH (OH1). In the second session, OH took the measurements first (OH2), 
followed by PV (PV2). The reference measure, dark measure and lens focus dial were 
 135 
common to both operators, i.e., these procedures were carried out by the first operator of 
the session, and were not repeated by the second. 
 
MASKING 
To avoid bias, neither operator looked at any prior MPOD results of any subjects 
(regardless whether collected by themselves or the other operator) before taking the 
measurements in either session. 
 
SAMPLE SIZE 
A sample size of 25 is in line with many studies examining the repeatability and 
agreement of MP measuring devices (e.g., Hammond et al. 1995; Ciulla et al. 2001b; de 
Kinkelder et al. 2011). 
 
STATISTICS 
Microsoft Excel and IBM SPSS were used for data analysis. Mean MPS-based MPOD for 
the two sessions was compared using a paired-samples t-test or its non-parametric 
equivalent, as appropriate in terms of normality. MPR-based MPOD for the two sessions, 
and between operators, was compared in the same way. Repeatability and reproducibility 
of each instrument was determined using Bland-Altman analysis and plots (Bland and 
Altman 1986), whereas Pearson’s r correlations were used to quantify the association 
between MPS and MPR MPODs, on account of their different measurement principles. 
 
7.3 Results 
MEAN MPOD 
Table 7.1 is a summary of the mean MPODs for the 23 final participants at the two 
sessions, and using the two devices. The means for L and Z are also given, as provided 
by the MPR.  
 
Instrument 
Mean (±SD) MPOD Mean (±SD) L Mean (±SD) Z 
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2 
MPS (OH) 0.324±0.148 0.328±0.146 N/A N/A N/A N/A 
MPR (PV) 0.590±0.202 0.571±0.222 0.287±0.172 0.276±0.113 0.304±0.133 0.296±0.139 
MPR (OH) 0.562±0.165 0.564±0.215 0.251±0.112 0.269±0.123 0.311±0.126 0.295±0.151 
 
Table 7.1 Mean MPODs for 23 subjects, as determined using the MPS and the MPR, 
along with the separate means for L and Z, where appropriate.  
PV = operator PV. OH = operator OH. N/A = not applicable. 
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Paired-samples t-tests and Wilcoxon signed rank tests (as appropriate) comparing within-
operator mean MPOD between the first and second sessions showed no statistically 
significant differences for the MPS or for the MPR (see table A9.1 in appendix 9 for 
details). The same was true when comparing L and Z separately. Moreover, comparing 
between-operator mean MPR-based MPOD at the first and second sessions (including L 
and Z separately) also showed no statistically significant differences. Finally, the four sets 
of MPR repeat data considered together (PV1, PV2, OH1, OH2) were not significantly 
different according to a one-way repeated measures ANOVA (F=0.373, p=0.774). Again, 
the same was true for L and Z values. These findings indicate an absence of any learning 
or fatigue effect with either instrument. 
 
INSTRUMENT AGREEMENT 
Paired-samples t-tests comparing the MPS-based mean MPODs with the MPR-based 
mean MPODs (i.e., MPS1 vs PV MPR1; MPS1 vs OH MPR1; MPS2 vs PV MPR2; MPS2 
vs OH MPR2) yielded highly significant differences between the two instruments 
(p<0.0005 in all cases), with consistently higher MPOD obtained on the MPR. However, 
there was a statistically significant correlation between the instruments in all cases, with r-
values ranging from 0.58 to 0.72 (figure 7.5). 
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Figure 7.5 The relationship between MPOD measured with the MPS (always operator 
OH) and MPOD measured with the MPR (operator OH or PV), at visits one and two.  
MPS1 vs PV MPR1: r=0.721, p<0.0005. MPS1 vs OH MPR1: r=0.580, p=0.004. MPS2 vs 
PV MPR2: r=0.703, p<0.0005. MPS2 vs OH MPR2: r=0.614, p=0.002. 
The diagonal dotted lines indicate what a perfect match between the two methods would 
look like. 
 
REPEATABILITY AND REPRODUCIBILITY 
As stated in chapters 2 and 3, accurate analysis of test-retest data can be achieved using 
the CR (Bland and Altman 1986), which gives the 95 percent confidence limits for the 
amount of difference between two sets of results. It is calculated as 1.96 multiplied by the 
standard deviation of the differences between two sets of data, and indicates the amount 
of change that can occur between readings and still be classed as measurement noise. In 
other words, only increases or decreases in MPOD greater than the CR should be 
classed as clinically significant. Table 7.2 and figure 7.6 show the inter-session 
agreement between MPOD values measured with the MPS for all 27 participants. Also 
shown is the inter-session agreement for C-only MPOD (peripheral estimate provided by 
the MPS, based on subject age). The CRs were 0.08 and 0.06 for MPOD and C-only 
MPOD respectively, using the protocol as per chapter 3. This shows that when the same 
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operator is taking repeated MPS readings over time, changes in MPOD greater than 
these values can be classed as clinically significant. 
 
 MPS1 – MPS2 C-only MPS1 – MPS2 
Mean difference -0.003 -0.005 
SD of mean difference 0.043 0.032 
Coefficient of repeatability 0.084 0.063 
 
Table 7.2 Determination of inter-session CR values for MPS-based MPOD (n=27).  
 
 
Figure 7.6 Bland-Altman plot representing the difference in MPS-based MPOD readings 
between visits one and two, compared with the mean of both visits (n=27). 
The solid line represents the mean difference, and the dashed lines represent the 95% 
confidence limits. 
 
Table 7.3 shows the inter-session agreement between MPOD values measured with the 
MPR for the 23 qualifying participants. Using the highest value of the two for repeatability, 
the data suggests that when the same operator is taking repeated MPR readings over 
time, only changes in MPOD of more than 0.4 can be classed as clinically significant 
(figure 7.7). The same was true for two different operators taking repeated readings over 
time. Using the highest value of the two for intra-session reproducibility, the data 
suggests that if two different operators are assessing MPR-based MPOD within the same 
session, differences of less than or equal to 0.25 are not clinically significant (figure 7.8). 
For the equivalent L/Z repeatability and reproducibility values, see table A9.2 in appendix 
9. 
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 MPR repeatability MPR reproducibility 
PV1-PV2 OH1-OH2 PV1-OH1 PV2-OH2 PV1-OH2 PV2-OH1 
Mean difference 0.019 -0.001 0.028 0.008 0.027 0.009 
SD of mean difference 0.204 0.180 0.126 0.086 0.196 0.203 
Coefficient of 
repeatability/reproducibility 
0.400 0.353 0.247 0.169 0.384 0.397 
 
Table 7.3 Determination of coefficient of repeatability/reproducibility values for MPR-
based MPOD (n=23).  
PV1 = MPR-derived MPOD at visit one by operator PV. PV2 = MPR-derived MPOD at 
visit two by operator PV. OH1 = MPR-derived MPOD at visit 1 by operator OH. OH2 = 
MPR-derived MPOD at visit 2 by operator OH. 
 
 
Figure 7.7 Bland-Altman plot representing the difference in MPR-based MPOD readings 
between visits one and two (operator PV), compared with the mean of both visits (n=23). 
 
 
Figure 7.8 Bland-Altman plot representing the difference in MPR-based MPOD readings 
between operators (at visit one), compared with the mean of both (n=23). 
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7.4 Discussion 
This study is the first independent assessment of the MPR, and as such will be beneficial 
to other independent research groups using this instrument. It also offers a further 
comparison with the MPS, whose repeatability using a set protocol was assessed for the 
first time. 
 
The overall mean MPOD for 27 subjects using the MPS was 0.35±0.16 (0.33±0.15 for 
n=23), and the overall mean MPOD for 23 subjects using the MPR was 0.57±0.20. These 
values are in line with previously reported MPS and MPR means (van de Kraats et al. 
2006; Makridaki et al. 2009; van der Veen et al. 2009a; van der Veen et al. 2009c; 
Bartlett et al. 2010c; de Kinkelder et al. 2011). The overall means for L and Z considered 
separately on the MPR were 0.27±0.13 and 0.30±0.14 respectively, and these means 
were statistically different (z=-3.398, p=0.001). Van de Kraats et al. (2008) found L and Z 
means of 0.20 and 0.49, so while a higher level of Z than L is common to both studies, 
the difference between the two appears to be less in the present study. It has been 
reported that the ratio of L:Z in the central 0 to 0.25 mm (1º) of the human retina is 1:2.4 
(Bone et al. 1988). This equates well with the results of van de Kraats et al. (2008) but 
not with the results from the present study, which perhaps indicates that the instrument, 
or use of the instrument, was not optimized in the current study, or that it was used in a 
different way from van de Kraats and colleagues. 
 
As per previous MPR/MPS comparative studies (van der Veen et al. 2009a; van der Veen 
et al. 2009b; de Kinkelder et al. 2011), in the vast majority of cases, MPOD measured 
with the MPS was lower than MPOD measured with the MPR (see figure 7.5). This is 
considered to be largely as a result of the ‘edge hypothesis’ of HFP – the well-adopted 
belief that HFP-based MPOD is mediated by the edge of the stimulus, so that for a one-
degree stimulus, the recorded MPOD corresponds to the MP level at 0.5 degrees from 
the centre of the fovea, rather than the true peak level at zero degrees, or the total MP in 
the central one degree (Werner et al. 1987; Hammond et al. 1997c). In contrast, the MPR 
measures and averages MPOD over the whole one-degree area (van der Veen et al. 
2009b), and can therefore be expected to give higher mean MPOD values than the MPS. 
It has also been suggested that the difference may be attributable, in part, to the 
peripheral reference of the MPS having residual MP, thus causing an underestimation in 
MPOD (van der Veen et al. 2009a; van der Veen et al. 2009b). The MPR does not rely on 
any such peripheral reference area. There is an assumption with HFP that the reference 
area always has negligible MP, and is therefore just a measure that accounts for any blue 
light absorption by the crystalline lens. Evidence for the latter has been demonstrated in 
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several ways (see Wooten et al. 1999; Cuilla et al. 2001b; Makridaki et al. 2009), but the 
negligible MP part of this assumption has been challenged (Robson et al. 2003; 
Rodriguez-Carmona et al. 2006; Bhosale et al. 2007). In fact, in two studies where the 
MPR itself was modified to determine MPOD spatial profiles, a measurable level of MP 
was still present eight degrees from the fovea (van de Kraats et al. 2008; van der Veen et 
al. 2009b), i.e., at the reference point used by the MPS and many other HFP devices. 
Interestingly, however, because the MPS also provides a fixed estimate peripheral 
measure based on subject age, it allowed for a further comparison with the MPR in the 
present study, without the bias of any potential peripheral MP. The number of cases with 
lower MPS than MPR-based MPOD remained the same, but as in chapter 2, the mean C-
only MPOD was significantly higher than the mean actual MPOD (paired-samples t-tests 
of MPS/C-only MPS at visits one and two, p<0.0005 in both cases for n=23). They were, 
though, very well correlated (r=0.97 in both cases for n=23, p<0.0005), with the straight-
line regression equations indicating that C-only MPOD is always slightly higher than 
actual MPOD (e.g., y = 1.09x + 0.01 for visit one). Consequently, a small but measurable 
level of MP at the peripheral reference may actually be the cause of this particular 
discrepancy, although it is clearly not enough to explain the large differences between 
MPS and MPR MPOD. 
 
Agreement (Pearson’s r) between the MPR and MPS varied from 0.58 to 0.72. Previously 
reported correlations are 0.78 (n=26, van der Veen et al. 2009a), 0.72 (n=19, van der 
Veen et al. 2009b) and 0.87 (n=23, de Kinkelder et al. 2011), so while the correlations in 
the present study are good, they are generally not as good as these earlier correlations. 
This inconsistency is discussed below. 
 
A high level of inter-session repeatability is important if MPOD is to be accurately 
monitored over time, especially in an intervention scenario, where a patient is increasing 
their L/Z/MZ intake via dietary modification and/or supplement use. In this study, the 
protocol previously described for reducing the CR on the MPS to a level at which clinically 
significant changes in MPOD can be realistically detected, was put to the test. The result 
was an inter-session CR of 0.084, which is the best repeatability for the MPS so far 
reported, and as good as, if not better than, any stated HFP reliability of the last 15 years 
(Bartlett et al. 2010b; Howells et al. 2011). It could be argued that the results were 
influenced by the fact that about half of the participants were already familiar with the 
MPS. However, further analysis of the data, using only those with no prior experience on 
the MPS (n=14) resulted in a CR of 0.072 (and 0.043 for C-only MPOD), thereby 
countering this issue. 
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The inter-session CR of the MPR was between 0.35 and 0.40 in this study. By 
comparison, van de Kraats et al. (2006) took inter-session repeat measurements for ten 
subjects, and although the CR was not stated in that particular paper, it was cited some 
time later as 0.18 by de Kinkelder et al. (2011). While it is still questionable whether the 
latter CR would allow accurate detection of MPOD changes with L/Z/MZ dietary 
modification/supplementation (see below), the roughly double CR obtained in the present 
study would almost certainly not. This is disappointing and requires evaluating. 
 
Firstly, it is worthwhile considering whether the differing number of participants in the two 
studies could be a reason for the CR discrepancy. Looking back over previous papers 
that have produced reliability indicators for MPOD measuring techniques, there appears 
to be a trend towards better inter-session repeatability being associated with fewer 
subject numbers, and vice-versa. This is illustrated in figure 7.9 (r=0.64, p=0.007). (Note 
that only HFP data was used here, since there is very limited data on inter-session 
repeatability for any of the other MPOD measurement techniques.) The fact that there 
were more than double the number of subjects in the present study than in the van de 
Kraats study could, in part, explain the difference in recorded repeatability.  
 
 
Figure 7.9 A summary of inter-session CR data from HFP studies.  
It shows the number of subjects tested and the associated CR (see table A9.3 in 
appendix 9 for derivation and references). The dotted line is the trend line. Not every 
study explicitly provided the CR, but it was calculable where a mean difference and 
standard deviation was given. The correlation, r, is 0.64 (p=0.007). 
* = published CR data for the MPS (van der Veen et al. 2009a; Bartlett et al. 2010c; de 
Kinkelder et al. 2011). 
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A second consideration is whether differing methodology might have influenced the data 
in the present investigation. The method followed here was carried out according to the 
instruction of one of the MPR developers. However, this does differ in several ways from 
the method described in the original published paper by van de Kraats et al. (2006). The 
main difference was in the procedure for dark calibration, which in the current study 
involved setting the lens focusing dial to the subject’s known distance refraction, 
calibrating with the appropriate tube, and then beginning measurements on the subject, 
as described in section 7.2. The van de Kraats approach was more protracted: the lens 
focusing dial was set to the subject’s spectacle refraction and adjusted, if necessary, until 
the subject reported that the edges of the light spot were sharply focused; a further lens 
dial adjustment was made, if required, while looking at the generated reflection spectrums 
for the highest amplitude outputs (with the subject set up as described in section 7.2); the 
dark calibration was carried out; and lastly, the actual measurements were taken. 
 
The issue of lens focusing adjustments was addressed with some of the first subjects in 
the present study. It was found that in general, those subjects reported an approximately 
±1.00 DS range (from their spectacle prescription) over which they thought the edge spot 
was in clear focus. It therefore seems unlikely that this would affect the results. Moreover, 
van de Kraats et al. (2006) remarked that “dark calibration changed very little over the 
course of hours, thus in fact it could have been taken less frequently”, i.e., not on every 
subject. Carrying out a lens focus adjustment while observing some initial outputs may 
have proved useful, though. With this in mind, the reflection outputs and data from the 
current study were re-examined. Twelve of the 23 subjects showed at some point an 
inter-session MPOD difference of greater than 0.1. Of these, all but two were still deemed 
to have good reflection outputs. Some reflection spectrums were visibly different between 
visits one and two, but they were also equally acceptable according to the prior stated 
criteria, and thus there was no reason to exclude them. The remaining two subjects were, 
in hindsight, of less optimal quality. Removing them from the analyses reduced the 
majority of the CRs considerably, as depicted in table 7.4. In addition, all the MPR/MPS 
correlations improved (table 7.5), putting the MPR/MPS instrument agreement in line with 
the previously published articles. Of interest, perhaps, is that from the original 25 
participants who had MPR measurements taken, four were eventually removed, and 
three of these had a BVS spectacle prescription of -6.25 DS or higher (-6.25, -6.50 and  
-8.75). The lens dial on the MPR has markings from +5 to -6, but it will only turn as far  
-5.25 for myopic prescriptions (the plus goes up well beyond +5). Subsequently, it seems 
advisable to limit future study intakes to participants with BVS prescriptions lower than  
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-5.25 DS. No mention of this was made in the earlier publications.  
 
 MPR repeatability MPR reproducibility 
PV1-PV2 OH1-OH2 PV1-OH1 PV2-OH2 PV1-OH2 PV2-OH1 
Original coefficient of 
repeatability/reproducibility 
0.400 0.353 0.247 0.169 0.384 0.397 
Coefficient of 
repeatability/reproducibility 
after removal of two 
subjects’ data 
0.244 0.215 0.226 0.175 0.230 0.289 
 
Table 7.4 Coefficient of repeatability/reproducibility values for the MPR, before and after 
the removal of two subjects’ data – see text for details. 
 
Comparison Original Pearson’s r 
Pearson’s r after removal 
of two subjects’ data 
MPS 1 and PV MPR 1 0.72* 0.82* 
MPS 1 and OH MPR 1 0.58** 0.60**^ 
MPS 2 and PV MPR 2 0.70* 0.83* 
MPS 2 and OH MPR 2 0.61** 0.75* 
 
Table 7.5 Pearson’s r correlations between MPOD measured with the MPS and MPR, 
before and after the removal of two subjects’ data – see text for details. 
*p<0.0005 **p<0.005  
^ Removal of a clear outlier, visible only on this comparison, improved the correlation 
further to r=0.71 (p<0.0005). 
 
Another methodology difference was in how many MPOD values to use for the analysis. 
Where mentioned, the suggestion has been that the mean of five measurements was 
used to give an overall MPOD value (van de Kraats et al. 2006; van de Veen et al. 
2009b). In the help guide that came with the MPR, the advice is to repeat measurements 
three to five times to allow for later selection. Selection was the final chosen method in 
the present study, although it made very little difference to the calculations.  
 
Overall, it is likely that the poor repeatability values of the MPR in the present study are 
not attributable solely to measurement noise. Small adjustments of the lens focus, and 
exclusion of participants with a moderate degree of myopia may well improve 
repeatability. Other things that may improve it are further operator experience/training on 
choosing an optimal reflection spectrum. The test may be objective on the part of the 
subject, but it is not for the examiner. This is evidenced by the outputs that varied in 
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appearance and MPOD value between visits one and two, but of which neither could be 
chosen as the better, despite following the advised criteria for a good output. Three 
‘normal’ reflection output examples came with the MPR software; it would be helpful to 
have more, along with some ‘abnormal’ examples. Even with this knowledge acquired, 
there is still a lot for the operator to observe all at once, namely; the beam position in the 
pupil and, away from that, the reflection output on a computer screen – high reflection in 
the 550 nm region, low reflection in the 450 nm region, small error bars, plus the help 
guide recommends looking at the MPOD values as they are generated (not done in the 
present study to avoid bias). It would seem that even in the experienced hands of the 
instrument developers, a sizeable amount of within-session variation can still occur. 
Figure 7.10 shows graphs of MPR-derived L and Z levels for three subjects over the 
course of a six-month Z supplementation trial and ten-month follow-up (van de Kraats et 
al. 2008). For the first subject, in particular, intra-session readings appear to vary by up to 
0.31.  
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Figure 7.10 Lutein (L) and zeaxanthin (Z) MPR-based measurements for three subjects 
(S1-S3) over the course of 18 months.  
From days 0 to 182, the subjects took a daily Z supplement (20 mg). Individual 
measurements at each visit are represented by the triangles. Trend lines before and after 
Z intake are shown; the bolder trend lines are significantly different from zero (p<0.05). 
(Reprinted from van de Kraats et al. 2008.) 
 
If, with a few changes, the repeatability of Aston University’s MPR device is brought in 
line with that reported by de Kinkelder et al. (CR 0.18, de Kinkelder et al. 2011), will that 
be sufficient to monitor any MPOD change over time? Connolly et al. (2010) recently 
produced a review table which showed that MPOD rarely increases by more than 0.07, 
on average, over the course of a 15 to 24 week intervention period with 5 to 30 mg of L, Z 
or MZ (via supplement use or dietary modification), so at first glance it would appear not. 
However, in the aforementioned Z supplementation study by van de Kraats et al. (2008), 
a statistically significant increase in Z was demonstrated by all three participating subjects 
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over the course of 16 months (figure 7.10). The data from figure 7.10 were subsequently 
extrapolated in the current investigation to calculate a mean value of L and Z for each 
subject at each visit, which in turn allowed for a combined MPOD value (L+Z) at each 
visit. The results are presented in figure 7.11. An increase is evident for all subjects. 
However, if the results are considered from a more practical and clinical point of view, in 
which a patient wishes to know whether their MPOD has increased from one eye test to 
another, the results would be less conclusive. For example, if one takes the MPOD at 
approximately -7 days as the initial eye test, i.e., a week before beginning Z 
supplementation, then the MPOD at the end of the supplementation period 
(approximately 180 days) as the six-month follow-up eye test, the MPOD increase is 
0.06, 0.07 and 0.13 for subjects one to three respectively. None of these would be 
considered clinically significant, going by the CR of 0.18. Nevertheless, it could be 
rightfully argued that the MPR is only a research-based instrument, in which more regular 
visits are to be expected, and therefore MPOD differences would be picked up. 
 
  
 
Figure 7.11 Data extrapolated from van de Kraats et al. (2008) (figure 7.10) to show 
MPOD values for three subjects (S1-S3) over the course of 18 months.  
From days 0 to 182, the subjects took a daily Z supplement (20 mg). 
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In conclusion, the MPR, as used in the current study, is a straightforward and fast task for 
the subject, requiring them simply to stare at a bright light for about one minute in total. It 
is not repeatable enough to detect changes in MPOD over time, but it does provide an 
accurate one-off measure of MPOD for most individuals, as assessed by comparison with 
the MPS. Modification to the methodology would increase the time required from the 
subject (by approximately two minutes), but it would potentially improve repeatability. The 
MPS, as used in the current study, is a more demanding task for the subject, requiring 
concentration and time (between 10 and 20 minutes in total, depending on the results). 
However, the repeatability is excellent, and as a result, it is more likely to detect a 
significant change in MPOD than the MPR. 
 
7.5 Summary 
This chapter has introduced a second MPOD measuring instrument, the MPR, whose 
reliability did not match that of the MPS. On account of its availability, however, the MPR 
is also used (along with the MPS) in the final study, in which another attempt to increase 
MPOD is made, this time using dietary modification. 
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CHAPTER 8: MACULAR PIGMENT RESPONSE TO DIETARY MODIFICATION WITH 
KALE: AN EXPLORATORY STUDY 
 
In the previous chapter, the inter-session repeatability of the MPS was shown to be very 
good when used in a set way. The inter-session repeatability of the MPR (an objective 
MPOD device) was not so good, although with some method modification it’s possible 
that its repeatability could be improved, as was the case with the MPS. In this final 
investigation, both instruments are used to monitor MPOD in a second intervention study. 
Unfortunately, the present research had already started before the last research had 
finished, so the same MPR protocol is employed. Here, a classic dietary modification 
study takes place using kale, a vegetable frequently advocated to patients by 
optometrists and ophthalmologists as being a rich source of L, yet also a vegetable that 
had yet to be included in any MPOD-based supplementation studies. 
  
8.1 Background and rationale 
Over the last 14 years there have been at least 31 studies in which MPOD has been 
monitored in humans following an increase in supplement or dietary intake of L, Z or MZ 
(Hammond et al. 1997a; Landrum et al. 1997; Berendschot et al. 2000; Johnson et al. 
2000; Aleman et al. 2001; Duncan et al. 2002; Bone et al. 2003; Cardinault et al. 2003; 
Bernstein et al. 2004; Koh et al. 2004; Richer et al. 2004; Franciose et al. 2006; Kopsell 
et al. 2006; Kvansakul et al. 2006; Rodriguez-Carmona et al. 2006; Wenzel et al. 2006a; 
Wenzel et al. 2006b; Aleman et al. 2007; Bone et al. 2007b; Schalch et al. 2007; 
Trieschmann et al. 2007; Wenzel et al. 2007b; Johnson et al. 2008; Stringham and 
Hammond 2008; van de Kraats et al. 2008; Berson et al. 2010; Bone and Landrum 2010; 
Connolly et al. 2010; Zeimer et al. 2010; Borel et al. 2011; Nolan et al. 2011). The dietary 
interventions have been fewer in number than the supplement interventions; they have 
focused on the foods spinach, corn and eggs, and all have used the HFP technique to 
measure MP (Hammond et al. 1997a; Johnson et al. 2000; Kopsell et al. 2006; Wenzel et 
al. 2006b).  
 
Subjects in a dietary MPOD study by Hammond et al. (1997a) consumed 60 g of spinach 
and/or 150 g of corn per day for up to 15 weeks. This equated to 10.8 mg of L and 0.3 mg 
of Z per day for the spinach, and 0.4 mg of L and 0.3 mg of Z per day for the corn. In 
observational MPOD studies, the mean daily intakes of L and Z have varied from 1.1 mg 
(Ciulla et al. 2001a) up to 3.7 mg (Beatty et al. 2001), so the spinach consumption 
represented a considerable increase in L/Z compared with a typical diet. In the spinach 
and corn combined group (n=11), MPOD notably increased for most of the subjects 
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(n=8), referred to as ‘retinal responders’, but it was unchanged for the remaining subjects 
(n=3), referred to as ‘retinal nonresponders’. In the corn only group (n=2), there was one 
retinal responder and one retinal nonresponder (Hammond et al. 1997a). A dietary 
MPOD study by Johnson et al. (2000) followed an almost identical premise to the 
previous one by Hammond et al., except that there were no subjects who just ate corn. 
The group as a whole (n=7) saw a statistically significant rise in MPOD (from 0.40 at 
baseline to 0.47 at 15 weeks, p<0.05), but individual responses were not provided. 
Kopsell et al. (2006) randomly assigned 30 volunteers to one of three treatment groups: 
high L spinach (n=10), low L spinach (n=10), and no spinach (n=10). The high and low L 
spinach groups each consumed 50 g of spinach, five days a week for 12 weeks. The high 
L spinach contained 6.05 mg of L per 50 g serving, and the low L spinach contained 4.2 
mg of L per 50 g serving. The high L group demonstrated a statistically significant 
increase in MPOD (from 0.34 at baseline to 0.37 at 12 weeks, p=0.021), but the low L 
group and no spinach group did not. Individual responses were not provided. Of note, the 
high L spinach still contained less L than the spinach in Hammond et al.’s study, but this 
was probably because the L values provided by Kopsell et al. related to fresh mass 
spinach, whereas the L values provided by Hammond et al. related to cooked spinach, 
which would result in different L quantities (USDA 2010). Moving away from spinach, 
Wenzel et al. (2006b) assigned 24 volunteers to one of three treatment groups: 
supermarket-bought eggs (n=8), organic-farm-bought eggs (n=8) and a placebo sugar pill 
(n=8). The egg groups ate six eggs per week (no more than two per day) for 12 weeks. 
Eggs are known to be a highly bioavailable source of L and Z (Handelman et al. 1999; 
Chung et al. 2004), so although the supermarket and organic eggs equated to only 0.284 
mg of L/Z per day and 0.826 mg of L/Z per day, respectively, there were statistically 
significant increases in MPOD for both groups (p=0.001 and p=0.04). The pill group saw 
no increase (p=0.51). Interestingly, the lower L/Z egg resulted in a greater augmentation 
of MPOD (by ~0.09 compared with ~0.05 in the higher L/Z egg), which may have been 
because the baseline MPOD of this group was significantly lower than the higher L/Z egg 
group (0.18±0.02 vs 0.37±0.06), and hence there may have been a limitation as to how 
much more L and Z could be captured by the retina in the latter group (Wenzel et al. 
2006b). Like Hammond et al. (1997a), Wenzel and colleagues reported on individual 
changes in MPOD; there were 11 retinal responders and five retinal nonresponders.  
 
Like spinach, kale is a vegetable that eye professionals frequently recommend to their 
patients, and according to the USDA national nutrient database, kale contains more L/Z 
per 100 g than spinach (USDA 2010). Nevertheless, it had yet to be included in any 
interventional MPOD studies, so the study described here aimed to explore the effect on 
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MPOD of incorporating a regular intake of kale to the diet. If kale were proven to increase 
MPOD, this would lend support to the recommendation of kale to members of the public.  
 
8.2 Methods 
SUBJECTS 
Six reliable and trustworthy subjects were personally recruited (3 males, 3 females); four 
were staff members from Aston University’s optometry department, one was an 
undergraduate optometry student, and the other was a close family member of the 
principle investigator (OH). They were all in good general and ocular health, with a VA of 
0.12 logMAR (Snellen 6/7.5–1) or better in the eye being tested. Refractive error (BVS) 
was between +3.00 DS and -8.00 DS (mean±SD: -2.50±4.50 DS). Exclusion criteria 
were: age younger than 18 years; VA worse than 0.2 logMAR (Snellen 6/9.5); the 
presence of any ocular disease; and, as a precaution, any kidney or gallbladder 
problems, because kale contains oxalates, which can be problematic for individuals with 
kidney or gallbladder troubles, although kale is considered a ‘low-oxalate’ vegetable 
(Heaney and Weaver 1990). 
 
Aston University’s Ethics Committee approved the study. All subjects signed an informed 
consent form, and all procedures adhered to the tenets of the Declaration of Helsinki. 
 
DIETARY MODIFICATION PROTOCOL 
The majority of kale was bought from one of two supermarkets. It was UK-grown, 
uncooked and supplied in 200 g bags, which were passed on weekly to the study 
participants for 16 consecutive weeks. One 200 g bag per week was chosen because it 
seemed a decent amount of kale to consume – a lot more than the vast majority of 
individuals would be expected to eat in a week, but not an unachievable amount to eat 
either. Going by the USDA database, it was also expected to contain a considerable 
amount of L/Z, somewhere in the realm of 36 mg per week (USDA 2010), although in 
hindsight this was an oversimplification (see discussion). The participants were asked to 
spread the 200 g of kale over three to five portions, cooking the kale each time and 
incorporating it into a meal (e.g., a stir-fry) or eating it with a meal (e.g., a roast dinner). 
 
At the end of the study period a short questionnaire was sent to each participant to 
establish more details on how the kale was cooked, what it was eaten with, exactly how 
much of it was eaten, etc. A copy of the questionnaire is provided in appendix 10. 
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MPOD MEASUREMENTS 
Measurements of MPOD were taken on seven separate occasions using the MPS and 
the MPR. There were two baseline measurements separated by 7 to 14 days (visits 1 and 
2), followed by measurements after 4, 8, 12 and 16 weeks of kale eating (visits 3 to 6), 
then a final measurement four weeks after finishing the kale eating part of the study (visit 
7). 
 
For measurement of MPOD using the MPS, at the first visit subjects received verbal 
instructions and completed a short practice test, after which the prior established protocol 
was used (chapter 3). After the initial visit, instructions were given only as necessary for 
individual subjects. The averages of the central minima and peripheral minima were used 
to calculate MPOD. Using this technique, all participants at every visit had two to three 
good quality central and peripheral curves to derive MPOD from. Measurements were 
taken in the right eye only, except for one subject whose MPOD was measured in both 
eyes (for reasons explained below). 
 
After the MPS-based measures, the MPR was used to measure MPOD as described in 
the previous chapter (section 7.2 in chapter 7), i.e., after the initial setup, subjects were 
asked to remain as still as possible while staring into the centre of a bright spot of light, 
which was aligned in the upper half of their pupil at a distance of one to two cm from the 
eye. Five or six spectral reflection outputs were saved according to criteria provided in 
chapter 7. In the subsequent analysis, only five outputs (spread between three subjects) 
were deemed too poor for inclusion (out of a total of 185 outputs). One subject 
participating in the study was also the investigator (OH), so whereas it was possible to 
self-complete MPOD measurements on the MPS, it was not possible to self-complete 
MPOD measurements on the MPR. Consequently, it was decided that they would 
measure MPS-based MPOD in both eyes instead of one, to examine the possibility of 
asymmetric changes; most studies of this nature tend to measure MPOD in one eye only 
(e.g., Kopsell et al. 2006; Rodriguez-Carmona et al. 2006; Trieschmann et al. 2007; van 
de Kraats et al. 2008; Connolly et al. 2010), but in studies in which both eyes have been 
assessed, an asymmetric change has been reported once (Bone et al. 2007b). 
 
The total time per visit was between 10 and 20 minutes. 
 
MASKING 
The investigator avoided looking at previous MPOD results prior to each session, in order 
to help prevent any inadvertent bias. For the MPR in particular, the spectral reflection 
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outputs were chosen purely on their appearance (at the time of data collection and in the 
later selection process) and not on what the MPOD readings were. 
 
SAMPLE SIZE 
As an exploratory study, a sample size of six was considered adequate, and it was also in 
line with several other diet and supplement modification MPOD studies (Berendschot et 
al. 2000; Johnson et al. 2000; Koh et al. 2004; Wenzel et al. 2006a; Wenzel et al. 2007b; 
van de Kraats et al. 2008; Connolly et al. 2010). 
 
STATISTICS 
Microsoft Excel and IBM SPSS were used for data analysis. Each data set met the 
assumption of normality, so mean MPOD values over time were compared by one-way 
repeated measures ANOVA. The differences between data sets were also normally 
distributed, so paired-samples t-tests were used when comparing mean MPOD values 
between two visits.  
 
8.3 Results 
MEAN MPOD 
Table 8.1 shows the mean MPOD over time for the six participants consuming 200 g of 
kale per week, using the MPS and MPR devices. Also shown is the mean C-only MPS-
based MPOD (peripheral estimate provided by the MPS, based on subject age), because 
for the purposes of monitoring change in MPOD over time, this test is acceptable, and the 
test-retest repeatability is better than it is for the standard (centre and peripheral derived) 
MPOD (see chapter 7). The MPR gives the breakdown of MPOD into its L and Z 
components, so this information is provided in the table as well. 
 
Visit Time 
Mean (±SD) MPOD 
MPS C-only MPS MPR Lutein Zeaxanthin 
1 Baseline i 0.24 ± 0.11 0.24 ± 0.11 0.51 ± 0.14 0.28 ± 0.07 0.22 ± 0.09 
2 Baseline ii 0.23 ± 0.09 0.24 ± 0.09 0.51 ± 0.12 0.33 ± 0.13 0.18 ± 0.09 
3 4 wks of kale 0.23 ± 0.09 0.25 ± 0.09 0.50 ± 0.16 0.29 ± 0.06 0.21 ± 0.12 
4 8 wks of kale 0.22 ± 0.08 0.24 ± 0.06 0.41 ± 0.10 0.21 ± 0.07 0.20 ± 0.08 
5 12 wks of kale 0.23 ± 0.09 0.24 ± 0.08 0.45 ± 0.11 0.28 ± 0.12 0.18 ± 0.10 
6 16 wks of kale 0.22 ± 0.07 0.24 ± 0.07 0.46 ± 0.12 0.24 ± 0.05 0.21 ± 0.10 
7 4 wks post-kale 0.22 ± 0.08 0.23 ± 0.09 0.54 ± 0.14 0.32 ± 0.10 0.22 ± 0.15 
 
Table 8.1 Mean MPOD of the six participants over the course of the study, determined 
using the MPS (n=6) and the MPR (n=5).  
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By observation only, taking into account the inter-session repeatability of each MPOD 
device as determined in the previous chapter, there did not appear to be any noticeable 
differences in the mean MPODs. Paired-samples t-tests comparing the two baseline 
measurements yielded insignificant differences (p=0.820, 0.921, 0.929, 0.576 and 0.250 
for MPS MPOD, C-only MPOD, MPR MPOD, L and Z, respectively), so in the subsequent 
analyses MPOD values were compared with the second baseline measure, i.e., just 
before kale intake began. Repeated measures analysis confirmed that there was no 
statistically significant change in MPOD from baseline to the end of the dietary 
modification period (table 8.2), as measured by the MPS or the MPR, including C-only 
MPOD, and L and Z. Paired-samples t-tests were used to compare two visits at a time. 
The results for baseline MPOD (visit 2) versus MPOD after 16 weeks of kale-eating (visit 
6) are shown in table 8.2, but the results of the other comparisons with baseline MPOD 
can be found in appendix 11 (table A11.1). In all cases there were no statistically 
significant differences. Figure 8.1 illustrates the lack of MPOD change over time. 
 
Comparison Statistic value Significance (p) value 
MPS MPOD visit 2 to 6 F = 0.883 0.489 
MPS MPOD visit 2 vs 6 t = 1.136 0.299 
C-only MPS MPOD visit 2 to 6 F = 0.156 0.959 
C-only MPS MPOD visit 2 vs 6 t = -0.183 0.861 
MPR MPOD visit 2 to 6 F = 1.102 0.389 
MPR MPOD visit 2 vs 6 t = 1.787 0.149 
Lutein (MPR) visit 2 to 6 F = 1.716* 0.245 
Lutein (MPR) visit 2 vs 6 t = 2.062 0.108 
Zeaxanthin (MPR) visit 2 to 6 F = 1.019 0.427 
Zeaxanthin (MPR) visit 2 vs 6 t = -1.122 0.325 
 
Table 8.2 Statistical comparisons of the mean MPOD from baseline (visit 2) through to 
the end of the dietary modification period (visit 6), and between visits 2 and 6 specifically.  
‘F’ refers to a one-way repeated measures ANOVA, and ‘t’ refers to a paired-samples t-
test (each data set, and the differences between each data set, were normally 
distributed). 
*Here, Mauchly’s test indicated that the assumption of sphericity was not met, and as a 
result, the Greenhouse-Geisser sphericity correction was used. 
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Figure 8.1 Mean MPOD (as measured by the MPS and the MPR) at each visit.  
The error bars are ± 1 SD. 
Visits: 1 = baseline i; 2 = baseline ii; 3 = after four weeks of kale intake; 4 = after eight 
weeks of kale intake; 5 = after twelve weeks of kale intake; 6 = after sixteen weeks of 
kale intake; 7 = four weeks post kale intake. 
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INDIVIDUAL MPOD – SUBJECT 1 
Background: 25-year-old Caucasian male. Had never eaten kale before beginning the 
study and did not eat any further kale between the final supply and the four-week post-
study check. The kale was eaten in addition to his usual vegetables, not as a 
replacement. It was stir-fried with three to four tablespoons of olive oil and eaten with a 
meal, e.g., pasta. 
MPOD: See table 8.3 and figure 8.2. 
MPS proficiency: Very good – virtually all optimal curves throughout the study. 
Outcome: No change in MPOD. 
 MPOD 
Visit MPS C-only MPS MPR Lutein Zeaxanthin 
1 0.11 0.13 0.33 0.21 0.12 
2 0.10 0.17 0.49 0.46 0.03 
3 0.12 0.17 0.29 0.26 0.02 
4 0.12 0.19 0.31 0.21 0.10 
5 0.10 0.16 0.47 0.46 0.01 
6 0.11 0.18 0.37 0.28 0.09 
7 0.12 0.14 0.48 0.48 0.00 
 
Table 8.3 MPOD over time for subject 1. 
  
 
Figure 8.2 MPOD over time for subject 1. 
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INDIVIDUAL MPOD – SUBJECT 2 
Background: 48-year-old Caucasian male. Had never eaten kale before beginning the 
study and did not eat any further kale between the final supply and the four-week post-
study check. The kale was eaten mainly in addition to his usual vegetables, not as a 
replacement. It was boiled and eaten with bacon as part of a soup (15% of the time); stir-
fried with vegetable oil (15% of the time) or steamed (70% of the time), and eaten with a 
meal, e.g., chicken curry. 
MPOD: See table 8.4 and figure 8.3. 
MPS proficiency: Excellent – consistently optimal curves produced throughout the study. 
Outcome: No change in MPOD. 
 MPOD 
Visit MPS C-only MPS MPR Lutein Zeaxanthin 
1 0.19 0.22 0.63 0.28 0.35 
2 0.25 0.23 0.68 0.47 0.21 
3 0.23 0.21 0.52 0.26 0.26 
4 0.25 0.24 0.41 0.12 0.29 
5 0.21 0.23 0.35 0.17 0.18 
6 0.22 0.22 0.59 0.27 0.31 
7 0.22 0.22 0.72 0.37 0.35 
 
Table 8.4 MPOD over time for subject 2. 
  
 
Figure 8.3 MPOD over time for subject 2. 
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INDIVIDUAL MPOD – SUBJECT 3 
Background: 34-year-old Caucasian male. Had occasionally eaten kale before beginning 
the study. Did not eat any further kale between the final supply and the four-week post-
study check. The kale was sometimes eaten in addition to his usual vegetables, and 
sometimes as a replacement for broccoli. It was stir-fried (most of the time) with 
vegetable oil, and boiled (about once a week or every other week). Always eaten with a 
main meal, e.g., beef stew, chicken curry, roast dinner.  
MPOD: See table 8.5 and figure 8.4. 
MPS proficiency: Very good – virtually all optimal curves throughout the study. 
Outcome: No change in MPOD. 
 MPOD 
Visit MPS C-only MPS MPR Lutein Zeaxanthin 
1 0.13 0.12 0.39 0.23 0.17 
2 0.16 0.12 0.35 0.18 0.17 
3 0.12 0.13 0.40 0.23 0.17 
4 0.13 0.14 0.32 0.17 0.15 
5 0.18 0.14 0.33 0.17 0.16 
6 0.14 0.14 0.30 0.16 0.14 
7 0.13 0.12 0.36 0.22 0.14 
 
Table 8.5 MPOD over time for subject 3. 
  
 
Figure 8.4 MPOD over time for subject 3. 
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INDIVIDUAL MPOD – SUBJECT 4 
Background: 27-year-old Asian female. Had never eaten kale before beginning the study 
but did continue to eat it regularly between the final supply and the four-week post-study 
check. The kale was eaten in addition to her usual vegetables, not as a replacement. It 
was stir-fried with one and a half tablespoons of sunflower oil and eaten with a meal, e.g., 
vegetable curry. 
MPOD: See table 8.6 and figure 8.5. 
MPS proficiency: Good – required three tests at a few visits but this always resulted in at 
least two optimal central and peripheral curves. 
Outcome: No change in MPOD. 
 MPOD 
Visit MPS C-only MPS MPR Lutein Zeaxanthin 
1 0.35 0.42 0.62 0.38 0.24 
2 0.31 0.38 0.54 0.28 0.26 
3 0.31 0.38 0.68 0.38 0.30 
4 0.23 0.31 0.54 0.28 0.26 
5 0.34 0.36 0.57 0.33 0.24 
6 0.26 0.37 0.50 0.28 0.22 
7 0.29 0.38 0.61 0.29 0.32 
 
Table 8.6 MPOD over time for subject 4. 
  
 
Figure 8.5 MPOD over time for subject 4. 
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INDIVIDUAL MPOD – SUBJECT 5 
Background: 52-year-old Caucasian female. Had occasionally eaten kale before 
beginning the study and did continue to eat it fairly regularly (in homemade soup) 
between the final supply and the four-week post-study check. The kale was eaten in 
addition to her usual vegetables, not as a replacement. It was boiled with a little butter 
and eaten as part of a soup, stir-fried with olive oil and eaten as part of a stir-fry meal, or 
boiled and eaten with a meal e.g., meat casserole, pasta, roast dinner. 
MPOD: See table 8.7 and figure 8.6. 
MPS proficiency: Excellent – consistently optimal curves produced throughout the study. 
Outcome: No change in MPOD. 
 MPOD 
Visit MPS C-only MPS MPR Lutein Zeaxanthin 
1 0.19 0.19 0.57 0.33 0.24 
2 0.17 0.22 0.50 0.26 0.24 
3 0.19 0.22 0.61 0.31 0.30 
4 0.18 0.23 0.48 0.26 0.22 
5 0.17 0.22 0.56 0.27 0.28 
6 0.22 0.24 0.55 0.23 0.32 
7 0.17 0.22 0.55 0.27 0.28 
 
Table 8.7 MPOD over time for subject 5. 
  
 
Figure 8.6 MPOD over time for subject 5. 
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INDIVIDUAL MPOD – SUBJECT 6 
Background: 28-year-old Caucasian female. Had sometimes eaten kale in the past, but 
none at all for two months before beginning the study. Continued to eat kale on and off 
between the final supply and the four-week post-study check. The kale was sometimes 
eaten in addition to her usual vegetables, and sometimes as a replacement for broccoli or 
sweetcorn. It was stir-fried (most of the time) with sprayed rapeseed or sunflower oil, and 
boiled (about once a week or every other week). Always eaten with a main meal, e.g., 
pasta, roast dinner, stir-fry. 
MPOD: See table 8.8 and figure 8.7. 
MPS proficiency: Good – required three tests at a few visits (only in one eye at any one 
visit) but this always resulted in two optimal central and peripheral curves. 
Outcome: No change in MPOD. 
 MPOD 
Visit MPS RE C-only MPS RE  MPS LE C-only MPS LE  
1 0.34 0.29 0.35 0.33 
2 0.31 0.27 0.35 0.30 
3 0.31 0.29 0.34 0.33 
4 0.29 0.26 0.32 0.30 
5 0.30 0.27 0.34 0.31 
6 0.29 0.26 0.30 0.29 
7 0.29 0.26 0.33 0.30 
Table 8.8 MPOD over time for subject 6. 
  
  
Figure 8.7 MPOD over time for subject 6. 
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8.4 Discussion 
The study described here explored MPOD over time in a group of healthy volunteers, 
following a substantial, but realistically achievable, increase in the consumption of the L-
rich vegetable, kale. As a possible preventer of AMD, efforts to increase MP levels 
through simple dietary methods are important, and consumption of other L-rich foods had 
resulted in increases in MPOD in previous studies, thus setting a precedent for this study. 
 
For 16 weeks, six subjects ate 200 g of UK-grown kale per week, distributed over several 
main meals. There was no apparent change in MPOD for the group as a whole or for any 
one individual, which raises the question, why not? 
 
Firstly, and a major limitation for this study given the insignificant results, the actual L/Z 
content of the kale distributed to the participants was unknown. The USDA database 
(USDA 2010) is a catalogue of nutrient data for foods available in the United States, 
compiled by comprehensively reviewing the literature for such data (e.g., Mangels et al. 
1993; Holden et al. 1999). From this it was assumed that the kale would contain a high 
level of L/Z (the values are combined in the database); ‘kale, cooked, boiled, drained, 
without salt’ is reported to contain 18.2 mg of L/Z per 100g (USDA 2010). As a result, 200 
g of cooked kale in the present study was expected to provide around 36 mg of L/Z, i.e., 9 
mg per meal if spread over four days per week. However, here lies the first problem with 
this assumption; it is unclear whether the 100 g of kale (containing 18.2 mg of L/Z after 
boiling) represents 100 g of originally raw kale that has subsequently been boiled and 
drained, or 100 g of boiled and drained kale. Boiled and drained kale increases in weight 
from the raw weight (e.g., 50 g of raw kale becomes 70 g drained, following ten minutes 
of boiling), so if the USDA data refers to the boiled and drained weight, then 200 g of 
kale, if boiled, would be expected to contain around 51 mg of L/Z, i.e., 12 to 13 mg per 
meal if spread over four days per week. Conversely, raw kale decreases in weight when 
stir-fried or microwaved – 50 g of raw kale becomes 38 g following stir-frying in one 
tablespoon of oil for eight minutes, and it becomes 20 g following microwaving without 
water (as per preparation instructions) for two minutes. Judging by the USDA data on 
spinach, which offers L/Z data on raw and cooked spinach, it would seem that the 
weights do refer to the weights of the foodstuffs as prepared, e.g., the weight of cooked 
kale after boiling and draining. Unfortunately, though, the USDA database does not 
provide L/Z information on raw, stir-fried, microwaved or steamed kale, so it is difficult to 
estimate how much was in the kale supplied in the present investigation, particularly as 
all the participants stir-fried at least some, if not all, of the kale. In looking elsewhere for 
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this information, it became abundantly clear just how much the reported L values in kale 
vary. For instance, reported L levels for raw kale vary from approximately 2.5 mg per 100 
g (Kobori et al. 2011) up to 51.4 mg per 100 g (Updike and Schwartz 2003), with values 
in between generally falling somewhere between 7 mg and 34 mg per 100 g (e.g., 
Khachik et al. 1986; Mercadante and Rodriguez-Amaya 1991; Humphries and Khachik 
2003). Few studies have measured the Z content of kale in any form, but it seems that 
this is because the Z levels are zero or close to zero in kale (Humphries and Khachik 
2003; Perry et al. 2009). Only one study (from Brazil) measured the L content of stir-fried 
kale; after ten minutes of stir-frying, there was 3.15 mg of L per 100 g of cooked kale, on 
average. This would therefore equate to less than 5 mg of L in the entire 200 g bag of 
kale from the current study (assuming a 25% weight loss on stir-frying). Besides the 
method of cooking, a recent series of papers by Lefsrud, Kopsell and co-workers has 
illustrated the range of variables that can affect the quantity of L in pre-harvested kale, 
such as type, season, air temperature, amount of light irradiance, and maturity (Kopsell et 
al. 2004; Lefsrud et al. 2005; Lefsrud et al. 2006a; Lefsrud et al. 2006b; Lefsrud et al. 
2007). Additionally, the conditions and duration of storage after kale has been harvested 
can affect its L levels (Kobori et al. 2011). Unfortunately, there do not appear to have 
been any L/Z papers published on UK kale, although research by Lefsrud et al. 
demonstrated that the L concentration of kale peaked when cultivated in an air 
temperature of 30ºC, and decreased linearly at air temperatures of 25, 20 and 15ºC 
(Lefsrud et al. 2005). Therefore, considering the typical climate in the UK, it is likely that 
UK-grown kale contains lower L levels than kale from warmer countries. Interestingly, the 
same study also showed that the L concentration of spinach peaked in an air temperature 
of 10ºC and decreased linearly as the air temperature increased to 15, 20 and 25ºC. 
Consequently, it may be that in the UK, spinach is a better source of L than kale. In any 
case, it is evident that the amount of L provided by this 16-week kale study could well 
have been a lot lower than anticipated, and thus it could offer one explanation for the lack 
of MP response. However, it could also be that even if the kale did contain the levels of L 
originally expected, this might not have been enough to influence the measured MPOD. 
 
Aside from the actual L concentration of the kale, another possibility for the lack of 
increase in MPOD is that the L wasn’t particularly bioavailable to the body. By instructing 
the subjects to eat the kale with a main meal, it was taken for granted that it would be 
consumed with a reasonable amount of fat. However, it was perhaps naïve to make this 
assumption, and instead there should have been a specific instruction to eat the kale with 
a fat source, since it has been demonstrated that absorption of L is enhanced by 
consumption with some form of dietary lipid (Roodenburg et al. 2000; Unlu et al. 2005; 
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Takeda et al. 2009). That said, L does appear to be considerably more bioavailable than 
another carotenoid, beta-carotene (Castenmiller et al. 1999; van het Hof et al. 1999), and 
all the post-study questionnaires completed by the volunteers did indicate that the kale 
was cooked and/or eaten with fat of some variety.  
 
Continuing with the bioavailability theme, carotenoids such as L and beta-carotene have 
been documented as competing with each other for absorption from the small intestine 
(Kostic et al. 1995; van den Berg and van Vliet 1998; Wang et al. 2010), so this is another 
possibility for the underlying cause of the poor macular response to kale intake, although 
if anything, L appears to compete more successfully for absorption than beta-carotene 
(van den Berg and van Vliet 1998). Moreover, spinach contains comparable amounts of 
beta-carotene to kale (USDA 2010), yet in the studies discussed earlier (section 8.1), 
dietary modification with spinach did increase MPOD (Hammond et al. 1997a; Johnson et 
al. 2000; Kopsell et al. 2006). However, it should be noted that in these studies the 
spinach was consumed more regularly than in the present study. In fact, in their 
questionnaire responses, four out of the six subjects stated that they ate the kale over the 
course of only two to three meals, so there may have been a limit to how much L could 
actually be absorbed at the serum or retinal level in one sitting. 
 
So-called ‘retinal nonresponders’ have been reported in other MPOD studies (e.g., 
Hammond et al. 1997a; Cardinault et al. 2003; Trieschmann et al. 2007; Johnson et al. 
2008; Stringham and Hammond 2008; Connolly et al. 2010; Nolan et al. 2011), so it 
should not be ruled out that all the subjects in the present investigation fit into that 
category. In several studies, though, it is often the subjects with the lowest baseline 
MPOD that demonstrate the greatest rise in MPOD in response to dietary or supplement 
L/Z modification (Wenzel et al. 2006b; Aleman et al. 2007; Richer et al. 2007; Borel et al. 
2011), and in this respect there were at least three subjects who could be classed as 
having a low starting MPOD. It has also been suggested that by not taking into account 
the spatial distribution of MP during supplementation, increases in MP at more eccentric 
locations may be missed, or indeed central MPOD increases may be missed or 
underestimated if the peripheral reference point accumulates any MP (Rodriguez-
Carmona et al. 2006; Bone et al. 2007b; Schalch et al. 2007; Wenzel et al. 2007b; 
Johnson et al. 2008; Connolly et al. 2010). With respect to the former, those studies 
demonstrating increases in MP beyond the central measure still tend to show the highest 
increases at the central points (Berendschot et al. 2000; Wenzel et al. 2007b; Connolly et 
al. 2010), so it is unlikely that an MPOD increase would have occurred outside of the 
central fovea in the current study. With respect to the latter, by observing the C-only 
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MPOD values as well as the actual MPOD values, any underestimation of MPOD caused 
by increases in peripheral MP was avoided, and there was still no change in MPOD over 
time. 
 
The duration of dietary modification was similar to most other MP studies, so this should 
not have been a limitation to achieving an MPOD increase, although in a recent study in 
which participants took a daily 12 mg L plus 1 mg Z supplement, there was no statistically 
significant increase in group MPOD until 12 months of supplementation (measurements 
were taken at baseline, three months and six months), despite statistically significant 
serum increases in L by three months (Nolan et al. 2011). Measurements of serum L/Z 
would have been extremely useful in the current investigation, because dietary L/Z intake 
is more closely correlated with serum L/Z than MPOD (Beatty et al. 2004), hence it would 
have provided a means of assessing whether there was a significant amount of L in the 
kale. 
 
A final possibility for the findings would be that the kale was used in place of other 
vegetables that may also have contained L/Z. As it turns out, though, this was generally 
not the case for any of the subjects (see section 8.3), so this can probably be ruled out. 
 
In conclusion, there was no MP response to dietary modification with kale in this 
exploratory study, which was most likely due to a lower than anticipated L content in the 
kale itself. In addition, it may simply have been that the amount of kale consumed was 
not enough to affect MPOD. For any similar future study, determination of the L/Z content 
of the kale, plus serum measures of L/Z, would be highly recommended. Furthermore, it 
would be wise to insist on boiling the kale rather than stir-frying it, to advise more 
thoroughly on the types of food to consume the kale with, and finally, to make sure that 
the kale is shared over more than three meals.  
 
8.5 Summary 
The results of the study described here cannot be used to add further support to the 
recommendation of kale to members of the public. This chapter marks the end of this 
body of research in which a variety of studies have aimed to add to MP knowledge. In the 
concluding chapter to follow, the findings of these studies are brought together. 
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CHAPTER 9: CONCLUSION 
 
Through use of a novel MPOD-measuring device (the MPS), which was first explored and 
optimized for accurate employment in the research and clinical environment, the 
investigations described over the course of the previous chapters aimed to contribute 
new information to the MP literature, with MPOD-based studies on anisometropia, South 
Asian race, blue-light-filtering CLs, and dietary modification with kale.  
 
In chapters 2 and 3, the aforementioned efforts to maximize the accuracy and 
consistency of MPOD measurements taken with the MPS were carried out. The eventual 
protocol that was established (chapter 3) proved useful for obtaining good inter-session 
repeatability (chapter 7). In fact, the CR (0.08, n=27) was half that of another MPS inter-
session repeatability study declaring ‘high agreement’ (de Kinkelder et al. 2011) 
(CR=0.18, n=20). It was also far better than that of an objective MPOD device (the MPR), 
which was assessed alongside the MPS in chapter 7. 
 
In chapter 4 it was established that occasional interocular MPOD differences could not be 
explained by anisometropic refractive errors, but the idea of refractive error having at 
least some influence on MPOD was not ruled out altogether. A future study could 
examine MPOD in two groups of individuals with contrasting refractive errors, such as 
myopic refractive errors greater than -5.00 DS and hyperopic refractive errors greater 
than +2.00 DS. 
 
A notable and statistically significant finding was obtained in chapter 5; South Asian 
individuals were found to have higher MPOD, on average, than Caucasian individuals. 
Within the Asian group, males had a statistically significant higher mean MPOD than 
females, and there was a tendency for participants with lighter irides to have lower 
MPODs; both these outcomes have been reported in MPOD studies with Caucasian 
subjects, and they have also been reported as possible associations with AMD (i.e., 
female gender and light iris colour), which is of course the chief motivation behind most 
MPOD research.  
 
As discussed in chapter 1, there is no definitive proof of a MP-AMD relationship, but there 
is enough evidence to justify the continued investigation of MP, particularly as it remains 
one of the few potential associations that is modifiable. However, novel and traditional 
efforts to augment MPOD were unsuccessful in the research studies described here. In 
chapter 6, blue-light-filtering CLs had no effect on MPOD, which could have been due to 
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the ages of the volunteers taking part, and in chapter 8, dietary modification with kale 
made no difference to MPOD either, which may well have been the result of a lower than 
anticipated L content in the kale itself. It was observed that reported L levels in kale vary 
widely, and moreover, that there does not appear to be any published L data for kale 
grown in the UK. In view of the latter, it would be beneficial to conduct a study in which 
the L (and Z) in UK-grown kale is quantified, the results of which might have a bearing on 
the advice given to patients regarding the ocular benefits of kale. 
 
Should a relationship between L/Z/MZ and AMD truly exist, it seems logical to suggest (in 
view of its location) that the amount of L and Z in the macula (i.e., MPOD) would have a 
stronger relationship with AMD than L and Z found elsewhere in the body. From the wide 
range of information available up to this point in time, combined with the results of the 
studies performed throughout the research period described here, it is the author’s 
opinion that MPOD does have an influence on the development of AMD, but that 
supplementing or modifying a diet to include high amounts of L and Z may not have as 
much effect as one would hope. The reasoning behind this belief comes from the 
knowledge that L/Z intake is not directly related to serum L/Z, which in turn is not directly 
related to MPOD. There appear to be many uncontrollable inter-individual variations that 
regulate the digestion, absorption, transport and eventual retinal uptake and maintenance 
of L and Z, and while some of these factors may eventually turn out to be controllable to 
some degree, it is likely that the majority will not. The body is a carefully balanced 
equilibrium, and arguably the best way to keep it that way is to adhere to the classic 
‘everything in moderation’ principle. For example, with a healthy diet and regular exercise 
(neither to excess), essentially there is there is a natural weight and shape for a body, 
and this varies from person to person. Analogous to this, it seems that MP also has a 
natural level, which like body weight and shape, varies from one individual to the next. It 
is receptive to a high intake of L etc., much like an extreme diet will cause most people to 
lose weight, and it may also be receptive to other alterations in lifestyle, such as 
cessation of smoking, but ultimately if a normal, healthy diet and lifestyle is followed, an 
individual’s MP level is what it is. Nevertheless, the results of the second Age-Related 
Eye Disease Study (AREDS2 2011), which is monitoring the progression of AMD in 
subjects taking 10 mg of L and 2 mg of Z (as well as other supplements and 
combinations of supplements), will be of great interest and will hopefully support the 
continued investigation of MP. 
 
In summary, this research aspired to add to the growing body of MP knowledge, and 
hopefully this was achieved. 
 168 
REFERENCES 
 
Age-Related Eye Disease Study (AREDS) Research Group (2000). Risk factors 
associated with age-related macular degeneration. A case-control study in the age-
related eye disease study: Age-Related Eye Disease Study Report Number 3. 
Ophthalmology 107: 2224-2232. 
 
Age-Related Eye Disease Study (AREDS) 2 (2011). The lutein/zeaxanthin and omega-3 
supplementation trial [online]. Available from: http://www.areds2.org. Accessed 23 
September 2011. 
 
Aleman TS, Duncan JL, Bieber ML, de Castro E, Marks DA, Gardner LM, Steinberg JD, 
Cideciyan AV, Maguire MG, Jacobson SG (2001). Macular pigment and lutein 
supplementation in retinitis pigmentosa and Usher syndrome. Invest Ophthalmol Vis Sci 
42: 1873-1881. 
 
Aleman TS, Cideciyan AV, Windsor EAM, Schwartz SB, Swider M, Chico JD, Sumaroka 
A, Pantelyat AY, Duncan KG, Gardner LM, Emmons JM, Steinberg JD, Stone EM, 
Jacobson SG (2007). Macular pigment and lutein supplementation in ABCA4-associated 
retinal degenerations. Invest Ophthalmol Vis Sci 48: 1319-1329. 
 
Algvere PV, Marshall J, Seregard S (2006). Age-related maculopathy and the impact of 
blue light hazard. Acta Ophthalmol Scand 84: 4-15. 
 
Anstis SM, Cavanagh P (1983). A minimum motion technique for judging equiluminance. 
In: Mollon JD, Sharpe LT (eds) Colour Vision: Physiology and Psychophysics. Academic 
Press, London, pp. 155-166. 
 
Barbur JL, Konstantakopoulou E, Rodriguez-Carmona M, Harlow JA, Robson AG, 
Moreland JD (2010). The Macular Assessment Profile test – a new VDU-based technique 
for measuring the spatial distribution of the macular pigment, lens density and rapid 
flicker sensitivity. Ophthalmic Physiol Opt 30: 470-483. 
 
Barker FM, Snodderly DM, Johnson EJ, Schalch W, Koepcke W, Gerss J, Neuringer M 
(2011). Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n-
3 fatty acids on retinal sensitivity to blue-light-induced damage. Invest Ophthalmol Vis Sci 
52: 3934-3942 
 
Bartlett HE, Eperjesi F (2007). Effect of lutein and antioxidant dietary supplementation on 
contrast sensitivity in age-related macular disease: a randomized controlled trial. Eur J 
Clin Nutr 61: 1121-1127. 
 
Bartlett H, Acton J, Eperjesi F (2010a). Clinical evaluation of the MacuScope macular 
pigment densitometer. Br J Ophthalmol 94: 328-331. 
 
Bartlett H, Howells O, Eperjesi F (2010b). The role of macular pigment assessment in 
clinical practice: a review. Clin Exp Optom 93: 300-308. 
 
Bartlett H, Stainer L, Singh S, Eperjesi F, Howells O (2010c). Clinical evaluation of the 
MPS 9000 Macular Pigment Screener. Br J Ophthalmol 94: 753-756. 
 
Beatty S, Boulton M, Henson D, Koh HH, Murray IJ (1999). Macular pigment and age 
related macular degeneration. Br J Ophthalmol 83: 867-877. 
 
 169 
Beatty S, Koh HH, Carden D, Murray IJ (2000a). Macular pigment optical density 
measurement: a novel compact instrument. Ophthalmic Physiol Opt 20: 105-111. 
 
Beatty S, Koh HH, Henson D, Boulton M (2000b). The role of oxidative stress in the 
pathogenesis of age-related macular degeneration. Surv Ophthalmol 45: 115-134. 
 
Beatty S, Murray IJ, Henson DB, Carden D, Koh HH, Boulton ME (2001). Macular 
pigment and risk for age-related macular degeneration in subjects from a Northern 
European population. Invest Ophthalmol Vis Sci 42: 439-446. 
 
Beatty S, Nolan J, Kavanagh H, O’Donovan O (2004). Macular pigment optical density 
and its relationship with serum and dietary levels of lutein and zeaxanthin. Arch Biochem 
Biophys 430: 70-76.  
 
Beatty S, van Kuijk F, Chakravarthy U (2008). Macular pigment and age-related macular 
degeneration: longitudinal data and better techniques of measurement are needed. Invest 
Ophthalmol Vis Sci 49: 843-845. 
 
Berendschot TTJM, Goldbohm RA, Klopping WAA, van de Kraats J, van Norel J, van 
Norren D (2000). Influence of lutein supplementation on macular pigment, assessed with 
two objective techniques. Invest Ophthalmol Vis Sci 41: 3322-3326. 
 
Berendschot TTJM, Broekmans WMR, Klöpping-Ketelaars IAA, Kardinaal AFM, van 
Poppel G, van Norren D (2002a). Lens aging in relation to nutritional determinants and 
possible risk factors for age-related cataract. Arch Ophthalmol 120:1732-1737. 
 
Berendschot TTJM, Willemse-Assink JJM, Bastiaanse M, de Jong PTVM, van Norren D 
(2002b). Macular pigment and melanin in age-related maculopathy in a general 
population. Invest Ophthalmol Vis Sci 43: 1928-1932. 
 
Berendschot TTJM, van Norren D (2004). Objective determination of the macular pigment 
optical density using fundus reflectance spectroscopy. Arch Biochem Biophys 430: 149-
155. 
 
Berendschot TTJM, van Norren D (2005). On the age dependency of the macular 
pigment optical density. Exp Eye Res 81: 602-609. 
 
Berendschot TTJM, van Norren D (2006). Macular pigment shows ringlike structures. 
Invest Ophthalmol Vis Sci 47: 709-714. 
 
Bernstein PS, Balashov NA, Tsong ED, Rando RR (1997). Retinal tubulin binds macular 
carotenoids. Invest Ophthalmol Vis Sci 38: 167-175. 
 
Bernstein PS, Yoshida MD, Katz NB, McClane RW, Gellermann W (1998). Raman 
detection of macular carotenoid pigments in intact human retina. Invest Ophthalmol Vis 
Sci 39: 2003-2011. 
 
Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao DY, Katz NB (2001). Identification 
and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp 
Eye Res 72: 215-223. 
 
Bernstein PS (2002). New insights into the role of the macular carotenoids in age-related 
macular degeneration. Resonance Raman studies. Pure Appl Chem 74: 1419-1425. 
 
 170 
Bernstein PS, Zhao DY, Wintch SW, Ermakov IV, McClane RW, Gellermann W (2002). 
Resonance Raman measurement of macular carotenoids in normal subjects and in age-
related macular degeneration patients. Ophthalmology 109: 1780-1787. 
 
Bernstein PS, Zhao DY, Sharifzadeh M, Ermakov IV, Gellermann W (2004). Resonance 
Raman measurement of macular carotenoids in the living human eye. Arch Biochem 
Biophys 430: 163-169. 
 
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC, 
Johnson EJ, Anderson EJ, Johnson CA, Gaudio AR, Willett WC, Schaefer EJ (2010). 
Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch 
Ophthalmol 128: 403-411. 
 
Bhosale P, Larson AJ, Frederick JM, Southwick K, Thulin CD, Bernstein PS (2004). 
Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) 
as a zeaxanthin-binding protein in the macula of the human eye. J Biol Chem 279: 
49447-49454. 
 
Bhosale P, Zhao DY, Bernstein PS (2007). HPLC measurement of ocular carotenoid 
levels in human donor eyes in the lutein supplementation era. Invest Ophthalmol Vis Sci 
48: 543-549. 
 
Bhosale P, Li BX, Sharifzadeh M, Gellermann W, Frederick JM, Tsuchida K, Bernstein 
PS (2009a). Purification and partial characterization of a lutein-binding protein from 
human retina. Biochemistry 48: 4798-4807. 
 
Bhosale P, Serban B, Bernstein PS (2009b). Retinal carotenoids can attenuate formation 
of A2E in the retinal pigment epithelium. Arch Biochem Biophys 483: 175-181. 
 
Bird AEC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, Dejong P, 
Klaver CCW, Klein BEK, Klein R, Mitchell P, Sarks JP, Sarks SH, Sourbane G, Taylor 
HR, Vingerling JR (1995). An international classification and grading system for age-
related maculopathy and age-related macular degeneration. Surv Ophthalmol 39: 367-
374. 
 
Bland JM, Altman DG (1986). Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet 1: 307-310. 
 
Bland JM, Altman DG (1999). Measuring agreement in method comparison studies. Stat 
Methods Med Res 8:135-160. 
 
Bockelbrink A, Roll S, Ruether K, Rasch A, Greiner W, Willich SN (2008). Cataract 
surgery and the development or progression of age-related macular degeneration: a 
systematic review. Surv Ophthalmol 53: 359-367. 
 
Bone RA, Sparrock JM (1971). Comparison of macular pigment densities in human eyes. 
Vision Res 11: 1057-1064. 
 
Bone RA (1980). The role of the macular pigment in the detection of polarized light. 
Vision Res 20: 213-220. 
 
Bone RA, Landrum JT, Tarsis SL (1985). Preliminary identification of the human macular 
pigment. Vision Res 25: 1531-1535. 
 
 171 
Bone RA, Landrum JT, Fernandez L, Tarsis SL (1988). Analysis of the macular pigment 
by HPLC - retinal distribution and age study. Invest Ophthalmol Vis Sci 29: 843-849. 
 
Bone RA, Landrum JT, Cains A (1992). Optical density spectra of the macular pigment in 
vivo and in vitro. Vision Res 32: 105-110. 
 
Bone RA, Landrum JT, Hime GW, Cains A, Zamor J (1993). Stereochemistry of the 
human macular carotenoids. Invest Ophthalmol Vis Sci 34: 2033-2040. 
 
Bone RA, Landrum JT, Friedes LM, Gomez CM, Kilburn MD, Menendez E, Vidal I, Wang 
W (1997). Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp 
Eye Res 64: 211-218. 
 
Bone RA, Landrum JT, Dixon Z, Chen Y, Llerena CM (2000). Lutein and zeaxanthin in 
the eyes, serum and diet of human subjects. Exp Eye Res 71: 239-245.  
 
Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE (2001). Macular 
pigment in donor eyes with and without AMD: A case-control study. Invest Ophthalmol 
Vis Sci 42: 235-240. 
 
Bone RA, Landrum JT, Guerra LH, Ruiz CA (2003). Lutein and zeaxanthin dietary 
supplements raise macular pigment density and serum concentrations of these 
carotenoids in humans. J Nutr 133: 992-998. 
 
Bone RA, Landrum JT (2004). Heterochromatic flicker photometry. Arch Biochem 
Biophys 430: 137-142. 
 
Bone RA, Brener B, Gibert JC (2007a). Macular pigment, photopigments, and melanin: 
distributions in young subjects determined by four-wavelength reflectometry. Vision Res 
47: 3259-3268. 
 
Bone RA, Landrum JT, Cao Y, Howard AN, Alvarez-Calderon F (2007b). Macular 
pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. 
Nutr Metab 4: 12. 
 
Bone RA, Landrum JT (2010). Dose-dependent response of serum lutein and macular 
pigment optical density to supplementation with lutein esters. Arch Biochem Biophys 504: 
50-55. 
 
Borel P, de Edelenyi FS, Vincent-Baudry S, Malezet-Desmoulin C, Margotat A, Lyan B, 
Gorrand JM, Meunier N, Drouault-Holowacz S, Bieuvelet S (2011). Genetic variants in 
BCMO1 and CD36 are associated with plasma lutein concentrations and macular 
pigment optical density in humans. Ann Med 43: 47-59. 
 
Bour LJ, Koo L, Delori FC, Apkarian P, Fulton AB (2002). Fundus photography for 
measurement of macular pigment density distribution in children. Invest Ophthalmol Vis 
Sci 43: 1450-1455. 
 
Brindley GS, Willmer EN (1952). The reflexion of light from the macular and peripheral 
fundus oculi in man. J Physiol 116: 350-356. 
 
Broekmans WMR, Berendschot TTJM, Klöpping-Ketelaars IAA, de Vries AJ, Goldbohm 
RA, Tijburg LBM, Kardinaal AFM, van Poppel G (2002). Macular pigment density in 
relation to serum and adipose tissue concentrations of lutein and serum concentrations of 
zeaxanthin. Am J Clin Nutr 76: 595-603. 
 172 
Brown PK, Wald G (1963). Visual pigments in human and monkey retinas. Nature 200: 
37-43. 
 
Bunce C, Wormald R (2008). Causes of blind certifications in England and Wales: April 
1999 to March 2000. Eye (Lond) 22: 905-911. 
 
Burke JD, Curran-Celentano J, Wenzel AJ (2005). Diet and serum carotenoid 
concentrations affect macular pigment optical density in adults 45 years and older. J Nutr 
135: 1208-1214. 
 
Cangemi FE (2007). TOZAL Study: an open case control study of an oral antioxidant and 
omega-3 supplement for dry AMD. BMC Ophthalmol 7: 3. 
 
Canovas R, Lima VC, Garcia P, Morini C, Prata TS, Rosen RB (2010). Comparison 
between macular pigment optical density measurements using two-wavelength 
autofluorescence and heterochromatic flicker photometry techniques. Invest Ophthalmol 
Vis Sci 51: 3152-3156. 
 
Cardinault N, Gorrand JM, Tyssandier V, Grolier P, Rock E, Borel P (2003). Short-term 
supplementation with lutein affects biomarkers of lutein status similarly in young and 
elderly subjects. Exp Gerontol 38: 573-582. 
 
Cardinault N, Abalain JH, Sairafi B, Coudray C, Grolier P, Rambeau M, Carre JL, Mazur 
A, Rock E (2005). Lycopene but not lutein nor zeaxanthin decreases in serum and 
lipoproteins in age-related macular degeneration patients. Clin Chim Acta 357: 34-42. 
 
Carpentier S, Knaus M, Suh M (2009). Associations between lutein, zeaxanthin, and age-
related macular degeneration: an overview. Crit Rev Food Sci Nutr 49: 313-326. 
 
Castenmiller JJ, West CE, Linssen JP, van het Hof KH, Voragen AG (1999). The food 
matrix of spinach is a limiting factor in determining the bioavailability of beta-carotene and 
to a lesser extent of lutein in humans. J Nutr 129: 349-355. 
 
Chaine G, Hullo A, Sahel J, Soubrane G, Espinasse-Berrod MA, Schutz D, Bourguignon 
C, Harpey C, Brault Y, Coste M, Moccatti D, Bourgeois H (1998). Case-control study of 
the risk factors for age related macular degeneration. France-DMLA Study Group. Br J 
Ophthalmol 82: 996-1002. 
 
Chang MA, Congdon NG, Bykhovskaya I, Muñoz B, West SK (2005). The association 
between myopia and various subtypes of lens opacity: SEE (Salisbury Eye Evaluation) 
project. Ophthalmology 112: 1395-1401. 
 
Chang TS, Hay D, Courtright P (1999). Age-related macular degeneration in Chinese-
Canadians. Can J Ophthalmol 34: 266-271. 
 
Chen SF, Chang Y, Wu JC (2001). The spatial distribution of macular pigment in humans. 
Curr Eye Res 23: 422-434. 
 
Chen SN, Lin KK, Chao AN, Kuo YH, Ho JD (2003) Nuclear sclerotic cataract in young 
patients in Taiwan. J Cataract Refract Surg 29: 983-988. 
 
Cho EY, Hankinson SE, Rosner B, Willett WC, Colditz GA (2008). Prospective study of 
lutein/zeaxanthin intake and risk of age-related macular degeneration. Am J Clin Nutr 87: 
1837-1843. 
 
 173 
Chucair AJ, Rotstein NP, SanGiovanni JP, During A, Chew EY, Politi LE (2007). Lutein 
and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: 
relation with docosahexaenoic acid. Invest Ophthalmol Vis Sci 48: 5168-5177. 
 
Chung HY, Rasmussen HM, Johnson EJ (2004). Lutein bioavailability is higher from 
lutein-enriched eggs than from supplements and spinach in men. J Nutr 134: 1887-1893. 
 
Ciulla TA, Curran-Celantano J, Cooper DA, Hammond BR, Danis RP, Pratt LM, Riccardi 
KA, Filloon TG (2001a). Macular pigment optical density in a midwestern sample. 
Ophthalmology 108: 730-737. 
 
Ciulla TA, Hammond BR, Yung CW, Pratt LM (2001b). Macular pigment optical density 
before and after cataract extraction. Invest Ophthalmol Vis Sci 42: 1338-1341. 
 
Ciulla TA, Hammond BR (2004). Macular pigment density and aging, assessed in the 
normal elderly and those with cataracts and age-related macular degeneration. Am J 
Ophthalmol 138: 582-587. 
 
Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL (2005). Risk factors for the 
incidence of advanced age-related macular degeneration in the Age-Related Eye 
Disease Study (AREDS). AREDS report no. 19. Ophthalmology 112: 533-539. 
 
Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor 
HR, Mitchell P (2004). Causes and prevalence of visual impairment among adults in the 
United States. Arch Ophthalmol 122: 477-485.  
 
Connell PP, Keane PA, O’Neill EC, Altaie RW, Loane E, Neelam K, Nolan JM, Beatty S 
(2009). Risk factors for age-related maculopathy. J Ophthalmol 2009: 360764. 
 
Connolly EE, Beatty S, Thurnham DI, Loughman J, Howard AN, Stack J, Nolan JM 
(2010). Augmentation of macular pigment following supplementation with all three 
macular carotenoids: an exploratory study. Curr Eye Res 35: 335-351. 
 
Connors R, Boseman P, Olson RJ (2002). Accuracy and reproducibility of biometry using 
partial coherence interferometry. J Cataract Refract Surg 28: 235-238. 
 
Cooper RL (1990). Blind registrations in Western Australia: a five-year study. Aust N Z J 
Ophthalmol 18: 421-426. 
 
Curran-Celentano J, Hammond BR, Ciulla TA, Cooper DA, Pratt LM, Danis RB (2001). 
Relation between dietary intake, serum concentrations, and retinal concentrations of 
lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr 74: 796-802. 
 
Cuthbertson FM, Peirson SN, Wulff K, Foster RG, Downes SM (2009). Blue light-filtering 
intraocular lenses: review of potential benefits and side effects. J Cataract Refract Surg 
35: 1281-1297. 
 
Darzins P, Mitchell P, Heller RF (1997). Sun exposure and age-related macular 
degeneration. An Australian case-control study. Ophthalmology 104: 770-776. 
 
Dasch B, Fuhs A, Schmidt J, Behrens T, Meister A, Wellmann J, Fobker M, Pauleikhoff 
D, Hense HW (2005). Serum levels of macular carotenoids in relation to age-related 
maculopathy: the Muenster Aging and Retina Study (MARS). Graefes Arch Clin Exp 
Ophthalmol 243: 1028-1035. 
 
 174 
Davies NP, Morland AB (2002). Color matching in diabetes: optical density of the 
crystalline lens and macular pigments. Invest Ophthalmol Vis Sci 43: 281-289. 
 
Davison JA, Patel AS, Cunha JP, Schwiegerling J, Muftuoglu O (2011). Recent studies 
provide an updated clinical perspective on blue light-filtering IOLs. Graefes Arch Clin Exp 
Ophthalmol 249: 957-968. 
 
de Kinkelder R, van der Veen RLP, Verbaak FD, Faber DJ, van Leeuwen TG, 
Berendschot TTJM (2011). Macular pigment optical density measurements: evaluation of 
a device using heterochromatic flicker photometry. Eye (Lond) 25: 105-112. 
 
Delaney WV, Oates RP (1982). Senile macular degeneration: a preliminary study. Ann 
Ophthalmol 14: 21-24. 
 
De La Paz M, Anderson RE (1992). Region and age-dependent variation in susceptibility 
of the human retina to lipid peroxidation. Invest Ophthalmol Vis Sci 33: 3497-3499. 
  
Delcourt C, Carrière I, Delage M, Barberger-Gateau P, Schalch WF (2006). Plasma lutein 
and zeaxanthin and other carotenoids as modifiable risk factors for age-related 
maculopathy and cataract: The POLA study. Invest Ophthalmol Vis Sci 47: 2329-2335. 
 
Delori FC, Pflibsen KP (1989). Spectral reflectance of the human ocular fundus. Appl Opt 
28: 1061-1077. 
 
Delori FC (1994). Spectrophotometer for noninvasive measurement of intrinsic 
fluorescence and reflectance of the ocular fundus. Appl Opt 33: 7439-7452. 
 
Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995). In vivo 
fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin 
characteristics. Invest Ophthalmol Vis Sci 36: 718-729. 
 
Delori FC, Goger DG, Hammond BR, Snodderly DM, Burns SA (2001). Macular pigment 
density measured by autofluorescence spectrometry: comparison with reflectometry and 
heterochromatic flicker photometry. J Opt Soc Am A Opt Image Sci Vis 18: 1212-1230. 
 
Delori FC (2004). Autofluorescence method to measure macular pigment optical densities 
fluorometry and autofluorescence imaging. Arch Biochem Biophys 430: 156-162. 
 
Delori FC, Goger DG, Keilhauer C, Salvetti P, Staurenghi G (2006). Bimodal spatial 
distribution of macular pigment: evidence of a gender relationship. J Opt Soc Am A Opt 
Image Sci Vis 23: 521-538. 
 
Duan Y, Mo J, Klein R, Scott IU, Lin HM, Caulfield J, Patel M, Liao D (2007). Age-related 
macular degeneration is associated with incident myocardial infarction among elderly 
Americans. Ophthalmology 114: 732-737. 
 
Duncan JL, Aleman TS, Gardner LM, De Castro E, Marks DA, Emmons JM, Bieber ML, 
Steinberg JD, Bennett J, Stone EM, Macdonald IM, Cideciyan AV, Maguire MG, 
Jacobson SG (2002). Macular pigment and lutein supplementation in choroideremia. Exp 
Eye Res 74: 371-381. 
 
Edwards KH, Gibson GA (2010). Intraocular lens short wavelength light filtering. Clin Exp 
Optom 93: 390-399. 
 
 175 
Elsner AE, Burns SA, Beausencourt E, Weiter JJ (1998). Foveal cone photopigment 
distribution: small alterations associated with macular pigment distribution. Invest 
Ophthalmol Vis Sci 39: 2394-2404. 
 
Engles M, Wooten B, Hammond B (2007). Macular pigment: a test of the acuity 
hypothesis. Invest Ophthalmol Vis Sci 48: 2922-2931. 
 
Erdman JW, Bierer TL, Gugger ET (1993). Absorption and transport of carotenoids. Ann 
N Y Acad Sci 691: 76-85. 
 
Ermakov IV, McClane RW, Gellermann W, Bernstein PS (2001). Resonant Raman 
detection of macular pigment levels in the living human retina. Opt Lett 26: 202-204. 
 
Ermakov I, Ermakova M, Gellermann W, Bernstein PS (2004). Macular pigment Raman 
detector for clinical applications. J Biomed Opt 9: 139-148. 
 
Ermakov IV, Sharifzadeh M, Ermakova M, Gellermann W (2005). Resonance Raman 
detection of carotenoid antioxidants in living human tissue. J Biomed Opt 10: 064028. 
 
Evans JR, Fletcher AE, Wormald RPL (2004). Causes of visual impairment in people 
aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and 
Management of Older People in the Community. Br J Ophthalmol 88: 365-370. 
 
Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P (2003). Influence of 
short-term antioxidant supplementation on macular function in age-related maculopathy: 
a pilot study including electrophysiologic assessment. Ophthalmology 110: 51-60. 
 
Feeney-Burns L, Neuringer M, Gao CL (1989). Macular pathology in monkeys fed 
semipurified diets. Prog Clin Biol Res 314: 601-622. 
 
Fletcher AE, Bentham GC, Agnew M, Young IS, Augood C, Chakravarthy U, de Jong 
PTVM, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, Vioque J 
(2008). Sunlight exposure, antioxidants, and age-related macular degeneration. Arch 
Ophthalmol 126: 1396-1403. 
 
Flood V, Smith W, Wang JJ, Manzi F, Webb K, Mitchell P (2002). Dietary antioxidant 
intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. 
Ophthalmology 109: 2272-2278. 
 
Food and Drink Federation (2010). GDA labelling [online]. GDA labelling home page, 
available from: http://www.gdalabel.org.uk. Accessed 22 September 2011. 
 
Franciose JL, Askew EW, Lang JC, Bernstein PS (2006). Serum and macular responses 
to antioxidant supplementation versus a carotenoid-rich dietary intervention in the elderly. 
Curr Top Nutraceutical Res 4: 69-78. 
 
Frank RN, Puklin JE, Stock C, Canter LA (2000). Race, iris color, and age-related 
macular degeneration. Trans Am Ophthalmol Soc 98: 109-117. 
 
Fraser-Bell S, Choudhury F, Klein R, Azen S, Varma R (2010). Ocular risk factors for 
age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 
149: 735-740. 
 
 176 
Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure 
B, Mitchell P, Kempen J (2004a). Prevalence of age-related macular degeneration in the 
United States. Arch Ophthalmol 122: 564-572. 
 
Friedman DS, West SK, Muñoz B, Park W, Deremeik J, Massof R, Frick K, Broman A, 
McGill W, Gilbert D, German P (2004b). Racial variations in causes of vision loss in 
nursing homes: the Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. 
Arch Ophthalmol 122: 1019-1024. 
 
Gale CR, Hall NF, Phillips DIW, Martyn CN (2003). Lutein and zeaxanthin status and risk 
of age-related macular degeneration. Invest Ophthalmol Vis Sci 44: 2461-2465. 
 
Gallaher KT, Mura M, Todd WA, Harris TL, Kenyon E, Harris T, Johnson KC, Satterfield 
S, Kritchevsky SB, Iannaccone A (2007). Estimation of macular pigment optical density in 
the elderly: test-retest variability and effect of optical blur in pseudophakic subjects. 
Vision Res 47: 1253-1259. 
 
Gärtner C, Stahl W, Sies H (1996). Preferential increase in chylomicron levels of the 
xanthophylls lutein and zeaxanthin compared to beta-carotene in the human. Int J Vitam 
Nutr Res 66: 119-125. 
 
Gellermann W, Ermakov IV, Ermakova MR, McClane RW, Zhao DY, Bernstein PS 
(2002a). In vivo resonant Raman measurement of macular carotenoid pigments in the 
young and the aging human retina. J Opt Soc Am A Opt Image Sci Vis 19: 1172-1186. 
 
Gellermann W, Ermakov IV, McClane RW, Bernstein PS (2002b). Raman imaging of 
human macular pigments. Opt Lett 27: 833-835. 
 
Gellermann W, Bernstein PS (2004). Noninvasive detection of macular pigments in the 
human eye. J Biomed Opt 9: 75-85. 
 
Goulinet S, Chapman MJ (1997). Plasma LDL and HDL subspecies are heterogenous in 
particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance 
to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 17: 786-796. 
Gray R, Perkins SA, Suryakumar R, Neuman B, Maxwell WA (2011). Reduced effect of 
glare disability on driving performance in patients with blue light-filtering intraocular 
lenses. J Cataract Refract Surg 37: 38-44. 
 
Gupta SK, Murthy GV, Morrison N, Price GM, Dherani M, John N, Fletcher AE, 
Chakravarthy U (2007). Prevalence of early and late age-related macular degeneration in 
a rural population in northern India: the INDEYE feasibility study. Invest Ophthalmol Vis 
Sci 48: 1007-1011. 
 
Ham WT, Mueller HA, Sliney DH (1976). Retinal sensitivity to damage from short 
wavelength light. Nature 260: 153-155. 
 
Ham WT, Ruffolo JJ, Mueller HA, Clarke AM, Moon ME (1978). Histologic analysis of 
photochemical lesions produced in rhesus retina by short-wave-length light. Invest 
Ophthalmol Vis Sci 17: 1029-1035. 
 
Ham WT, Ruffolo JJ, Mueller HA, Guerry D (1980). The nature of retinal radiation 
damage: dependence on wavelength, power level and exposure time. Vision Res 20: 
1105-1011. 
 
 177 
Ham WT, Mueller HA, RuffoloJJ, Guerry D, Guerry RK (1982). Action spectrum for retinal 
injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol 93: 299-
306. 
 
Hammond BR, Fuld K (1992). Interocular Differences in Macular Pigment Density. Invest 
Ophthalmol Vis Sci 33: 350-355. 
 
Hammond BR, Fuld K, Curran-Celentano J (1995). Macular pigment density in 
monozygotic twins. Invest Ophthalmol Vis Sci 36: 2531-2541. 
 
Hammond BR, Curran-Celentano J, Judd S, Fuld K, Krinsky NI, Wooten BR, Snodderly 
DM (1996a). Sex differences in macular pigment optical density: relation to plasma 
carotenoid concentrations and dietary patterns. Vision Res 36: 2001-2012. 
 
Hammond BR, Fuld K, Snodderly DM (1996b). Iris color and macular pigment optical 
density. Exp Eye Res 62: 715-720. 
 
Hammond BR, Wooten BR, Snodderly DM (1996c). Cigarette smoking and retinal 
carotenoids: implications for age-related macular degeneration. Vision Res 36: 3003-
3009. 
 
Hammond BR, Johnson EJ, Russell RM, Krinsky NI, Yeum KJ, Edwards RB, Snodderly 
DM (1997a). Dietary modification of human macular pigment density. Invest Ophthalmol 
Vis Sci 38: 1795-1801. 
 
Hammond BR, Wooten BR, Snodderly DM (1997b). Density of the human crystalline lens 
is related to the macular pigment carotenoids, lutein and zeaxathin. Optom Vis Sci 74: 
499-504. 
 
Hammond BR, Wooten BR, Snodderly DM (1997c). Individual variations in the spatial 
profile of human macular pigment. J Opt Soc Am A Opt Image Sci Vis 14: 1187-1196. 
 
Hammond BR, Wooten BR, Snodderly DM (1998). Preservation of visual sensitivity of 
older subjects: association with macular pigment density. Invest Ophthalmol Vis Sci 39: 
397-406. 
 
Hammond BR, Caruso-Avery M (2000). Macular pigment optical density in a 
southwestern sample. Invest Ophthalmol Vis Sci 41: 1492-1497. 
 
Hammond BR, Ciulla TA, Snodderly DM (2002). Macular pigment density is reduced in 
obese subjects. Invest Ophthalmol Vis Sci 43: 47-50. 
 
Hammond BR, Wooten BR (2005). CFF thresholds: relation to macular pigment optical 
density. Ophthalmic Physiol Opt 25: 315-319. 
 
Hammond BR, Wooten BR, Smollon B (2005). Assessment of the validity of in vivo 
methods of measuring human macular pigment optical density. Optom Vis Sci 82: 387-
404. 
 
Hammond BR, Renzi LM, Sachak S, Brint SF (2010). Contralateral comparison of blue-
filtering and non-blue-filtering intraocular lenses: glare disability, heterochromatic 
contrast, and photostress recovery. Clin Ophthalmol 4: 1465-1473. 
 
Handelman GJ, Dratz EA, Reay CC, Vankuijk F (1988). Carotenoids in the human 
macula and whole retina. Invest Ophthalmol Vis Sci 29: 850-855. 
 178 
Handelman GJ, Snodderly DM, Krinsky NI, Russett MD, Adler AJ (1991). Biological 
control of primate macular pigment - biochemical and densitometric studies. Invest 
Ophthalmol Vis Sci 32: 257-267. 
 
Handelman GJ, Nightingale ZD, Lichtenstein AH, Schaefer EJ, Blumberg JB (1999). 
Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg 
yolk. Am J Clin Nutr 70: 247-251. 
 
Heaney RP, Weaver CM (1990). Calcium absorption from kale. Am J Clin Nutr 51: 656-
657. 
 
Henderson BA, Grimes KJ (2010). Blue-blocking IOLs: a complete review of the 
literature. Surv Ophthalmol 55: 284-289. 
 
Hirakawa M, Tanaka M, Tanaka Y, Okubo A, Koriyama C, Tsuji M, Akiba S, Miyamoto K, 
Hillebrand G, Yamashita T, Sakamoto T (2008). Age-related maculopathy and sunlight 
exposure evaluated by objective measurement. Br J Ophthalmol 92: 630-634. 
 
Ho L, van Leeuwen R, Witteman JC, van Duijn CM, Uitterlinden AG, Hofman A, de Jong 
PT, Vingerling JR, Klaver CC (2011). Reducing the genetic risk of age-related macular 
degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam 
study. Arch Ophthalmol 129: 758-766. 
 
Hogg RE, Anderson RS, Stevenson MR, Zlatkova MB, Chakravarthy U (2007). In vivo 
macular pigment measurements: a comparison of resonance Raman spectroscopy and 
heterochromatic flicker photometry. Br J Ophthalmol 91: 485-490. 
 
Holden Jm, Eldridge AL, Beecher GR, Buzzard IM, Bhagwat S, Davis CS, Douglass LW, 
Gebhardt S, Haytowitz D, Schakel S (1999). Carotenoid content of U.S. foods: an update 
of the database. J Food Compost Anal 12:169-196. 
 
Howells O, Eperjesi F, Bartlett H (2011). Measuring macular pigment optical density in 
vivo: a review of techniques. Graefes Arch Clin Exp Ophthalmol 249: 315-347. 
 
Hu DN, Simon JD, Sarna T (2008). Role of ocular melanin in ophthalmic physiology and 
pathology. Photochem Photobiol 84: 639-644. 
 
Humphries JM and Khachik F (2003). Distribution of lutein, zeaxanthin, and related 
geometrical isomers in fruit, vegetables, wheat, and pasta products. J Agric Food Chem 
51: 1322-1327. 
 
Hyman LG, Lilienfeld AM, Ferris FL, Fine SL (1983). Senile macular degeneration: a 
case-control study. Am J Epidemiol 118: 213-227. 
 
Iannaccone A, Mura M, Gallaher KT, Johnson EJ, Todd WA, Kenyon E, Harris TL, Harris 
T, Satterfield S, Johnson KC, Kritchevsky SB (2007). Macular pigment optical density in 
the elderly: findings in a large biracial midsouth population sample. Invest Ophthalmol Vis 
Sci 48: 1458-1465. 
 
Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT (2003). Relationship 
between refraction and prevalent as well as incident age-related maculopathy: the 
Rotterdam Study. Invest Ophthalmol Vis Sci 44: 3778-3782. 
 
 179 
Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y (2006). 
Prevalence and causes of low vision and blindness in a Japanese adult population: the 
Tajimi Study. Ophthalmology 113: 1354-1362. 
 
Jahn C, Wüstemeyer H, Brinkmann C, Trautmann S, Möner A, Wolf S (2005). Macular 
pigment density in age-related maculopathy. Graefes Arch Clin Exp Ophthalmol 243: 
222-227. 
 
Johnson EJ, Hammond BR, Yeum K-J, Qin J, Wang XD, Castaneda C, Snodderly DM, 
Russell RM (2000). Relation among serum and tissue concentrations of lutein and 
zeaxanthin and macular pigment density. Am J Clin Nutr 71: 1555-1562. 
  
Johnson EJ, Neuringer M, Russell RM, Schalch W, Snodderly DM (2005). Nutritional 
manipulation of primate retinas, III: Effects of lutein or zeaxanthin supplementation on 
adipose tissue and retina of xanthophyll-free monkeys. Invest Ophthalmol Vis Sci 46: 
692-702. 
 
Johnson EJ, Chung HY, Caldarella SM, Snodderly DM (2008). The influence of 
supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular 
pigmentation. Am J Clin Nutr 87: 1521-1529. 
 
Junghans A, Sies H, Stahl W (2001). Macular pigments lutein and zeaxanthin as blue 
light filters studied in liposomes. Arch Biochem Biophys 391: 160-164. 
 
Kanis MJ, Berendschot TTJM, van Norren D (2007a). Influence of macular pigment and 
melanin on incident early AMD in a white population. Graefes Arch Clin Exp Ophthalmol 
245: 767-773. 
 
Kanis MJ, Berendschot TTJM, van Norren D (2007b). Interocular agreement in melanin 
and macular pigment optical density. Exp Eye Res 84: 934-938. 
 
Kanis MJ, Wisse RPL, Berendschot TTJM, van de Kraats J, van Norren D (2008). Foveal 
cone-photoreceptor integrity in aging macula disorder. Invest Ophthalmol Vis Sci 49: 
2077-2081. 
 
Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, Mitchell P, Wong TY 
(2010). The prevalence of age-related macular degeneration in Asians: a systematic 
review and meta-analysis. Ophthalmology 117: 921-927. 
 
Kay CD, Gebauer SK, West SG, Kris-Etherton PM (2010). Pistachios increase serum 
antioxidants and lower serum oxidized-LDL in hypercholesterolemic adults. J Nutr 140: 
1093-1098. 
 
Khachik F, Beecher GR, Whittaker NF (1986). Separation, identification, and 
quantification of the major carotenoid and chlorophyll constituents in extracts of several 
green vegetables by liquid chromatography. J Agric Food Chem 34: 603-616. 
 
Khachik F, Beecher GR, Goli MB, Lusby WR, Smith JC (1992). Separation and 
identification of carotenoids and their oxidation products in the extracts of human plasma. 
Anal Chem 64: 2111-2122. 
 
Khachik F, Bernstein PS, Garland DL (1997a). Identification of lutein and zeaxanthin 
oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 38: 1802-
1811. 
 
 180 
Khachik F, Spangler CJ, Smith JC, Canfield LM, Steck A, Pfander H (1997b). 
Identification, quantification, and relative concentrations of carotenoids and their 
metabolites in human milk and serum. Anal Chem 69: 1873-1881. 
 
Khan JC, Shahid H, Thurlby DA, Bradley M, Clayton DG, Moore AT, Bird AC, Yates JRW 
(2006). Age related macular degeneration and sun exposure, iris colour, and skin 
sensitivity to sunlight. Br J Ophthalmol 90: 29-32. 
 
Kielhorn I, Rajan MS, Tesha PM, Subryan VR, Bell JA (2003). Clinical assessment of the 
Zeiss IOLMaster. J Cataract Refract Surg 29: 518-522. 
 
Kim SR, Nakanishi K, Itagaki Y, Sparrow JR (2006). Photooxidation of A2-PE, a 
photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Exp 
Eye Res 82: 828-839. 
 
Kirby ML, Galea M, Loane E, Stack J, Beatty S, Nolan JM (2009). Foveal anatomic 
associations with the secondary peak and the slope of the macular pigment spatial 
profile. Invest Ophthalmol Vis Sci 50: 1383-1391. 
 
Kirby ML, Beatty S, Loane E, Akkali MC, Connolly EE, Stack J, Nolan JM (2010). A 
central dip in the macular pigment spatial profile is associated with age and smoking. 
Invest Ophthalmol Vis Sci 51: 6722-6728. 
 
Klein R, Clegg L, Cooper LS, Hubbard LD, Klein BE, King WN, Folsom AR (1999). 
Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities 
Study. Arch Ophthalmol 117: 1203-1210. 
 
Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL, Hubbard LD (2003). Early 
age-related maculopathy in the cardiovascular health study. Ophthalmology 110: 25-33. 
 
Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB (2011). Prevalence of 
age-related macular degeneration in the US population. Arch Ophthalmol 129: 75-80. 
 
Kobori CN, Huber LS, Sarantópoulos CI, Rodriguez-Amaya DB (2011). Behavior of 
flavonols and carotenoids of minimally processed kale leaves during storage in passive 
modified atmosphere packaging. J Food Sci 76: H31-H37. 
 
Koh HH, Murray IJ, Nolan D, Carden D, Feather J, Beatty S (2004). Plasma and macular 
response to lutein supplement in subjects with and without age-related maculopathy: a 
pilot study. Exp Eye Res 79: 21-27. 
 
Kopsell DA, Kopsell DE, Lefsrud MG, Curran-Celentano J, Dukach LE (2004). Variation 
in lutein, beta-carotene, and chlorophyll concentrations among Brassica oleracea 
cultigens and seasons. HortScience 39: 361-364. 
 
Kopsell DA, Lefsrud MG, Kopsell DE, Wenzel AJ, Gerweck C, Curran-Celentano J 
(2006). Spinach cultigen variation for tissue carotenoid concentrations influences human 
serum carotenoid levels and macular pigment optical density following a 12-week dietary 
intervention. J Agric Food Chem 54: 7998-8005. 
 
Kostic D, White WS, Olson JA (1995). Intestinal absorption, serum clearance, and 
interactions between lutein and beta-carotene when administered to human adults in 
separate or combined oral doses. Am J Clin Nutr 62: 604-610. 
 
 181 
Koyama Y, Takatsuka I, Nakata M, Tasumi M (1988). Raman and infrared spectra of the 
all-trans, 7-cis, 9-cis, 13-cis and 15-cis isomers of beta carotene - key bands 
distinguishing stretched or terminal-bent configurations from central-bent configurations. J 
Raman Spectrosc 19: 37-49. 
 
Krishnaiah S, Das T, Nirmalan PK, Nutheti R, Shamanna BR, Rao GN, Thomas R (2005). 
Risk factors for age-related macular degeneration: findings from the Andhra Pradesh Eye 
Disease Study in South India. Invest Ophthalmol Vis Sci 46: 4442-4449. 
 
Krishnaiah S, Das TP, Kovai V, Rao GN (2009). Associated factors for age-related 
maculopathy in the adult population in southern India: the Andhra Pradesh Eye Disease 
Study. Br J Ophthalmol 93: 1146-1150. 
 
Kvansakul J, Rodriguez-Carmona M, Edgar DF, Barker FM, Kopcke W, Schalch W, 
Barbur JL (2006). Supplementation with the carotenoids lutein or zeaxanthin improves 
human visual performance. Ophthalmic Physiol Opt 26: 362-371. 
 
Kwok LS, Kuznetsov VA, Ho A, Coroneo MT (2003). Prevention of the adverse photic 
effects of peripheral light-focusing using UV-blocking contact lenses. Invest Ophthalmol 
Vis Sci 44: 1501-1507. 
 
Lam RF, Rao SK, Fan DSP, Lau FTC, Lam DSC (2005). Macular pigment optical density 
in a Chinese sample. Curr Eye Res 30: 729-735. 
 
Landrum JT, Bone RA, Joa H, Kilburn MD, Moore LL, Sprague KE (1997). A one year 
study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 
65: 57-62. 
 
Landrum JT, Bone RA (2001). Lutein, zeaxanthin, and the macular pigment. Arch 
Biochem Biophys 385: 28-40. 
 
LaRowe TL, Mares JA, Snodderly DM, Klein ML, Wooten BR, Chappell R (2008). 
Macular pigment density and age-related maculopathy in the Carotenoids in Age-Related 
Eye Disease Study - an ancillary study of the Women's Health Initiative. Ophthalmology 
115: 876-883. 
 
Lavanya R, Kawasaki R, Tay WT, Cheung GC, Mitchell P, Saw SM, Aung T, Wong TY 
(2010). Hyperopic refractive error and shorter axial length are associated with age-related 
macular degeneration: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci 51: 
6247-6252. 
 
Lefsrud MG, Kopsell DA, Kopsell DE, Curran-Celentano J (2005). Air temperature affects 
biomass and carotenoid pigment accumulation in kale and spinach grown in a controlled 
environment. HortScience 40: 2026-2030. 
 
Lefsrud MG, Kopsell DA, Auge RM, Both AJ (2006a). Biomass production and pigment 
accumulation in kale grown under increasing photoperiods. HortScience 41: 603-606. 
 
Lefsrud MG, Kopsell DA, Kopsell DE, Curran-Celentano J (2006b). Irradiance levels 
affect growth parameters and carotenoid pigments in kale and spinach grown in a 
controlled enviroment. Physiol Plant 127: 624-631. 
 
Lefsrud M, Kopsell D, Wenzel A, Sheehan J (2007). Changes in kale (Brassica oleracea 
L. var. acephala) carotenoid and chlorophyll pigment concentrations during leaf ontogeny. 
Sci Hortic 112: 136-141. 
 182 
Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, 
Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR (1980). The Framingham Eye 
Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, 
diabetic retinopathy, macular degeneration, and visual acuity in a general population of 
2631 adults, 1973-1975. Surv Ophthalmol 24: 335-610. 
 
Leske MC, Wu SY, Hennis A, Nemesure B, Yang L, Hyman L, Schachat AP (2006). Nine-
year incidence of age-related macular degeneration in the Barbados Eye Studies. 
Ophthalmology 113: 29-35. 
 
Leung IYF, Tso MOM, Li WY, Lam TT (2001). Absorption and tissue distribution of 
zeaxanthin and lutein in rhesus monkeys after taking Fructus lycii (Gou Qi Zi) extract. 
Invest Ophthalmol Vis Sci 42: 466-471. 
 
Li SY, Fu ZJ, Ma H, Jang WC, So KF, Wong D, Lo ACY (2009). Effect of lutein on retinal 
neurons and oxidative stress in a model of acute retinal ischemia/reperfusion. Invest 
Ophthalmol Vis Sci 50: 836-843. 
 
Li SY, Lo ACY (2010). Lutein protects RGC-5 cells against hypoxia and oxidative stress. 
Int J Mol Sci 11: 2109-2117. 
 
Li Y, Xu L, Jonas JB, Yang H, Ma Y, Li J (2006). Prevalence of age-related maculopathy 
in the adult population in China: the Beijing Eye Study. Am J Ophthalmol 142: 788-793. 
 
Liew SHM, Gilbert CE, Spector TD, Mellerio J, Marshall J, van Kuijk FJ, Beatty S, Fitzke 
F, Hammond CJ (2005). Heritability of macular pigment: a twin study. Invest Ophthalmol 
Vis Sci 46: 4430-4436. 
 
Liew SHM, Gilbert CE, Spector TD, Mellerio J, Van Kuijk FJ, Beatty S, Fitzke F, Marshall 
J, Hammond CJ (2006). Central retinal thickness is positively correlated with macular 
pigment optical density. Exp Eye Res 82: 915-920. 
 
Lima VC, Rosen RB, Maia M, Prata TS, Dorairaj S, Farah ME, Sallum J (2010). Macular 
pigment optical density measured by dual-wavelength autofluorescence imaging in 
diabetic and nondiabetic patients: a comparative study. Invest Ophthalmol Vis Sci 51: 
5840-5845. 
 
Loane E, Stack J, Beatty S, Nolan JM (2007). Measurement of macular pigment optical 
density using two different heterochromatic flicker photometers. Curr Eye Res 32: 555-
564. 
 
Loane E, Kelliher C, Beatty S, Nolan JM (2008). The rationale and evidence base for a 
protective role of macular pigment in age-related maculopathy. Br J Ophthalmol 92: 1163-
1168. 
 
Loane E, McKay GJ, Nolan JM, Beatty S (2010a). Apolipoprotein E genotype is 
associated with macular pigment optical density. Invest Ophthalmol Vis Sci 51: 2636-
2643. 
 
Loane E, Nolan JM, Beatty S (2010b). The respective relationships between lipoprotein 
profile, macular pigment optical density, and serum concentrations of lutein and 
zeaxanthin. Invest Ophthalmol Vis Sci 51: 5897-5905. 
 
 183 
Loughman J, Akkali MC, Beatty S, Scanlon G, Davison PA, O’Dwyer V, Cantwell T, Major 
P, Stack J, Nolan JM (2010a). The relationship between macular pigment and visual 
performance. Vision Res 50: 1249-1256. 
 
Loughman J, Davison PA, Nolan JM, Akkali MC, Beatty S (2010b). Macular pigment and 
its contribution to visual performance and experience. J Optom 3: 74-90. 
 
Maguire P, Vine AK (1986). Geographic atrophy of the retinal pigment epithelium. Am J 
Ophthalmol 102: 621-625. 
 
Mainster MA, Turner PL (2010). Blue-blocking IOLs decrease photoreception without 
providing significant photoprotection. Surv Ophthalmol 55: 272-283. 
 
Makridaki M, Carden D, Murray IJ (2009). Macular pigment measurement in clinics: 
controlling the effect of the ageing media. Ophthalmic Physiol Opt 29: 338-344. 
 
Malinow MR, Feeney-Burns L, Peterson LH, Klein ML, Neuringer M (1980). Diet-related 
macular anomalies in monkeys. Invest Ophthalmol Vis Sci 19: 857-863. 
 
Mallen EA, Wolffsohn JS, Gilmartin B, Tsujimura S (2001). Clinical evaluation of the Shin-
Nippon SRW-5000 autorefractor in adults. Ophthalmic Physiol Opt 21: 101-107. 
 
Maltzman BA, Mulvihill MN, Greenbaum A (1979). Senile macular degeneration and risk 
factors: a case-control study. Ann Ophthalmol 11: 1197-1201. 
 
Mangels AR, Holden JM, Beecher GR, Forman MR, Lanza E (1993). Carotenoid content 
of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc 93: 284-296. 
 
Maoka T, Arai A, Shimizu M, Matsuno T (1986). The first isolation of enantiomeric and 
meso-zeaxanthin in nature. Comp Biochem Physiol B 83: 121-124. 
 
Mares JA, LaRowe TL, Snodderly DM, Moeller SM, Gruber MJ, Klein ML, Wooten BR, 
Johnson EJ, Chappell RJ (2006). Predictors of optical density of lutein and zeaxanthin in 
retinas of older women in the Carotenoids in Age-Related Eye Disease Study, an 
ancillary study of the Women’s Health Initiative. Am J Clin Nutr 84: 1107-1122. 
 
Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M, 
Palta M (1995). Serum antioxidants and age-related macular degeneration in a 
population-based case-control study. Arch Ophthalmol 113: 1518-1523. 
 
Mares-Perlman JA, Fisher AI, Klein R, Block G, Millen AE, Wright JD (2001). Lutein and 
zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third 
national health and nutrition examination survey. Am J Epidemiol 153: 424-432. 
 
Margrain TH, Boulton M, Marshall J, Sliney DH (2004). Do blue light filters confer 
protection against age-related macular degeneration? Prog Retin Eye Res 23: 523-531. 
 
Mellerio J, Ahmadi-Lari S, van Kuijk F, Pauleikhoff D, Bird A, Marshall J (2002). A 
portable instrument for measuring macular pigment with central fixation. Curr Eye Res 25: 
37-47. 
 
Mercadente AZ, Rodriguez-Amaya DB (1991). Carotenoid composition of a leafy 
vegetable in relation to some agricultural variables. J Agric Food Chem 39: 1094-1097. 
 
 184 
Mitchell P, Smith W, Wang JJ (1998). Iris color, skin sun sensitivity, and age-related 
maculopathy. The Blue Mountains Eye Study. Ophthalmology 105: 1359-1363. 
 
Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB, Mares JA (2006). 
Associations between intermediate age-related macular degeneration and lutein and 
zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS): ancillary 
study of the Women's Health Initiative. Arch Ophthalmol 124: 1151-1162. 
 
Moeller SM, Voland R, Sarto GE, Gobel VL, Streicher SL, Mares JA (2009). Women’s 
Health Initiative diet intervention did not increase macular pigment optical density in an 
ancillary study of a subsample of the Women’s Health Initiative. J Nutr 139: 1692-1699. 
 
Moreland JD (1980). A modified Moreland anomaloscope using optokinetic nystagmus to 
define colour matches objectively. In: Verriest G (ed) Colour Vision Deficiencies V. Hilger, 
Bristol, pp. 189-191. 
 
Moreland JD (1982). Spectral sensitivity measurements by motion photometry. Doc 
Ophthalmol Proc Ser 33: 61-66. 
 
Moreland JD, Bhatt P (1984). Retinal distribution of macular pigment. Doc Ophthalmol 
Proc Ser 39: 127-132. 
 
Moreland JD, Alexander EC (1997). Effect of macular pigment on colour matching with 
field sizes in the 1° to 10° range. Doc Ophthalmol Proc Ser 59: 363-368. 
 
Moreland JD, Robson AG, Soto-Leon N, Kulikowski JJ (1998). Macular pigment and the 
colour-specificity of visual evoked potentials. Vision Res 38: 3241-3245. 
 
Moreland JD, Robson AG, Kulikowski JJ (2001). Macular pigment assessment using a 
colour monitor. Color Res Appl 26: S261-S263. 
 
Moreland JD (2004). Macular pigment assessment by motion photometry. Arch Biochem 
Biophys 430: 143-148. 
 
Morris MS, Jacques PF, Chylack LT, Hankinson SE, Willett WC, Hubbard LD, Taylor A 
(2007). Intake of zinc and antioxidant micronutrients and early age-related maculopathy 
lesions. Ophthalmic Epidemiol 14: 288-298. 
 
Muñoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB, Bandeen-Roche K 
(2000). Causes of blindness and visual impairment in a population of older Americans: 
the Salisbury Eye Evaluation Study. Arch Ophthalmol 118: 819-825.  
 
Nakajima Y, Shimazawa M, Ishibashi T, Otsubo K, Hara H (2009). Zeaxanthin, a retinal 
carotenoid, protects retinal cells against oxidative stress. Curr Eye Res 34: 311-318. 
 
Neelam K, O'Gorman N, Nolan J, O'Donovan O, Wong HB, Eong KGA, Beatty S (2005). 
Measurement of macular pigment: Raman spectroscopy versus heterochromatic flicker 
photometry. Invest Ophthalmol Vis Sci 46: 1023-1032. 
 
Neelam K, Nolan J, Loane E, Stack J, O’Donovan O, Au Eong KG, Beatty S (2006). 
Macular pigment and ocular biometry. Vision Res 46: 2149-2156. 
 
Neelam K, Hogg RE, Stevenson MR, Johnston E, Anderson R, Beatty S, Chakravarthy U 
(2008). Carotenoids and co-antioxidants in age-related maculopathy: design and 
methods. Ophthalmic Epidemiol 15: 389-401. 
 185 
Neuringer M, Sandstrom MM, Johnson EJ, Snodderly DM (2004). Nutritional 
manipulation of primate retinas, I: effects of lutein or zeaxanthin supplements on serum 
and macular pigment in xanthophyll-free rhesus monkeys. Invest Ophthalmol Vis Sci 45: 
3234-3243. 
 
Nicolas CM, Robman LD, Tikellis G, Dimitrov PN, Dowrick A, Guymer RH, McCarty CA 
(2003). Iris colour, ethnic origin and progression of age-related macular degeneration. 
Clin Experiment Ophthalmol 31: 465-469. 
 
Nolan J, O'Donovan O, Kavanagh H, Stack J, Harrison M, Muldoon A, Mellerio J, Beatty 
S (2004). Macular pigment and percentage of body fat. Invest Ophthalmol Vis Sci 45: 
3940-3950. 
 
Nolan JM, Stack J, Mellerio J, Godhinio M, O'Donovan O, Neelam K, Beatty S (2006). 
Monthly consistency of macular pigment optical density and serum concentrations of 
lutein and zeaxanthin. Curr Eye Res 31: 199-213. 
 
Nolan JM, Stack J, O'Connell E, Beatty S (2007a). The relationships between macular 
pigment optical density and its constituent carotenoids in diet and serum. Invest 
Ophthalmol Vis Sci 48: 571-582. 
 
Nolan JM, Stack J, O'Donovan O, Loane E, Beatty S (2007b). Risk factors for age-related 
maculopathy are associated with a relative lack of macular pigment. Exp Eye Res 84: 61-
74. 
 
Nolan JM, Stringham JM, Beatty S, Snodderly DM (2008). Spatial profile of macular 
pigment and its relationship to foveal architecture. Invest Ophthalmol Vis Sci 49: 2134-
2142. 
 
Nolan JM, O’Reilly P, Loughman J, Stack J, Loane E, Connolly E, Beatty S (2009). 
Augmentation of macular pigment following implantation of blue light-filtering intraocular 
lenses at the time of cataract surgery. Invest Ophthalmol Vis Sci 50: 4777-4785.  
 
Nolan JM, Kenny R, O'Regan C, Cronin H, Loughman J, Connolly EE, Kearney P, Loane 
E, Beatty S (2010). Macular Pigment Optical Density in an Ageing Irish Population: The 
Irish Longitudinal Study on Ageing. Ophthalmic Res 44: 131-139. 
 
Nolan JM, Loughman J, Akkali MC, Stack J, Scanlon G, Davison P, Beatty S (2011). The 
impact of macular pigment augmentation on visual performance in normal subjects: 
COMPASS. Vision Res 51: 459-469. 
 
Nussbaum JJ, Pruett RC, Delori FC (1981). Historic perspectives. Macular yellow 
pigment. The first 200 years. Retina 1: 296-310.  
 
Obana A, Hiramitsu T, Gohto Y, Ohira A, Mizuno S, Hirano T, Bernstein PS, Fujii H, Iseki 
K, Tanito M, Hotta Y (2008). Macular carotenoid levels of normal subjects and age-
related maculopathy patients in a Japanese population. Ophthalmology 115: 147-157. 
 
Olmedilla B, Granado F, Blanco I, Vaquero M, Cajigal C (2001). Lutein in patients with 
cataracts and age-related macular degeneration: a long-term supplementation study. J 
Sci Food Agric 81: 904-909. 
 
Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S (2008). 
Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal 
electroretinogram modifications after 1 year. Ophthalmology 115: 324-333. 
 186 
Pease PL, Adams AJ (1983). Macular pigment difference spectrum from sensitivity 
measures of a single cone mechanism. Am J Optom Physiol Opt 60: 667-672. 
 
Pease PL, Adams AJ, Nuccio E (1987). Optical density of human macular pigment. 
Vision Res 27: 705-710. 
 
Perry A, Rasmussen H, Johnson EJ (2009). Xanthophyll (lutein, zeaxanthin) content in 
fruits, vegetables and corn and egg products. J Food Compost Anal 22: 9-15. 
 
Pokorny J, Smith VC, Lutze M (1987). Aging of the human lens. Appl Opt 26: 1437-1440. 
 
Praveen MR, Vasavada AR, Jani UD, Trivedi RH, Choudhary PK (2008). Prevalence of 
cataract type in relation to axial length in subjects with high myopia and emmetropia in an 
Indian population. Am J Ophthalmol 145: 176-181. 
 
Rahmani B, Tielsch JM, Katz J, Gottsch J, Quigley H, Javitt J, Sommer A (1996). The 
cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye 
Survey. Ophthalmology 103: 1721-1726. 
 
Random.Org (2011). True random number service [online]. Available from: 
http://www.random.org/sequences/. Accessed 22 September 2011. 
 
Rapp LM, Maple SS, Choi JH (2000). Lutein and zeaxanthin concentrations in rod outer 
segment membranes from perifoveal and peripheral human retina. Invest Ophthalmol Vis 
Sci 41: 1200-1209. 
 
Reboul E, Abou L, Mikail C, Ghiringhelli O, Andre M, Portugal H, Jourdheuil-Rahmani D, 
Amiot M-J, Lairon D, Borel P (2005). Lutein transport by Caco-2 TC-7 cells occurs partly 
by a facilitated process involving the scavenger receptor class B type I (SR-BI). Biochem 
J 387: 455-461. 
 
Remington LA (1998). The retina. In: Clinical Anatomy of the Visual System. Butterworth-
Heinemann, Boston, MA, pp.49-77. 
 
Renzi LM, Hammond BR (2010a). The effect of macular pigment on heterochromatic 
luminance contrast. Exp Eye Res 91: 896-900. 
 
Renzi LM, Hammond BR (2010b). The relation between the macular carotenoids, lutein 
and zeaxanthin, and temporal vision. Ophthalmic Physiol Opt 30: 351-357. 
 
Richer S (1999). ARMD – pilot (case series) environmental intervention data. J Am 
Optom Assoc 70: 24-36. 
 
Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, 
Nyland J (2004). Double-masked, placebo-controlled, randomized trial of lutein and 
antioxidant supplementation in the intervention of atrophic age-related macular 
degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). 
Optometry 75: 216-230. 
 
Richer S, Devenport J, Lang JC (2007). LAST II: Differential temporal responses of 
macular pigment optical density in patients with atrophic age-related macular 
degeneration to dietary supplementation with xanthophylls. Optometry 78: 213-219. 
 
 187 
Robson AG, Moreland JD, Pauleikhoff D, Morrissey T, Holder GE, Fitzke FW, Bird AC, 
van Kuijk F (2003). Macular pigment density and distribution: comparison of fundus 
autofluorescence with minimum motion photometry. Vision Res 43: 1765-1775. 
 
Robson AG, Harding G, van Kuijk F, Pauleikhoff D, Holder GE, Bird AC, Fitzke FW, 
Moreland JD (2005). Comparison of fundus autofluorescence and minimum-motion 
measurements of macular pigment distribution profiles derived from identical retinal 
areas. Perception 34: 1029-1034. 
 
Robson AG, Holder GE, Moreland JD, Kulikowski JJ (2006). Chromatic VEP assessment 
of human macular pigment: comparison with minimum motion and minimum flicker 
profiles. Vis Neurosci 23: 275-283. 
 
Robson AG, Parry NRA (2008). Measurement of macular pigment optical density and 
distribution using the steady-state visual evoked potential. Vis Neurosci 25: 575-583. 
 
Rodriguez J, Sanchez R, Muñoz B, West SK, Broman A, Snyder RW, Klein R, Quigley H 
(2002). Causes of blindness and visual impairment in a population-based sample of U.S. 
Hispanics. Ophthalmology 109: 737-743. 
 
Rodriguez-Carmona M, Kvansakul J, Harlow JA, Kopcke W, Schalch W, Barbur JL 
(2006). The effects of supplementation with lutein and/or zeaxanthin on human macular 
pigment density and colour vision. Ophthalmic Physiol Opt 26: 137-147. 
 
Roodenburg AJC, Leenen R, van het Hof KH, Weststrate JA, Tijburg LBM (2000). 
Amount of fat in the diet affects bioavailability of lutein esters but not of alpha-carotene, 
beta-carotene, and vitamin E in humans. Am J Clin Nutr 71: 1187-1193. 
 
Ruddock KH (1963). Evidence for macular pigmentation from colour matching data. 
Vision Res 61: 417-429. 
 
Sandberg MA, Tolentino MJ, Miller S, Berson EL, Gaudio AR (1993). Hyperopia and 
neovascularization in age-related macular degeneration. Ophthalmology 100: 1009-1013. 
 
Sandberg MA, Gaudio AR, Miller S, Weiner A (1994). Iris pigmentation and extent of 
disease in patients with neovascular age-related macular degeneration. Invest 
Ophthalmol Vis Sci 35: 2734-2740. 
 
Sandberg MA, Johnson EJ, Berson EL (2010). The relationship of macular pigment 
optical density to serum lutein in retinitis pigmentosa. Invest Ophthalmol Vis Sci 51: 1086-
1091. 
 
SanGiovanni JP, Chew EY, Clemons TE, Ferris FL, Gensler G, Linblad AS, Milton RC, 
Seddon JM, Sperduto RD (2007). The relationship of dietary carotenoid and vitamin A, E, 
and C intake with age-related macular degeneration in a case-control study - AREDS 
report no. 22. Arch Ophthalmol 125: 1225-1232. 
 
Santodomingo-Rubido J, Mallen EA, Gilmartin B, Wolffsohn JS (2002). A new non-
contact optical device for ocular biometry. Br J Ophthalmol 86: 458-462. 
 
Sarks JP, Sarks SH, Killingsworth MC (1988). Evolution of geographic atrophy of the 
retinal pigment epithelium. Eye (Lond) 2: 552-577. 
 
 188 
Sasaki M, Ozawa Y, Kurihara T, Kubota S, Yuki K, Noda K, Kobayashi S, Ishida S, 
Tsubota K (2010). Neurodegenerative influence of oxidative stress in the retina of a 
murine model of diabetes. Diabetologia 53: 971-979. 
 
Sasamoto Y, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Hamasaki T (2010). Macular 
pigment optical density in central serous chorioretinopathy. Invest Ophthalmol Vis Sci 51: 
5219-5225. 
 
Sasamoto Y, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Nishida K (2011). Effect of 
cataract in evaluation of macular pigment optical density by autofluorescence 
spectrometry. Invest Ophthalmol Vis Sci 52: 927-932. 
 
Schalch W, Cohn W, Barker FM, Kopcke W, Mellerio J, Bird AC, Robson AG, Fitzke FF, 
van Kuijk FJGM (2007). Xanthophyll accumulation in the human retina during 
supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye 
Accumulation) study. Arch Biochem Biophys 458: 128-135. 
 
Schatz H, McDonald HR (1989). Atrophic macular degeneration. Rate of spread of 
geographic atrophy and visual loss. Ophthalmology 96: 1541-1551. 
 
Schupp C, Olano-Martin E, Gerth C, Morrissey BM, Cross CE, Werner JS (2004). Lutein, 
zeaxanthin, macular pigment, and visual function in adult cystic fibrosis patients. Am J 
Clin Nutr 79: 1045-1052. 
 
Schweitzer D, Jentsch S, Dawczynski J, Hammer M, Wolf-Schnurrbusch UEK, Wolf S 
(2010). Simple and objective method for routine detection of the macular pigment 
xanthophyll. J Biomed Opt 15: 061714. 
 
Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas 
ES, Haller J, Miller DT, Yannuzzi LA, Willett W (1994). Dietary carotenoids, vitamins A, C, 
and E, and advanced age-related macular degeneration. Eye Disease Case-Control 
Study Group. JAMA 272: 1413-1420. 
 
Seddon JM, Reynolds R, Rosner B (2010). Associations of smoking, body mass index, 
dietary lutein, and the LIPC genetic variant rs10468017 with advanced age-related 
macular degeneration. Mol Vis 16: 2412-2424. 
 
Sharifzadeh M, Bernstein PS, Gellermann W (2006). Nonmydriatic fluorescence-based 
quantitative imaging of human macular pigment distributions. J Opt Soc Am A Opt Image 
Sci Vis 23: 2373-2387. 
 
Sharifzadeh M, Zhao DY, Bernstein PS, Gellermann W (2008). Resonance Raman 
imaging of macular pigment distributions in the human retina. J Opt Soc Am A Opt Image 
Sci Vis 25: 947-957. 
 
Sheng H, Bottjer CA, Bullimore MA (2004). Ocular component measurement using the 
Zeiss IOLMaster. Optom Vis Sci 81: 27-34. 
 
Sies H, Stahl W (1995). Vitamins E and C, beta-carotene, and other carotenoids as 
antioxidants. Am J Clin Nutr 62: 1315S-1321S. 
 
Sivaprasad S, Membrey WL, Sivagnanavel V, Gonzalez JG, Liu DT, Chan WM, Lam DS, 
Jackson H, Chong NV (2006). Second eye of patients with unilateral neovascular age-
related macular degeneration: Caucasians vs Chinese. Eye (Lond) 20: 923-926. 
 
 189 
Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang 
JJ, de Jong PT (2001). Risk factors for age-related macular degeneration: pooled findings 
from three continents. Ophthalmology 108: 697-704. 
 
Snellen ELM, Verbeek ALM, van den Hoogen GWP, Cruysberg JRM, Hoyng CB (2002). 
Neovascular age-related macular degeneration and its relationship to antioxidant intake. 
Acta Ophthalmol Scand 80: 368-371. 
 
Snodderly DM, Auran JD, Delori FC (1984a). The macular pigment. II. Spatial distribution 
in primate retinas. Invest Ophthalmol Vis Sci 25: 674-685. 
 
Snodderly DM, Brown PK, Delori FC, Auran JD (1984b). The macular pigment. I. 
Absorbance spectra, localization, and discrimination from other yellow pigments in 
primate retinas. Invest Ophthalmol Vis Sci 25: 660-673. 
 
Snodderly DM (1995). Evidence for protection against age-related macular degeneration 
by carotenoids and antioxidant vitamins. Am J Clin Nutr 62: 1448S-1461S. 
 
Snodderly DM, Hammond BR (1999). In vivo psychophysical assessment of nutritional 
and environmental influences on human ocular tissues: lens and macular pigment. In: 
Taylor A (ed) Nutritional and Environmental Influences on the Eye. CRC Press, Boca 
Raton, FL, pp. 251-273. 
 
Snodderly DM, Mares JA, Wooten BR, Oxton L, Gruber M, Ficek T (2004). Macular 
pigment measurement by heterochromatic flicker photometry in older subjects: the 
carotenoids and age-related eye disease study. Invest Ophthalmol Vis Sci 45: 531-538. 
 
Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, Martone JF, Royall 
RM, Witt KA, Ezrine S (1991). Racial differences in the cause-specific prevalence of 
blindness in east Baltimore. N Engl J Med 325: 1412-1417. 
 
Sommerburg O, Keunen JEE, Bird AC, van Kuijk F (1998). Fruits and vegetables that are 
sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 
82: 907-910. 
 
Sommerburg O, Siems WG, Hurst JS, Lewis JW, Kliger DS, van Kuijk FJGM (1999). 
Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye 
Res 19: 491-495. 
 
Stabell U, Stabell B (1980). Variation in density of macular pigmentation and in short-
wave cone sensitivity with eccentricity. J Opt Soc Am 70: 706-711. 
 
Stringham JM, Hammond BR (2007). The glare hypothesis of macular pigment function. 
Optom Vis Sci 84: 859-864. 
 
Stringham JM, Hammond BR (2008). Macular pigment and visual performance under 
glare conditions. Optom Vis Sci 85: 82-88. 
 
Stringham JM, Hammond BR, Nolan JM, Wooten BR, Mammen A, Smollon W, Snodderly 
DM (2008). The utility of using customized heterochromatic flicker photometry (cHFP) to 
measure macular pigment in patients with age-related macular degeneration. Exp Eye 
Res 87: 445-453. 
 
Stringham JM, Bovier ER, Wong JC, Hammond BR (2010). The influence of dietary lutein 
and zeaxanthin on visual performance. J Food Sci 75: R24-R29. 
 190 
Stumpf P (1911). On the dependence of the visual sensation of movement and its 
negative aftereffect on the stimulation processes on the retina. Z Psychol 59: 321-330. 
 
Subczynski WK, Wisniewska A, Widomska J (2010). Location of macular xanthophylls in 
the most vulnerable regions of photoreceptor outer-segment membranes. Arch Biochem 
Biophys 504: 61-66. 
 
Sujak A, Gabrielska J, Grudzinski W, Borc R, Mazurek P, Gruszecki WI (1999). Lutein 
and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural 
aspects. Arch Biochem Biophys 371: 301-307. 
 
Sundelin SP, Nilsson SEG (2001). Lipofuscin-formation in retinal pigment epithelial cells 
is reduced by antioxidants. Free Radic Biol Med 31: 217-225. 
 
Takeda S, Masuda Y, Usuda M, Marushima R, Ueji T, Hasegawa M, Maruyama C 
(2009). Effects of mayonnaise on postprandial serum lutein/zeaxanthin and beta-carotene 
concentrations in humans. J Nutr Sci Vitaminol 55: 479-485. 
 
Tan JSL, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P (2008). Dietary 
antioxidants and the long-term incidence of age-related macular degeneration: the Blue 
Mountains Eye Study. Ophthalmology 115: 334-341. 
 
Tang CY, Yip HS, Poon MY, Yau WL, Yap MKH (2004). Macular pigment optical density 
in young Chinese adults. Ophthalmic Physiol Opt 24: 586-593. 
 
Tao Y, Jonas JB (2010). Refractive error and smoking habits in exudative age-related 
macular degeneration in a hospital-based setting. Eye (Lond) 24: 648-652. 
 
Taylor HR, West S, Muñoz B, Rosenthal FS, Bressler SB, Bressler NM (1992). The long-
term effects of visible light on the eye. Arch Ophthalmol 110: 99-104. 
 
Thomson LR, Toyoda Y, Langner A, Delori FC, Garnett KM, Craft N, Nichols CR, Cheng 
KM, Dorey CK (2002). Elevated retinal zeaxanthin and prevention of light-induced 
photoreceptor cell death in quail. Invest Ophthalmol Vis Sci 43: 3538-3549. 
 
Todorović D (1996). A gem from the past: Pleikart Stumpf's (1911) anticipation of the 
aperture problem, Reichardt detectors, and perceived motion loss at equiluminance. 
Perception 25: 1235-1242. 
 
Tomany SC, Cruickshanks KJ, Klein R, Klein BEK, Knudtson MD (2004). Sunlight and 
the 10-year incidence of age-related maculopathy - The Beaver Dam Eye Study. Arch 
Ophthalmol 122: 750-757. 
 
Trevithick-Sutton CC, Foote CS, Collins M, Trevithick JR (2006). The retinal carotenoids 
zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence 
and ESR study. Mol Vis 12: 1127-1135. 
 
Trieschmann M, Spital G, Lommatzsch A, van Kuijk E, Fitzke F, Bird AC, Pauleikhoff D 
(2003). Macular pigment: quantitative analysis on autofluorescence images. Graefes Arch 
Clin Exp Ophthalmol 241: 1006-1012. 
 
Trieschmann M, Heimes B, Hense HW, Pauleikhoff D (2006). Macular pigment optical 
density measurement in autofluorescence imaging: comparison of one- and two-
wavelength methods. Graefes Arch Clin Exp Ophthalmol 244: 1565-1574. 
 
 191 
Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, Fobker M, 
Pauleikhoff D (2007). Changes in macular pigment optical density and serum 
concentrations of its constituent carotenoids following supplemental lutein and 
zeaxanthin: the LUNA study. Exp Eye Res 84: 718-728. 
 
Trieschmann M, van Kuijk F, Alexander R, Hermans P, Luthert P, Bird AC, Pauleikhoff D 
(2008). Macular pigment in the human retina: histological evaluation of localization and 
distribution. Eye (Lond) 22: 132-137. 
 
United States Department of Agriculture (USDA), Agricultural Research Service (2010). 
USDA National Nutrient Database for Standard Reference, Release 23 [online]. Nutrient 
data laboratory home page, available from: 
http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed 22 September 2011. 
 
Unlu NZ, Bohn T, Clinton SK, Schwartz SJ (2005). Carotenoid absorption from salad and 
salsa by humans is enhanced by the addition of avocado or avocado oil. J Nutr 135: 431-
436. 
 
Updike AA, Schwartz SJ (2003). Thermal processing of vegetables increases cis isomers 
of lutein and zeaxanthin. J Agric Food Chem 51: 6184-6190. 
 
van de Kraats J, Berendschot TTJM, van Norren D (1996). The pathways of light 
measured in fundus reflectometry. Vision Res 36: 2229-2247. 
 
van de Kraats J, Berendschot TTJM, Valen S, van Norren D (2006). Fast assessment of 
the central macular pigment density with natural pupil using the macular pigment 
reflectometer. J Biomed Opt 11: 064031. 
 
van de Kraats J, van Norren D (2007). Optical density of the aging human ocular media in 
the visible and the UV. J Opt Soc Am A Opt Image Sci Vis 24: 1842-1857. 
 
van de Kraats J, Kanis MJ, Genders SW, van Norren D (2008). Lutein and zeaxanthin 
measured separately in the living human retina with fundus reflectometry. Invest 
Ophthalmol Vis Sci 49: 5568-5573. 
 
van de Kraats J, van Norren D (2008). Directional and nondirectional spectral reflection 
from the human fovea. J Biomed Opt 13: 024010. 
 
van den Berg H, van Vliet T (1998). Effect of simultaneous, single oral doses of beta-
carotene with lutein or lycopene on the beta-carotene and retinyl ester responses in the 
triacylglycerol-rich lipoprotein fraction of men. Am J Clin Nutr 68: 82-89. 
 
VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BEK, Brady WE, Palta M 
(1998). Associations between antioxidant and zinc intake and the 5-year incidence of 
early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 148: 204-
214. 
 
Vanderbeek BL, Zacks DN, Talwar N, Nan B, Musch DC, Stein JD (2011). Racial 
differences in age-related macular degeneration rates in the United States: a longitudinal 
analysis of a managed care network. Am J Ophthalmol 152: 273-282. 
 
van der Veen RLP, Berendschot TTJM, Hendrikse F, Carden D, Makridaki M, Murray IJ 
(2009a). A new desktop instrument for measuring macular pigment optical density based 
on a novel technique for setting flicker thresholds. Ophthalmic Physiol Opt 29: 127-137. 
 
 192 
van der Veen RLP, Berendschot TTJM, Makridaki M, Hendrikse F, Carden D, Murray IJ 
(2009b). Correspondence between retinal reflectometry and a flicker-based technique in 
the measurement of macular pigment spatial profiles. J Biomed Opt 14: 064046. 
 
van der Veen RLP, Ostendorf S, Hendrikse F, Berendschot TTJM (2009c). Macular 
pigment optical density relates to foveal thickness. Eur J Ophthalmol 19: 836-841. 
 
van het Hof KH, Brouwer IA, West CE, Haddeman E, Steegers-Theunissen RP, van 
Dusseldorp M, Weststrate JA, Eskes TK, Hautvast JG (1999). Bioavailability of lutein 
from vegetables is 5 times higher than that of beta-carotene. Am J Clin Nutr 70: 261-268. 
 
van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JCM, Klaver CCW, Hofman A, de 
Jong PTVM (2005). Dietary intake of antioxidants and risk of age-related macular 
degeneration. JAMA 294: 3101-3107. 
 
van Norren D, Tiemeijer LF (1986). Spectral reflectance of the human eye. Vision Res 26: 
313-320. 
 
Varma R, Foong AW, Lai MY, Choudhury F, Klein R, Azen SP (2010). Four-year 
incidence and progression of age-related macular degeneration: the Los Angeles Latino 
Eye Study. Am J Ophthalmol 149: 741-751. 
 
Viner C (2003). Measuring macular pigment levels: an in-practice procedure? Optician 
226: 24-26. 
 
Vogel A, Dick HB, Krummenauer F (2001). Reproducibility of optical biometry using 
partial coherence interferometry: intraobserver and interobserver reliability. J Cataract 
Refract Surg 27: 1961-1968. 
 
von Rückmann A, Fitzke FW, Bird AC (1995). Distribution of fundus autofluorescence 
with a scanning laser ophthalmoscope. Br J Ophthalmol 79: 407-412. 
 
Wakamatsu K, hu DN, McCormick SA, Ito S (2008). Characterization of melanin in 
human iridal and choroidal melanocytes from eyes with various colored irides. Pigment 
Cell Melanoma Res 21: 97-105. 
 
Wald G (1945). Human vision and the spectrum. Science 101: 653-658. 
 
Wald G (1949). The photochemistry of vision. Doc Ophthalmol 3: 94-137. 
 
Walsh JE, Bergmanson JP (2011). Does the eye benefit from wearing ultraviolet-blocking 
contact lenses? Eye Contact Lens 37: 267-272. 
 
Wang W, Connor SL, Johnson EJ, Klein ML, Hughes S, Connor WE (2007). Effect of 
dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in 
age-related macular degeneration. Am J Clin Nutr 85: 762-769. 
 
Wang YM, Illingworth DR, Connor SL, Duell PB, Connor WE (2010). Competitive 
inhibition of carotenoid transport and tissue concentrations by high dose supplements of 
lutein, zeaxanthin and beta-carotene. Eur J Nutr 49: 327-336. 
 
Weiter JJ, Delori FC, Wing GL, Fitch KA (1985). Relationship of senile macular 
degeneration to ocular pigmentation. Am J Ophthalmol 99: 185-187. 
 
 193 
Weiter JJ, Delori FC, Wing GL, Fitch KA (1986). Retinal pigment epithelial lipofuscin and 
melanin and choroidal melanin in human eyes. Invest Ophthalmol Vis Sci 27: 145-152. 
 
Weiter JJ, Delori F, Dorey CK (1988). Central sparing in annular macular degeneration. 
Am J Ophthalmol 106: 286-292. 
 
Wensor M, McCarty CA, Taylor HR (1999). Prevalence and risk factors of myopia in 
Victoria, Australia. Arch Ophthalmol 117: 658-663. 
 
Wenzel AJ, Fuld K, Stringham JM, Curran-Celentano J (2006a). Macular pigment optical 
density and photophobia light threshold. Vision Res 46: 4615-4622. 
 
Wenzel AJ, Gerweck C, Barbato D, Nicolosi RJ, Handelman GJ, Curran-Celentano J 
(2006b). A 12-wk egg intervention increases serum zeaxanthin and macular pigment 
optical density in women. J Nutr 136: 2568-2573. 
 
Wenzel AJ, Sheehan JP, Burke JD, Lefsrud MG, Curran-Celentano J (2007a). Dietary 
intake and serum concentrations of lutein and zeaxanthin, but not macular pigment 
optical density, are related in spouses. Nutr Res 27: 462-469. 
 
Wenzel AJ, Sheehan JP, Gerweck C, Stringham JM, Fuld K, Curran-Celentano J 
(2007b). Macular pigment optical density at four retinal loci during 120 days of lutein 
supplementation. Ophthalmic Physiol Opt 27: 329-335. 
 
Werner JS, Wooten BR (1979). Opponent chromatic response functions for an average 
observer. Percept Psychophys 25: 371-374. 
 
Werner JS, Donnelly SK, Kliegl R (1987). Aging and human macular pigment density. 
Appended with translations from the work of Max Schultze and Ewald Hering. Vision Res 
27: 257-268. 
 
Werner JS, Bieber ML, Schefrin BE (2000). Senescence of foveal and parafoveal cone 
sensitivities and their relations to macular pigment density. J Opt Soc Am A Opt Image 
Sci Vis 17: 1918-1932. 
 
Wilkinson P (1999). Surface treatments. In: Jalie M (ed) Ophthalmic Lenses and 
Dispensing. Butterworth-Heinemann, Oxford, pp. 77-83. 
 
Wolf-Schnurrbusch UEK, Roosli N, Weyermann E, Heldner MR, Hohne K, Wolf S (2007). 
Ethnic differences in macular pigment density and distribution. Invest Ophthalmol Vis Sci 
48: 3783-3787. 
 
Wong TY, Foster PJ, Hee J, Ng TP, Tielsch JM, Chew SJ, Johnson GJ, Seah SK (2000). 
Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest 
Ophthalmol Vis Sci 41: 2486-2494. 
 
Wong TY, Klein BE, Klein R, Tomany SC, Lee KE (2001). Refractive errors and incident 
cataracts: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 42: 1449-1454. 
 
Wooten BR, Hammond BR, Land RI, Snodderly DM (1999). A practical method for 
measuring macular pigment optical density. Invest Ophthalmol Vis Sci 40: 2481-2489. 
 
Wrona M, Rózanowska M, Sarna T (2004). Zeaxanthin in combination with ascorbic acid 
or alpha-tocopherol protects ARPE-19 cells against photosensitized peroxidation of lipids. 
Free Radic Biol Med 36: 1094-1101. 
 194 
Wüstemeyer H, Jahn C, Nestler A, Barth T, Wolf S (2002). A new instrument for the 
quantification of macular pigment density: first results in patients with AMD and healthy 
subjects. Graefes Arch Clin Exp Ophthalmol 240: 666-671. 
 
Wüstemeyer H, Moessner A, Jahn C, Wolf S (2003). Macular pigment density in healthy 
subjects quantified with a modified confocal scanning laser ophthalmoscope. Graefes 
Arch Clin Exp Ophthalmol 241: 647-651. 
 
Wyszecki G, Stiles WS (1982). The eye. In: Color Science: Concepts and Methods, 
Quantitative Data and Formulae. Wiley-Interscience, New York, pp. 112-114. 
 
Xu L, Li Y, Zheng Y, Jonas JB (2006). Associated factors for age related maculopathy in 
the adult population in China: the Beijing Eye Study. Br J Ophthalmol 90: 1087-1090. 
 
Xu L, You QS, Jonas JB (2010). Refractive error, ocular and general parameters and 
ophthalmic diseases. The Beijing Eye Study. Graefes Arch Clin Exp Ophthalmol 248: 
721-729. 
 
Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, Iida M, Ishibashi T 
(2009). Nine-year incidence and risk factors for age-related macular degeneration in a 
defined Japanese population the Hisayama study. Ophthalmology 116: 2135-2140. 
 
Yemelyanov AY, Katz NB, Bernstein PS (2001). Ligand-binding characterization of 
xanthophyll carotenoids to solubilized membrane proteins derived from human retina. 
Exp Eye Res 72: 381-392. 
 
Yeum KJ, Taylor A, Tang G, Russell RM (1995). Measurement of carotenoids, retinoids, 
and tocopherols in human lenses. Invest Ophthalmol Vis Sci 36: 2756-2761. 
 
Zagers NPA, van Norren D (2004). Absorption of the eye lens and macular pigment 
derived from the reflectance of cone photoreceptors. J Opt Soc Am A Opt Image Sci Vis 
21: 2257-2268. 
 
Zeimer MB, Krömer I, Spital G, Lommatzsch A, Pauleikhoff D (2010). Macular 
telangiectasia patterns of distribution of macular pigment and response to 
supplementation. Retina 30: 1282-1293.  
 
Zhao DY, Wintch SW, Ermakov IV, Gellermann W, Bernstein PS (2003). Resonance 
Raman measurement of macular carotenoids in retinal, choroidal, and macular 
dystrophies. Arch Ophthalmol 121: 967-972. 
 
Zhou H, Zhao X, Johnson EJ, Lim A, Sun E, Yu J, Zhang Y, Liu X, Snellingen T, Shang 
F, Liu N (2011). Serum carotenoids and risk of age-related macular degeneration in a 
Chinese population sample. Invest Ophthalmol Vis Sci 52: 4338-4344. 
 
Zhou L, Leung I, Tso MOM, Lam KW (1999). The identification of dipalmityl zeaxanthin as 
the major carotenoid in Gou Qi Zi by high pressure liquid chromatography. J Ocular 
Pharmacol Ther 15: 557-565. 
 
 
 
 195 
APPENDICES 
 
Appendix 1: Peer-reviewed publication 
 
  
 
 Pages removed for copyright restrictions. 
  
 228 
Appendix 2: References for table 1.1 in chapter 1 
 
See reference list (starting on page 168) for the references in full. 
 
1. Aleman et al. 2001 36. Hammond et al. 1996c  
2. Aleman et al. 2007 37. Hammond et al. 1997b 
3. Barbur et al. 2010 38. Hammond et al. 1998 
4. Bartlett et al. 2010a 39. Hammond and Caruso-Avery 2000 
5. Bartlett et al. 2010c 40. Hammond et al. 2002 
6. Beatty et al. 2001 41. Hammond and Wooten 2005 
7. Berendschot et al. 2000 42. Handelman et al. 1988 
8. Berendschot et al. 2002a 43. Hogg et al. 2007 
9. Berendschot et al. 2002b 44. Iannaccone et al. 2007 
10. Berendschot and van Norren 2005 45. Jahn et al. 2005 
11. Bernstein et al. 2002 46. Johnson et al. 2000 
12. Bernstein et al. 2004 47. Kanis et al. 2007a 
13. Bhosale et al. 2007 48. Kanis et al. 2007b 
14. Bone et al. 1988 49. Kanis et al. 2008 
15. Bone et al. 2000 50. Kirby et al. 2009 
16. Bone et al. 2001 51. Kirby et al. 2010 
17. Borel et al. 2011 52. Koh et al. 2004 
18. Broekmans et al. 2002 53. Kvansakul et al. 2006 
19. Burke et al. 2005 54. Lam et al. 2005 
20. Cardinault et al. 2003 55. LaRowe et al. 2008 
21. Chen et al. 2001 56. Liew et al. 2005 
22. Ciulla et al. 2001a 57. Liew et al. 2006 
23. Ciulla and Hammond 2004 58. Lima et al. 2010 
24. Curran-Celentano et al. 2001 59. Loane et al. 2007 
25. Davies and Morland 2002 60. Loane et al. 2010a 
26. Delori et al. 2001 61. Loane et al. 2010b 
27. Delori 2004 62. Loughman et al. 2010a 
28. Delori et al. 2006 63. Mares et al. 2006 
29. Duncan et al. 2002 64. Mellerio et al. 2002 
30. Elsner et al. 1998 65. Moeller et al. 2009 
31. Engles et al. 2007 66. Neelam et al. 2005 
32. Gellermann et al. 2002a 67. Neelam et al. 2006 
33. Hammond et al. 1995 68. Nolan et al. 2004 
34. Hammond et al. 1996a 69. Nolan et al. 2006 
35. Hammond et al. 1996b 70. Nolan et al. 2007a 
 229 
71. Nolan et al. 2007b 
72. Nolan et al. 2008 
73. Nolan et al. 2010 
74. Nolan et al. 2011 
75. Obana et al. 2008 
76. Renzi and Hammond 2010a 
77. Renzi and Hammond 2010b 
78. Richer et al. 2004 
79. Richer et al. 2007 
80. Sandberg et al. 2010 
81. Sasamoto et al. 2010 
82. Sasamoto et al. 2011 
83. Schupp et al. 2004  
84. Schweitzer et al. 2010 
85. Sharifzadeh et al. 2006 
86. Sharifzadeh et al. 2008 
87. Stringham and Hammond 2007 
88. Stringham and Hammond 2008 
89. Tang et al. 2004 
90. Trieschmann et al. 2003 
91. Trieschmann et al. 2007 
92. Trieschmann et al. 2008 
93. van de Kraats et al. 2006 
94. van de Kraats et al. 2008 
95. van der Veen et al. 2009a 
96. van der Veen et al. 2009c 
97. Wenzel et al. 2006a 
98. Wenzel et al. 2006b 
99. Wenzel et al. 2007a 
100. Werner et al. 1987 
101. Werner et al. 2000 
102. Wolf-Schnurrbusch et al. 2007 
103. Wooten et al. 1999 
104. Wüstemeyer et al. 2002 
105. Wüstemeyer et al. 2003 
106. Zagers and van Norren 2004 
107. Zhao et al. 2003 
 230 
Appendix 3: MPS instructions to patient 
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Appendix 4: Additional analysis for chapter 2 
 
See chapter 2 for further explanation, if required. 
 
 
Comparison 
Difference 
(significance, p) 
S
D
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, 
2
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d
 3
 
CP RE and C-only RE t = 3.223 (p = 0.004) 
CP LE and C-only LE t = 4.094 (p<0.0005) 
CP RE and CP LE t = 2.013 (p = 0.055) 
C-only RE and C-only LE t = 2.910 (p = 0.008) 
C
V
 b
e
tw
e
e
n
 
m
e
a
s
u
re
s
 1
, 
2
 a
n
d
 3
 
CP RE and C-only RE t = 3.669 (p = 0.001) 
CP LE and C-only LE t = 4.449 (p<0.0005) 
CP RE and CP LE t = 1.916 (p = 0.067) 
C-only RE and C-only LE t = 3.223 (p = 0.004) 
 
Table A4.1 Comparisons of the mean individual standard deviations of the three 
repeated MPOD measurements, and comparisons of the mean individual coefficients of 
variation (n=25). 
‘t’ refers to a paired-samples t-test (the differences between each data set were normally 
distributed). 
 
Comparison Difference (significance, p) Correlation (significance, p) 
CP R1 and L1  t = 1.075 (p = 0.293) r = 0.699 (p<0.0005) 
CP R2 and L2 z = -1.864 (p = 0.062) rho = 0.655 (p<0.0005) 
CP R3 and L3 t = -0.079 (p = 0.938) r = 0.846 (p<0.0005) 
C-only R1 and L1 z = -0.931 (p = 0.352) r = 0.865 (p<0.0005) 
C-only R2 and L2 z = -0.521 (p = 0.602) r = 0.921 (p<0.0005) 
C-only R3 and L3 z = -0.242 (p = 0.809) rho = 0.918 (p<0.0005) 
 
Table A4.2 Interocular mean MPOD comparisons, plus correlations (n=25). 
‘t’ refers to a paired-samples t-test, which was used where the differences between each 
data set were normally distributed. Otherwise, the Wilcoxon signed rank test (‘z’) was 
used. ‘r’ refers to Pearson’s r, which was used where both data sets were normally 
distributed. Otherwise, Spearman’s rho was used. 
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Appendix 5: Lifestyle questionnaire 
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Appendix 6: Food diary 
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Appendix 7: Additional analysis for chapter 5  
 
See chapter 5 for further explanation, if required. 
 
Variable Comparison Statistic value 
Significance (p) 
value 
MPOD 
Male/Female 
Indian/Pakistani 
Meat-eater/Vegetarian 
t = 2.285 
t = 0.249 
t = -0.294 
0.027 
0.804 
0.770 
Body mass index 
Male/Female 
Indian/Pakistani 
Meat-eater/Vegetarian 
t = 4.007 
t = -1.631 
t = 0.572 
0.001 
0.120 
0.570 
Vegetable + Fruit + Egg 
intake per week 
Male/Female 
Indian/Pakistani 
Meat-eater/Vegetarian 
t = 0.607 
t = 0.623 
U = 137.5 
0.547 
0.536 
0.156 
Energy (kilocalories) Male/Female t = 4.196 <0.0005 
Carbohydrate (grams) Male/Female U = 141.0 0.004 
Total fat (grams) Male/Female U = 94.0 <0.0005 
Lutein + Zeaxanthin 
(milligrams) 
Male/Female 
Indian/Pakistani 
Meat-eater/Vegetarian 
VFE ≤15/VFE >15 
U = 214.0 
U = 205.0 
U = 104.0 
U = 258.5 
0.173 
0.650 
0.023 
0.366 
 
Table A7.1 Statistical comparisons of mean values for the 50 Asian subjects with 
completed questionnaires and food diaries (see table 5.3 for details). 
VFE ≤15 = less than or equal to 15 vegetable+fruit+egg servings per week. 
‘t’ refers to an independent-samples t-test, which was used when each data set was 
normally distributed. Otherwise, the Mann-Whitney U test (‘U’) was used. For all t-tests, 
the assumption of homogeneity of variance was checked; where this assumption was not 
met, the adjusted t and p values are reported. 
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Nutrient 
Mean (±SD) from 
food diaries 
Nutrient 
Mean (±SD) from 
food diaries 
Alcohol g 2.00 ± 5.53 Pantothenic acid mg 4.34 ± 1.93 
Biotin mcg 22.4 ± 9.4 Phosphorus mg 1165 ± 422 
Calcium mg 797.6 ± 302.1 Polyunsaturated fat g 15.3 ± 7.3 
Carbohydrate g 248.4 ± 80.3 Potassium mg 2718 ± 881 
Carotene mcg 2760 ± 2744 Protein g 75.8 ± 32.9 
Chloride mg 3801 ± 1332 Retinol mcg 375.1 ± 271.3 
Cholesterol mg 201.1 ± 129.2 Riboflavin mg 1.43 ± 0.67 
Copper mg 1.22 ± 0.75 Saturated fat g 26.5 ± 10.5 
Energy kcal 1950 ± 615 Selenium mcg 40.1 ± 19.6 
Fat (total) g 78.2 ± 29.6 Sodium g 2.66 ± 1.03 
Fibre g 17.1 ± 7.1 Starch g 141.9 ± 47.8 
Folate mcg 228.7 ± 99.9 Sugars g 96.9 ± 42.4 
Iodine mcg 118.4 ± 60.8 Thiamin mg 2.38 ± 3.26 
Iron mg 11.8 ± 4.9 Vitamin B6 mg 1.94 ± 0.89 
Lutein and Zeaxanthin mg 1.31 ± 2.46 Vitamin B12 mcg 3.87 ± 2.31 
Magnesium mg 240.4 ± 86.2 Vitamin C mg 109.9 ± 76.5 
Manganese mg 2.92 ± 1.28 Vitamin D mcg 1.56 ± 1.26 
Monounsaturated fat g 24.5 ± 10.3 Vitamin E mg 9.03 ± 3.93 
Niacin equivalent mg 20.0 ± 10.3 Vitamin K mcg 21.9 ± 81.1 
Nitrogen g 12.4 ± 5.3 Zinc mg 7.45 ± 3.09 
 
Table A7.2 Mean nutrient values per day, derived from analysis of the 50 food diaries. 
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Appendix 8: Additional analysis for chapter 6  
 
See chapter 6 for further explanation, if required. 
 
  Yellow CL eye Normal CL eye 
 
Comparison 
Statistic (t) 
value  
Significance (p) 
value 
Statistic (t) 
value  
Significance (p) 
value 
M
P
O
D
 (
C
e
n
tr
e
 a
n
d
 P
e
ri
p
h
e
ra
l)
 
Measure 1 vs 2 0.262 0.802 -1.214 0.270 
Measure 1 vs 3 1.805 0.121 -1.478 0.190 
Measure 1 vs 4 0.214 0.838 -1.483 0.188 
Measure 1 vs 5 -0.617 0.560 -1.592 0.162 
Measure 1 vs 6 -0.064 0.951 0.811 0.448 
Measure 2 vs 3 0.800 0.454 -1.309 0.238 
Measure 2 vs 4 -0.030 0.977 -0.198 0.850 
Measure 2 vs 5 -0.664 0.532 0.431 0.681 
Measure 2 vs 6 -0.252 0.810 1.485 0.188 
Measure 3 vs 4 -1.494 0.186 0.659 0.534 
Measure 3 vs 5 -1.508 0.182 0.914 0.396 
Measure 3 vs 6 -1.333 0.231 1.641 0.152 
Measure 4 vs 5 -1.095 0.315 0.451 0.668 
Measure 4 vs 6 -0.283 0.787 1.410 0.208 
Measure 5 vs 6 0.508 0.630 2.499 0.047 
 
C
e
n
tr
e
-o
n
ly
 M
P
O
D
 
Measure 1 vs 2 -0.982 0.364 0.440 0.675 
Measure 1 vs 3 0.383 0.715 -0.402 0.702 
Measure 1 vs 4 -0.378 0.718 -0.127 0.903 
Measure 1 vs 5 -0.634 0.549 1.641 0.152 
Measure 1 vs 6 -0.673 0.526 1.887 0.108 
Measure 2 vs 3 1.228 0.266 -1.511 0.182 
Measure 2 vs 4 0.426 0.685 -0.609 0.565 
Measure 2 vs 5 0.084 0.936 1.350 0.226 
Measure 2 vs 6 0.357 0.734 1.262 0.254 
Measure 3 vs 4 -0.633 0.550 0.510 0.628 
Measure 3 vs 5 -0.766 0.473 1.609 0.159 
Measure 3 vs 6 -0.942 0.382 1.435 0.201 
Measure 4 vs 5 -0.346 0.741 1.196 0.277 
Measure 4 vs 6 -0.256 0.807 1.130 0.302 
Measure 5 vs 6 0.251 0.810 0.577 0.585 
 
Table A8.1 Mean MPOD comparisons (n=7) from baseline (measure 1) to one month 
post CL wear (measure 6), assessed by paired-samples t-tests (the differences between 
each data set were normally distributed). 
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Appendix 9: Additional analysis for chapter 7 
 
See chapter 7 for further explanation, if required. 
 
 
Comparison Statistic value 
Significance (p) 
value 
W
it
h
in
-o
p
e
ra
to
r 
MPS 1 and MPS 2 t = -0.463 0.648 
PV MPR 1 and PV MPR 2 z = -0.198 0.843 
PV Lutein 1 and PV Lutein 2 z = -0.122 0.903 
PV Zeaxanthin 1 and PV Zeaxanthin 2 z = -0.821 0.411 
OH MPR 1 and OH MPR 2 z = -1.065 0.287 
OH Lutein 1 and OH Lutein 2 t = -0.603 0.553 
OH Zeaxanthin 1 and OH Zeaxanthin 2 z = -0.03 0.976 
MPS 1 and C-only MPS 1 t = -4.278 <0.0005 
MPS 2 and C-only MPS 2 t = -4.398 <0.0005 
B
e
tw
e
e
n
-o
p
e
ra
to
r 
PV MPR 1 and OH MPR 1 t = 1.078 0.293 
PV MPR 2 and OH MPR 2 t = 0.427 0.673 
PV Lutein 1 and OH Lutein 1 t = 1.279 0.214 
PV Lutein 2 and OH Lutein 2 z = -0.593 0.553 
PV Zeaxanthin 1 and OH Zeaxanthin 1 z = -0.274 0.784 
PV Zeaxanthin 2 and OH Zeaxanthin 2 t = 0.078 0.938 
A
ll
 
MPR: PV1/PV2/OH1/OH2 F = 0.373 0.774 
Lutein: PV1/PV2/OH1/OH2 
2
 = 2.528 0.470 
Zeaxanthin: PV1/PV2/OH1/OH2 F = 0.372 0.774 
B
e
tw
e
e
n
- 
in
s
tr
u
m
e
n
t MPS 1 and PV MPR 1 t = -8.927 <0.0005 
MPS 1 and OH MPR 1 t = -7.941 <0.0005 
MPS 2 and PV MPR 2 t = -7.399 <0.0005 
MPS 2 and OH MPR 2 t = -6.637 <0.0005 
 
Table A9.1 Mean MPOD comparisons (n=23). 
‘t’ refers to a paired-samples t-test, which was used where the differences between each 
data set were normally distributed. Otherwise, the Wilcoxon signed rank test (‘z’) was 
used. ‘F’ refers to a one-way repeated measures ANOVA, which was used where each 
data set was normally distributed. Otherwise, Friedman’s ANOVA (‘2’) was used. (For 
the one-way repeated measures ANOVAs, the assumption of sphericity was not met 
according to Mauchly’s test, so with the sample size in mind [n=23], multivariate test 
statistics were used for interpretation.)  
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 L/Z repeatability L/Z reproducibility 
PV1-PV2 OH1-OH2 PV1-OH1 PV2-OH2 PV1-OH2 PV2-OH1 
Lutein original 0.413 0.278 0.264 0.194 0.403 0.345 
Lutein after removal of 
two subjects’ data 
0.244 0.222 0.201 0.201 0.261 0.297 
Zeaxanthin original 0.148 0.164 0.094 0.083 0.154 0.147 
Zeaxanthin after removal 
of two subjects’ data 
0.078 0.105 0.069 0.087 0.077 0.088 
 
Table A9.2 Coefficients of repeatability/reproducibility for L and Z on the MPR (n=23). 
 
Number of 
subjects 
Coefficient of 
repeatability 
Reference 
6 0.11 Koh et al. 2004 
6 0.12 Tang et al. 2004 
8 0.08 Hammond and Caruso-Avery 2000 
10 0.06 Hammond and Fuld 1992 
11 0.09 Van der Veen et al. 2009a 
13 0.14 Hammond et al. 1997a 
17 0.22 Liew et al. 2005 
20 0.2 Hammond et al. 1995 
20 0.18 de Kinkelder et al. 2011 
23 0.32 de Kinkelder et al. 2011 
32 0.16 Hammond et al. 1997c 
37 0.18 Hammond et al. 1998 
38 0.52 Bartlett et al. 2010a 
40 0.31 Bartlett et al. 2010c 
40 0.31 Gallaher et al. 2007 
48 0.19 Snodderly et al. 2004 
 
Table A9.3 A summary of inter-session CR data from HFP studies (derivation for figure 
7.9, plus references). 
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Appendix 10: Post-kale questionnaire 
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Appendix 11: Additional analysis for chapter 8 
 
See chapter 8 for further explanation, if required. 
 
 Comparison Statistic (t) value  Significance (p) value 
M
P
S
 M
P
O
D
 
Visit 2 vs 3 0.459 0.662 
Visit 2 vs 4 1.478 0.190 
Visit 2 vs 5 0.109 0.917 
Visit 2 vs 6 1.136 0.299 
Visit 2 vs 7 2.039 0.088 
 
C
e
n
tr
e
-o
n
ly
 
M
P
S
 M
P
O
D
 
Visit 2 vs 3 -0.735 0.490 
Visit 2 vs 4 0.203 0.846 
Visit 2 vs 5 -0.087 0.933 
Visit 2 vs 6 -0.183 0.861 
Visit 2 vs 7 1.457 0.195 
 
M
P
R
 M
P
O
D
 
Visit 2 vs 3 0.201 0.851 
Visit 2 vs 4 1.834 0.141 
Visit 2 vs 5 0.793 0.472 
Visit 2 vs 6 1.787 0.149 
Visit 2 vs 7 -2.154 0.098 
 
L
u
te
in
 (
M
P
R
) 
Visit 2 vs 3 0.637 0.559 
Visit 2 vs 4 1.624 0.180 
Visit 2 vs 5 0.785 0.476 
Visit 2 vs 6 2.062 0.108 
Visit 2 vs 7 0.227 0.831 
 
Z
e
a
x
a
n
th
in
 
(M
P
R
) 
Visit 2 vs 3 -2.156 0.097 
Visit 2 vs 4 -1.084 0.339 
Visit 2 vs 5 0.431 0.689 
Visit 2 vs 6 -1.122 0.325 
Visit 2 vs 7 -1.204 0.295 
 
Table A11.1 Mean MPOD comparisons (n=5/6) from baseline (visit 2) through to 16 
weeks of kale intake (visits 3 to 6), and four weeks post kale intake (visit 7), assessed by 
paired-samples t-tests (the differences between each data set were normally distributed). 
 
 
 
